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The genus Acinetobacter currently contains 34 species, the vast majority of which 
are not regularly implicated in causing infection. However, incidences of hospital-
acquired infection with Acinetobacter species are increasing, mainly due to the rise 
in the number of infections caused by the species Acinetobacter baumannii in 
immunocompromised patients particularly in intensive care units (ICUs). Due to high 
levels of resistance in A. baumannii to many classes of antibiotic, the carbapenems 
have been portrayed as the ‘drugs of choice’ for treating infections with this species. 
However, the activity of the carbapenems against A. baumannii has come under 
threat with the identification of four groups of class D β-lactamases carried by 
members of the species. Of these, the OXA-51-like enzymes have been suggested to 
be ubiquitous and intrinsic enzymes within A. baumannii. This presents the worrying 
scenario of the potential for all A. baumannii to become carbapenem resistant, 
leaving few treatment options available for this species. This project aimed to 
investigate the epidemiological spread of the OXA-51-like β-lactamases, examine 
the diversity within these enzymes, and whether this diversity may have implications 
for their ability to confer resistance to the carbapenems. 
 
A functional map showing the amino-acid similarities between the OXA-51-like 
enzymes demonstrated that the enzymes fall into distinct closely-related groups, with 
notable clusters surrounding OXA-66, OXA-69 and OXA-98. PCR and sequencing 
analysis of a geographically diverse group of 64 A. baumannii isolates demonstrated 
that isolates forming specific sequence groups (SGs) as defined by Turton et al 
(2007) also contained the same or closely related blaOXA-51-like gene. Higher minimum 
 ii
inhibitory concentrations (MICs) of carbapenems were found in association with 
acquired carbapenemases, or with the presence of ISAba1 upstream of the blaOXA-51-
like gene. Pulsed-field gel electrophoresis (PFGE) analysis of the isolates did not 
demonstrate relatedness between isolates which formed the same sequence group. 
Multilocus sequence typing (MLST) of a subset of 44 isolates grouped isolates more 
consistently with the SGs and blaOXA-51-like alleles, indicating that PFGE is unreliable 
for use with A. baumannii unless studying a short time period, and that blaOXA-51-like 
alleles are a good epidemiological marker. 
 
Mutation studies using meropenem with five A. baumannii isolates encoding 
different OXA-51-like enzymes, while resulting in an increase in meropenem MICs 
of between 8- and 128-fold, did not result in a nucleotide substitution in the blaOXA-
51-like genes or a change in the upstream region of the genes in any isolate suggesting 
that the carbapenems may not be producing a strong selective pressure on the blaOXA-
51-like genes. Analysis of πN/πS ratios for the blaOXA-51-like genes, MLST genes and the 
TEM, SHV and CTX-M β-lactamase families showed the blaOXA-51-like genes to be 
under less positive selection than these other β-lactamases, though under less 
purifying selection than the MLST genes. Phylogenetic analysis of the MLST genes 
and the blaOXA-51-like genes indicates that the blaOXA-51-like genes have been evolving 
within A. baumannii since its speciation, and that different groups of blaOXA-51-like 
genes have been evolving at different rates corresponding to different rates of 
evolution within their parent lineages. 
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Structural modelling studies based upon the published crystal structure for OXA-40 
indicated that amino-acid variation at particular sites in the OXA-51-like enzymes 
are likely to have an effect of enzyme function. Alterations at amino-acid position 
167 change the shape of the entrance to the active site which may affect hydrolysis 
by accommodating the antibiotic differently, or may affect the substrate profile of the 
enzyme. The substitution of glutamine for proline at position 194 may significantly 
alter the shape of the enzyme thereby affecting substrate hydrolysis. 
 
This project found that specific groups of blaOXA-51-like genes are associated with 
specific A. baumannii lineages and that these genes could serve as convenient 
epidemiological markers. Most of the diversity within the OXA-51-like enzymes is 
due to their continued evolution within A. baumannii since the species’ emergence. 
However, certain amino-acid changes may play a role in altering the rate of 
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1.1 The genus Acinetobacter. 
1.1.1  The origin of the genus Acinetobacter. 
The history of the genus Acinetobacter is a complicated one. It begins in 1911 with 
the description by Beijerinck of an organism isolated from a soil sample, which was 
named Micrococcus calcoaceticus (Henriksen, 1973). Between 1911 and 1957 a 
number of bacterial species were described, sometimes by different authors who 
assigned different names to the same organism; these included Bacterium anitratum, 
Moraxella glucidolytica, Neisseria winogradsky, Alcaligenes haemolysans, Mima 
polymorpha, and Moraxella lwoffii (Henriksen, 1973). The genus Acinetobacter was 
created in 1957 with the proposal that it should include all non-motile 
Achromobacter species. However, it wasn’t until 1971 that taxonomists officially 
recognised the genus Acinetobacter following comparative biochemical studies by 
Baumann that demonstrated that all of these organisms belonged to the same genus, 
and the type species Acinetobacter calcoaceticus was proposed (Baumann et al., 
1968, Henriksen, 1973). 
 
1.1.2  Current taxonomic status of the genus Acinetobacter. 
Modern DNA-DNA hybridisation techniques and DNA sequ ncing analysis have 
facilitated the classification of the genus Acinetobacter and the species that it 
contains.  The genus is a member of the order Gammaproteobacteria nd belongs to 
the family Moraxellaceae. Phenotypically the genus Acinetobacter is defined as 
Gram-negative, strictly aerobic coccobacilli that are non-fermenting, catalase-  
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Acinetobacter  species Sources Clinical relevance
A. calcoaceticus Humans (clinical and non-clinical samples) and soil +
A. baumannii Humans (clinical and non-clinical samples) soil, meat and vegetables ++++
A. haemolyticus Humans (clinical and non-clinical samples) +
A. junii Humans (clinical and non-clinical samples) +
A. johnsonii Humans (clinical and non-clinical samples) and animals +
A. lwoffii Humans (clinical and non-clinical samples) and animals +
A. radioresistens Humans (clinical and non-clinical samples), soil and cotton +
A. ursingii Humans (clinical and non-clinical samples) +
A. schindleri Humans (clinical and non-clinical samples) +
A. parvus Humans (clinical and non-clinical samples) and animals +
A. baylyi Activated sludge and soil -
A. bouvetii Activated sludge -
A. towneri Activated sludge -
A. tandoii Activated sludge -
A. grimontii Activated sludge -
A. tjernbergiae Activated sludge -
A. generi Activated sludge -
A. venetianus Seawater -
A. beijerinckii Humans (clinical and non-clinical samples), horses, soil, surface water +
A. gyllenbergii Humans (clinical samples) +
genomic species 3 Humans (clinical and non-clinical samples), soil and vegetables +++
genomic species 6 Humans (clinical and non-clinical samples) +
genomic species 10 Humans (clinical and non-clinical samples), soil and vegetables +
genomic species 11 Humans (clinical and non-clinical samples) and animals +
genomic species 13BJ or 14TU Humans (clinical and non-clinical samples) +
genomic species 14BJ Humans (clinical and non-clinical samples) +
genomic species 15BJ Humans (clinical and non-clinical samples) +
genomic species 16 Humans (clinical and non-clinical samples) and vegetables +
genomic species 17 Humans (clinical and non-clinical samples) and soil +
genomic species 13TU Humans (clinical and non-clinical samples) +++
genomic species 15TU Humans (clinical and non-clinical samples) +
genomic species 'between 1 and 3' Humans (clinical samples) +
genomic species 'close to 13TU' Humans (clinical samples) +  
Table 1: Species within the genus Acinetobacter (Dijkshoorn et al., 2007, Nemec et 
al., 2009).  
 
positive, oxidase-negative, non-motile and non-fastidious, with a G+C DNA content 
of between 39% and 47% (Peleg t al., 2008). There are currently 33 species 
recognised within the genus, of which 20 have been named (Table 1) (Dijkshoorn et 
al., 2007, Nemec et al., 2009) . Acinetobacter species identification can be 
performed phenotypically for some species, and there are commercially available kits 
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such as the API 20 NE system that can be used for this purpose. However some of 
the species are very difficult to distinguish phenotypically. Four species – A. 
calcoaceticus, A. baumannii, Acinetobacter g nomic species 3 and Acinetobacter 
genomic species 13TU – can only be distinguished using molecular techniques, and 
are often referred to as the A. calcoaceticus-A. baumannii complex (Peleg et al., 
2008). A number of different methods have been proposed for discriminating 
between some or all of these species. These include tRNA spacer fingerprinting, 
sequencing of the 16S rDNA, gyrB  and rpoB genes, PCR amplification of the r cA 
gene, sequencing of the 16S-23S intergenic rDNA region, restriction analysis of the 
16S rDNA gene (ARDRA), restriction analysis of the 16S-23S rDNA region, PCR 
amplification of the gyrB gene, and multilocus PCR followed by electrospray 
ionisation mass spectrometry (PCR/ESI-MS) (Ehrenstei  et al., 1996, Ibrahim et al., 
1997, Yamamoto et al., 1999, La Scola et al., 2006, Nowak and Kur, 1995, Chang et 
al., 2005, Vaneechoutte et al., 1995, Higgins et al., 2007, Dolzani et al., 1995, Ecker 
et al., 2006). However, there is no consensus on which met odology should be used. 
The variety of methods that are utilised by different laboratories can be problematic 
as methods vary in their specificity and sensitivity, making direct comparisons 
between data sets obtained following identification by different means less reliable. 
 
1.1.3  The natural habitat of Acinetobacter species. 
Most Acinetobacter species are generally isolated from environmental samples such 
as soil and sludge, or from non-clinical human samples such as skin swabs (Table 1). 
Many members of the genus are generally considered to be environmental organisms 
(Peleg et al., 2008). In a study of soil and water samples from California, USA, 28 of 
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30 soil samples and 29 of 30 water samples were culture-positive for members of the 
genus (Baumann, 1968). In a recent study of the microbial communities from the 
extreme environments of six Andean lakes, a total of five different acinetobacters 
were isolated, one of which was determined to be A. johnsonii (Ordonez et al., 2009). 
Members of the species A. calcoaceticus have been isolated from the soil 
surrounding plant roots and have been shown to promote plant growth in vitro (Peix 
et al., 2009), while A. baylyi, another organism isolated from the soil, has been 
shown to be able to acquire plant DNA through horizontal gene transfer (Pontiroli et
al., 2009). An A. baumannii solate has even been recovered from petroleum-
contaminated desert soil in Kuwait, and has been shown to be able to degrade crude 
oil (Obuekwe et al., 2009).  
 
A series of studies to examine the association of Acinetobacter species with humans 
have produced varied results. In a study of skin carriage in 192 healthy humans in 
London, UK, an Acinetobacter carriage rate of 44% was found, with A. lwoffii 
accounting for 61% of isolates, Acinetobacter genospecies 15BJ accounting for 
12.5%, and A. radioresistens accounting for 8% (Berlau et al., 1999). A similar result 
was found in Cologne, Germany, where a study of 40 healthy people found an 
Acinetobacter carriage rate of 42.5%, with 58% of isolates accounted for by A. 
lwoffii, 20% by A. johnsonii, and 10% by A. junii (Seifert et al., 1997). However, a 
study of skin carriage by student nurses and medical students in Hong Kong found an 
Acinetobacter carriage rate of 37.8%, but that Acinetobacter genospecies 3 was the 
most prevalent accounting for 32% of isolates, with Acinetobacter genospecies 13TU 
the second most prevalent accounting for 12% (Chu et al., 1999). It is possible that 
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the difference in the skin flora observed in the study from Hong Kong may be due to 
the study group being in contact with hospitalised patients, where carriage of 
Acinetobacter species 3 and 13TU is more common. 
While it is clear that the natural environment of many of the members of the genus 
Acinetobacter is aquatic or in soil, there is debate as to the natural habitat of a few 
species. In particular, A. baumannii, Acinetobacter genospecies 3 and Acinetobacter 
genospecies 13TU are generally not found in environmental samples, but rather in 
the hospital environment and in clinical samples.  
 
1.2 Acinetobacter infections. 
1.2.1  Acinetobacter community-acquired infections. 
Some members of the genus Acinetobacter have risen to prominence relatively 
recently due to the increasing number of human infections that they are causing. 
While many members of the genus have been identified as causing infection, the 
majority of these species have only been associated wi h infection rarely, or indeed 
on only one recorded occasion. However, three species are implicated in causing 
infections far more regularly. These are A. baumannii, Acinetobacter genospecies 3 
and Acinetobacter genospecies 13TU. In particular, infections with A. baumannii are 
a particular problem as they can be difficult to trea . Acinetobacter species are 
opportunistic pathogens, and generally only cause infections in people who are 
immunocompromised due to a previous underlying condition. In the community 
setting, reports of infections due to Acinetobacter species have been reported, though 
they are infrequent. A review of these reports found that in the majority of 
community cases patients were diagnosed with pneumonia, with most of the 
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remaining cases diagnosed as bacteraemia. The vast majority of patients were found 
to have underlying co-morbidities including chronic obstructive pulmonary disease, 
diabetes mellitus, renal disease, excess alcohol consumption and smoking. Infections 
were almost all reported to be due to A. baumannii; however due to the difficulties in 
species identification within the genus, and particularly between members of the A. 
baumannii-A. calcoaceticus complex, it is possible that other species were involved. 
Mortality associated with infections was high at 56%, though this is likely to be an 
over-estimation as mild cases of Acinetobacter infection will not have been reported. 
Interestingly the majority of the reports originated from areas with tropical or sub-
tropical climates. Whether this is due to geographical and climatic, or social factors 
is not clear (Falagas et al., 2007). 
 
1.2.2 Acinetobacter hospital-acquired infections. 
While community-acquired Acinetobacter infections are rare, hospital-acquired 
infections are far more common, and of a greater concern. Infections are associated 
with immunocompromised patients, with infection rates often being highest in 
intensive care units (ICUs) and surgical wards. Comm nly the organisms cause 
pneumonia, particularly associated with mechanical ventilation, and bloodstream 
infections following invasive procedures (Peleg et al., 2008). The three species that 
are regularly implicated in cases of hospital-acquired nfection are A. baumannii, 
Acinetobacter genospecies 3 and Acinetobacter genospecies 13TU. Usually, 
epidemiological surveys have identified A. baumannii to be by far the most frequent 
cause of infection, though there are reports of higher rates of isolation of 
Acinetobacter genospecies 3 (Lim et al., 2007, Chen et al., 2007, Ecker et al., 2006, 
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Boo et al., 2009). While Acinetobacter genospecies 3 and 13TU tend to cause 
infections sporadically and are usually relatively susceptible to antimicrobials, the 
same cannot be said of A. baumannii. Crude mortality rates for Acinetobacter species 
other than A. baumannii have been found to be low, with values between 7% and 
18% being reported (Choi et al., 2006, Seifert et al., 1994). However, crude mortality 
rates of between 8% and 43% have been reported for A. baumannii (Falagas et al., 
2006). Additionally, the length of stay in hospital associated with A. baumannii 
infection was significantly longer than that for other Acinetobacter species (Choi et 
al., 2006). Outbreaks of A. baumannii are often clonal, and the spread of clones or 
lineages can be seen nationally and internationally. A arge number of infections 
globally can be attributed to three of these epidemc lineages, that have been termed 
European clones I, II and III (Dijkshoorn et al., 1996, van Dessel t al., 2004). In the 
UK there is an ongoing infection control problem relating to the circulation of 
several clonal lineages of A. baumannii, termed the South-East clone (SE clone), 
OXA-23 clone I and OXA-23 clone II (Coelho et al., 2006b). The reason why some 
lineages of A. baumannii are particularly successful and spread internationlly is 
unclear, but at least part of the answer is likely to lie in the relatively high level of 
multiple antimicrobial resistance, and the ability to acquire and maintain resistance 
determinants, that these lineages possess. It is for the reasons mentioned above that 
of all of the species belonging to the Acinetobacter genus, it is A. baumannii that is 





1.3 Antimicrobials and A. baumannii. 
The rise in the number of infections caused by A. baumannii over the recent decades 
is of great concern due to the difficulties that are faced in administrating effective 
antimicrobial treatment. Intrinsic properties of the species such as chromosomally-
encoded β-lactamases, an effective permeability barrier, and the ability to acquire 
and maintain resistance determinants on mobile genetic el ments, have severely 
reduced the number of effective antibiotics that can be used against some isolates, in 
a few cases to zero (Valencia et al., 2009). These features have resulted in the 
elimination of the penicillins, cephalosporins, aminoglycosides, quinolones and 
tetracyclines as effective treatment options for many A. baumannii solates. This has 
left the carbapenems as the only sustainable group of antibiotics to treat infections 
with A. baumannii, due to their good activity and low toxicity. 
 
The carbapenems are a subgroup of the β-lactam antibiotics and have the broadest 
spectrum of activity within this group. The first carbapenem to be approved for use 
was imipenem in 1985, a stable derivative of thienamycin, discovered in the 1970s to 
be produced by Streptomyces cattleya. This was followed by meropenem in 1993, 
ertapenem in 2001, and most recently by doripenem in 2007 (Livermore, 2009). As 
with other β-lactams, the carbapenems bind to the penicillin-binding proteins in the 
bacterium, preventing the final transpeptidation of the peptidoglycan in the cell wall, 
ultimately resulting in the cell breaking down its own cell wall, causing cell death. 
The carbapenems are stable in the presence of most β-lactamases due to the presence 
of a trans-α-1-hydroxyethyl group at position 6, which protects the molecule from 
hydrolysis of the bond between positions 4 and 7 (Figure 1) (Zhanel et al., 2007). 
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However, in recent years there has been a worrying ise in the number of A. 
baumannii infections that are resistant to the carbapenems. The ability of A. 
baumannii isolates to resist the action of the carbapenems by various mechanisms 





Figure 1: Chemical structures of the carbapenem β-lactams. The positions on the 
penem and β-lactam rings are numbered in the imipenem structure. 
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1.4 A. baumannii non-enzymatic β-lactam resistance mechanisms. 
1.4.1  Penicillin-binding proteins. 
Alterations to penicillin-binding proteins (PBPs) such that β-lactam antibiotics can 
no longer bind to them is a mechanism of resistance that is observed in many 
bacterial species (Zapun et al., 2008). In A. baumannii there have been few reports 
where PBPs have been examined. Where they have, it has been concluded that this 
resistance mechanism may be able to confer a low level of resistance to the 
carbapenems (Gehrlein et al., 1991, Fernandez-Cuenca et al., 2003). However, in 
these studies the β-lactam resistance observed could also be attributed to other 
enzymatic and non-enzymatic mechanisms of resistance (see below). Indeed, since 
the discovery of the enzymatic mechanisms of resistance described below, β-lactam 
resistance could be attributed to these mechanisms. Alteration of PBPs in A. 
baumannii is poorly studied, and it is likely that alterations in PBPs make a small but 
important contribution towards carbapenem resistance, particularly in A. baumannii 
isolates that lack an acquired carbapenemase. Further studies examining all the 
varied elements that may contribute to β-lactam resistance in A. baumannii would 
allow the role of the PBPs to be elucidated fully. 
 
1.4.2  Outer membrane proteins. 
A resistance mechanism that is found in many bacteri  hat can confer reduced 
susceptibilities to a number of antibiotic classes i  the loss of outer membrane 
proteins (OMPs) that facilitate the transport of the antibiotic molecules across the 
cell membrane (Delcour, 2009). In A. baumannii, the loss of OMPs of several 
different sizes has been reported. Decreased expression of OMPs of sizes 33-36 kDa, 
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22 and 33 kDa, 29 kDa (subsequently named CarO), and 43 kDa (a protein with 
similarities to the important OprD OMP from Pseudomonas aeruginosa) have been 
observed in isolates that are resistant to the carbapenems (Clark, 1996, Bou et al., 
2000a, Limansky et al., 2002, Dupont et al., 2005). Additionally, it has been 
demonstrated that a carbapenem-resistant A. baumannii solate had a modified form 
of the CarO protein when compared to a sensitive isolate (Siroy et al., 2006). As with 
the PBPs, it is likely that reduced expression or mdification of OMPs, while not 
conferring high levels of carbapenem resistance by themselves, make an important 
contribution in concert with other mechanisms to increased carbapenem resistance. 
 
1.4.3  Efflux. 
Efflux systems that actively pump antibiotics out of he cell are able to confer 
resistance to a wide range of antibiotic classes and are common amongst bacteria 
(Van Bambeke et al., 2000). There are a number of different families of related 
efflux pumps, but in A. baumannii the best studied of these belong to the resistance-
nodulation-division (RND) family, in particular the AdeABC pump, and these have 
been found to be able to transport β-lactams out of the bacterium. There are three 
components of this pump, the adeA, adeB and adeC genes, which encode the 
membrane fusion component, the drug transporter component and the outer 
membrane porin respectively. Together with the two regulatory genes adeR and 
adeS, they are widespread in A. baumannii solates particularly within the epidemic 
lineages, though adeC is less frequent as it is not thought to be an essential 
component for efflux (Nemec et al., 2007). The pump has been shown to contribute 
towards cefotaxime resistance, and to high levels of carbapenem resistance in 
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combination with acquired carbapenemases (Heritier e  al., 2005b, Magnet et al., 
2001). 
 
1.5 A. baumannii enzymatic β-lactam resistance mechanisms. 
1.5.1  Class A β-lactamases. 
The Ambler class A β-lactamases hydrolyse variously the penicillins andthe 
cephalosporins and are generally susceptible to β-lactamase inhibitors. This enzyme 
group includes the majority of the extended-spectrum β-lactamases (ESBLs) as it 
encompasses the TEM, SHV and CTX-M enzyme families. Class A β-lactamases 
appear to be reasonably widespread in A. baumannii. The gene encoding the enzyme 
PER-1 has been found in many isolates in the USA, Korea and Turkey (Hujer et al., 
2006, Kim et al., 2008, Poirel et al., 2005a), and a large number of isolates from 
France and Belgium possess the gene for the VEB-1 enzyme (Naas et al., 2006b, 
Naas et al., 2006a). Isolates encoding TEM-, SHV- and CTX-M-type enzymes have 
also been described (Naas et al., 2007, Nagano et al., 2004, Hujer et al., 2006). Due 
to generally widespread high levels of resistance i A. baumannii to the penicillins 
and cephalosporins conferred by the intrinsic class C β-lactamases, these drugs are 
not usually considered appropriate for treatment of A. baumannii nfections. As such, 
the prevalence of the class A β-lactamases in A. baumannii s not of major public 
health concern in itself; however the potential of this species to act as a reservoir for 





1.5.2  Class B β-lactamases. 
The Ambler class B β-lactamases (often called the metallo-β-lactamases) differ from 
the class A, C and D enzymes in that they have one or two metal ions, usually zinc, 
in their active site rather than a serine residue. Th se enzymes are able to hydrolyse 
to various degrees all of the β-lactam antibiotics except for aztreonam, and are not 
inhibited by β-lactamase inhibitors (Walsh et al., 2005). Enzymes of the IMP and 
VIM families in particular are becoming more common in A. baumannii especially in 
areas such as the Far East, South America, and Greece (J ong et al., 2006, Koh et al., 
2007, Tsakris et al., 2008, Fritsche t al., 2005). The enzymes are usually carried on 
integrons, and this mobility combined with their ability to hydrolyse the 
carbapenems makes these enzymes a potential problem for successful antibiotic 
therapy. However, in A. baumannii the metallo-enzymes often appear to be 
expressed at low levels, and their presence can be difficult to detect phenotypically 
(Ikonomidis et al., 2008). 
 
1.5.3  Class C β-lactamases. 
The genes for Ambler Class C β-lactamases, also referred to as AmpC enzymes, are 
commonly found on the chromosome in Gram-negative organisms. As well as these 
intrinsic enzymes, there are several families of plasmid-borne ampC genes that are 
spreading particularly within the Enterobacteriaceae (Jacoby, 2009). In 
Acinetobacter species the class C enzymes are referred to as ADC enzymes, for 
Acinetobacter-derived cephalosporinases (Hujer et al., 2005). As this name implies, 
these enzymes are able to hydrolyse penicillins and the narrow-spectrum 
cephalosporins. When over-expressed, the enzymes can confer resistance to the 
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extended-spectrum cephalosporins, except for the fourth-generation cephalosporins. 
In other Gram-negative species, expression of the ampC gene is inducible, but in A. 
baumannii the genes are expressed when the insertion sequence ISAba1 inserts 
upstream of the gene where it provides a promoter fr gene expression (Corvec t al., 
2003). The widespread nature of the blaADC genes is the major reason for high levels 
of resistance in A. baumannii to the penicillins and cephalosporins and as such these 
drugs are generally not effective for treatment of this organism. 
 
1.5.4  Class D β-lactamases. 
1.5.4.1   The OXA-23-like enzymes. 
The enzyme OXA-23, originally named ARI-1, was first dentified in an A. 
baumannii strain from Scotland isolated in 1985 with an MIC for imipenem of 16 mg 
L-1 (Paton et al., 1993). The enzyme was shown to confer resistance to imipenem, 
and subsequent sequence analysis identified the enzyme as belonging to the Ambler 
class D β-lactamases (Donald et al., 2000). Two further enzymes with 99% amino-
acid identity to OXA-23 have been identified in A. baumannii and named OXA-27 
and OXA-49. OXA-27 was identified in an isolate from Singapore isolated between 
1995 and 1997 (Afzal-Shah et al., 2001), and OXA-49 was associated with an isolate 
from China and the sequence published online in 2003 (accession number 
AY288523). Recently, five further enzymes named OXA-102, OXA-103, OXA-105, 
OXA-133 and OXA-134 have been identified in isolates of Acinetobacter 
radioresistens (Poirel et al., 2008, Mendes et al., 2009, Boo and Crowley, 2009). 
These eight enzymes constitute the OXA-23-like enzyme group (Table 2). Limited 
kinetic analyses of the OXA-23, OXA-27 and OXA-49 enzymes demonstrate they 
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OXA-23-like OXA-23, OXA-27, OXA-49, OXA-102, C and P A. baumannii, A. junii, A. radioresistens, Acinetobacter
OXA-103, OXA-105, OXA-133, OXA-134 genomic species 3, Proteus mirabilis, Acinetobacter phenon 5,  
Acinetobacter phenon 6/ct 13TU, Acinetobacter genomic species 13TU,
Acinetobacter genomic species 10/11, A. lwoffii
OXA-40-like OXA-40, OXA-25, OXA-26, OXA-72 C and P A. baumannii, A. haemolyticus, Acinetobacter genomic species 3,
A. baylyi, Pseudomonas aeruginosa
OXA-51-like OXA-51, OXA-64 to OXA-71, C A. baumannii, Acinetobacter  genomic species 13TU
OXA-75 to OXA-80, OXA-82 to OXA-84, 
OXA-86 to OXA-95, OXA-98 to OXA-100, 
OXA-104, OXA-106 to OXA-113, 
OXA-115 to OXA-117, OXA-120 to OXA-127
OXA-58-like OXA-58, OXA-96, OXA-97 C and P A. baumannii, A. junii, Acinetobacter genomic species 3,
Acinetobacter genospecies 13TU, Acinetobacter phenon 6/ct 13TU,
Acinetobacter  genomic species 9, Acinetobacter  genomic species 10,
A. calcoaceticus, A. radioresistens
Group Group Members Host SpeciesLocation
 
Table 2: Summary of the class D OXA-type β-lactamases found in Acinetobacter species (Poirel et al., 2008, De Champs et al., 2002, 
Villegas et al., 2007, Heritier et al., 2005b, Marque t al., 2005, Wang et al., 2007, Afzal-Shah et al., 2001, Bou et al., 2000b, Ruiz et al., 
2007, Da Silva et al., 2004, Turton et al., 2006a, Merkier and Centron, 2006, Brown et al., 2005, Brown and Amyes, 2005, Vahaboglu et 
al., 2006, Tsakris et al., 2007, Evans et al., 2007, Heritier et al., 2005a, Koh et al., 2007, Naas et al., 2007, Bogaerts et al., 2006, Coelho et 
al., 2006b, van Dessel t al., 2004, Poirel et al., 2006, Coelho et al., 2006a, Lee t al., 2009, Sevillano et al., 2008, Boo and Crowley, 2009, 
Mendes et al., 2009b, Chu et al., 2009). C, chromosomal; P, plasmid.
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hydrolyse aminopenicillins and oxacillin, and weakly hydrolyse oxyimino-
cephalosporins and carbapenems (Paton e  al., 1993, Afzal-Shah et al., 2001). 
However, differences were observed between OXA-23 and OXA-27, with OXA-23 
having a higher activity against cephaloridine and oxacillin and less activity against 
carbapenems than OXA-27 (Afzal-Shah et al., 2001). 
 
The OXA-23-like enzymes have been found in a variety of Acinetobacter species, as 
well as in isolates of Proteus mirabilis, and their genes can be chromosomally 
located or located on a variety of different plasmids (Table 2) (Bogaerts et al., 2006, 
Bonnet et al., 2002). The G+C content of the blaOXA-23-like genes is 37.6-37.9 % 
(Bergogne-Berezin and Towner, 1996), which is outside the 39-47% range for the A.
baumannii genome, suggesting that these genes have evolved in another species. The 
recent identification of blaOXA-23, blaOXA-102, blaOXA-103, blaOXA-105, blaOXA-133 and 
blaOXA-134 genes on the chromosome of several Acinetobacter radioresistens i olates 
suggests that the OXA-23-like enzymes may have originated in that species (Poirel et 
al., 2008). Isolates encoding OXA-23 have been found worldwide and are frequently 
associated with outbreaks of hospital infection (Villegas et al., 2007, Zhou et al., 
2007, Coelho et al., 2006b, Heritier et al., 2005b, Marque t al., 2005). Of particular 
concern is the recent increase in reports of carbapenem-resistant A. baumannii 
isolates encoding OXA-23 from South America and South-East Asia. A survey of 
542 A. baumannii solates from 10 institutions in Colombia found an average of 
33.6% of isolates resistant to a carbapenem, and in a subset of 66 of these resistant 
isolates, 65 were positive by PCR for blaOXA-23 (Villegas et al., 2007). In a teaching 
hospital in China rates of carbapenem resistance hav  increased from 5% in the 
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period 1993 to 2003 to greater than 50% in isolates from ICU wards and 20% in non-
ICU isolates in 2004; and a subsequent study of 221 resistant isolates from 11 
institutions, including 117 isolates from the same teaching hospital, found 97.7% 
were positive for a blaOXA-23-like gene (Wang et al., 2007). 
 
In vivo the OXA-23 β-lactamase contributes towards resistance to amoxicillin, 
ticarcillin, meropenem and imipenem. When transformed into susceptible blaOXA-23-
negative recipient strains, the enzyme confers intermediate to low level resistance to 
carbapenems, with the higher of these values achieved in combination with over-
expression of the RND-type AdeABC efflux pump. However, when a naturally-
occurring plasmid containing the blaOXA-23 gene is electro-transformed into the same 
recipient strains, moderate to high MICs are achieved of 16 to >32 mg L-1, with the 
highest values again found in the recipient over-expr ssing the AdeABC efflux 
pump, indicating the involvement of other genetic fa tors associated with the blaOXA-
23 gene in conferring resistance (Heritier et al., 2005b).  
 
1.5.4.2   The OXA-40-like enzymes 
OXA-40, originally named OXA-24, was first identified in A. baumannii solates 
responsible for an outbreak of infection in a hospital in Spain in 1997 (Bou et al., 
2000b). Two further enzymes named OXA-25 and OXA-26, both with >99% amino-
acid identity to OXA-40, were identified in isolates from Belgium and Spain isolated 
between 1995 and 1997 respectively (Afzal-Shah et al., 2001). A fourth enzyme also 
with >99% amino-acid identity to OXA-40, named OXA-72, was identified in an 
isolate from Thailand and the sequence published online in 2004 (accession number 
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AY739646). These four enzymes constitute the OXA-40-like enzyme group (Table 
2). 
 
Kinetic studies carried out on OXA-40, OXA-25 and OXA-26 demonstrate that these 
enzymes are capable of hydrolysing penicillins, have weak activity against 
carbapenems, and very weak activity against some cephalosporins (Heritier et al., 
2003, Afzal-Shah et al., 2001, Bou et al., 2000b). All three enzymes show greater 
hydrolytic activity against imipenem than meropenem, with OXA-40 being the most 
active. The recent description of the crystal structure of OXA-40 provides insights 
into the substrate specificity of the enzyme (Figure 2) (Santillana et al., 2007). 
Analysis of the arrangement of the active site elemnts demonstrates similarities 
between OXA-40 and the structures of other non-A. baumannii class D oxacillinases, 
and therefore does not explain the different substrate specificity of increased 
carbapenem and reduced oxacillin hydrolysis of this enzyme. However two residues, 
Tyr-112 and Met-223, interact to form a hydrophobic tunnel that restricts access to 
the active site of the enzyme. Modelling predicts that molecules such as oxacillin, 
which has a large methylphenylisoxazolyl moiety, will therefore have their access to 
the active site reduced, while imipenem and meropenem with their small 
hydroxyethyl moieties are able to gain access more easily. Experiments on the OXA-
40 β-lactamase with the Tyr-112 and Met-223 residues replac d with alanine 
demonstrated that the more enclosed hydrophobic environment surrounding the 
active site is also responsible for correctly orientati g carbapenems for hydrolysis, 




Figure 2: Structure of OXA-40 (modified from Santillana et al., 2007). The α-helix 
domain is shown in dark blue, the β-sheet of the mixed α/β domain is in cyan, and 
the α-helices are in red. The active site residues are found in the β4 strand, the α3 
helix, and the loop between the α4 and α5 helices. 
 
 
Despite only weak activity against the carbapenems of the purified enzyme, isolates 
encoding an OXA-40-like enzyme typically return MICs of >16 mg L-1 (Ruiz et al., 
2007). A study by Heritier et al (2005b) demonstrated that in vivo the OXA-40 
enzyme confers resistance to carbapenems as well as raising MICs to penicillins and 
cephalosporins. However, when transformed into susceptible reference A. baumannii 
strains the enzyme only confers intermediate to low level resistance, with the higher 
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of these values associated with an isolate over-expessing the AdeABC efflux pump, 
suggesting that a combination of mechanisms is requir d to achieve the high levels of 
resistance seen in clinical isolates. 
 
The G+C content of the blaOXA-40-like genes is 33.9-34.3%, which differs from the 
content of the A. baumannii genome of 39-47%, suggesting that these genes 
originated in another species (Bergogne-Berezin and Towner, 1996). The blaOXA-40-
like genes have been found in four species of Acinetobacter and in Pseudomonas 
aeruginosa, and to be both chromosomally and plasmid located (Table 2). While it 
has been found on a variety of different plasmids, the specific plasmid sizes have not 
been reported. Isolates encoding the enzymes have been reported in Asia (Wang et
al., 2007, Mendes et al., 2009b, Lee et al., 2009), Belgium (Afzal-Shah et al., 2001) 
and the USA (Lolans et al., 2006), but the major geographic foci of the enzymes are 
Spain and Portugal (Ruiz et al., 2007, Da Silva et al., 2004, Quinteira et al., 2007, 
Sevillano et al., 2008). It is of concern that on the Iberian Peninsula there appears to 
be a high prevalence of the blaOXA-40-like genes. A recent study of 83 carbapenem-
resistant A. baumannii solates from 12 hospitals in Spain found 42% of is lates were 
positive for a blaOXA-40-like gene (Ruiz et al., 2007). A second recent study from a 
hospital in Portugal found that of 222 imipenem-resistant A. baumannii collected 
over the period of January 2001 to October 2004, 36.6% carried a blaOXA-40 gene, the 
majority of which were associated with plasmid DNA, which was also found in 
Acinetobacter haemolyticus i olates in the same institution (Quinteira et al., 2007). 
The identification of a high percentage of blaOXA-40-like genes on plasmids presents 
the worrying possibility of these genes becoming more globally established. 
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1.5.4.3   The OXA-51-like enzymes 
The OXA-51-like β-lactamases are an enzyme group that are intrinsic a d ubiquitous 
in A. baumannii (Merkier and Centron, 2006, Turton et al., 2006b). The first enzyme 
of the group, OXA-51, was reported in 2004 in isolates obtained from Argentina in 
1996 (Brown et al., 2005), and a large number of related enzymes have since been 
discovered. At the start of this project there were 32 enzymes making up the OXA-
51-like group. The OXA-51-like enzymes now represent one of the largest groups of 
β-lactamases, with 60 enzymes currently identified (Table 2) (The Lahey Clinic, 
http://www.lahey.org/Studies/, accessed on 15th July 2009). The blaOXA-51-like genes 
have generally been found to be chromosomally located nd non-transferable. 
However, in one report, PCRs for blaOXA-51-like genes using plasmid DNA as a 
template were positive, and the blaOXA-51-like gene could be cured from these isolates 
(Pournaras et al., 2006), and a second report mentions that the invstigators were 
able to transfer a blaOXA-51-like gene to Escherichia coli (Vahaboglu et al., 2006), 
suggesting that it may be possible for these genes to be plasmid-borne. All blaOXA-51-
like genes identified so far have been found in A. baumannii except for one, blaOXA-
138. This gene has been identified in an Acinetobacter genospecies 13TU isolate from 
Taiwan, further suggesting that there is the potential for these genes to be mobilised 
(Genbank accession number EU670845). However, the difficulties of species 
identification in the genus should be borne in mind when interpreting such data. The 
G+C content of the genes is 38.4-39.9%, which is similar to the content of the A. 
baumannii genome of 39-47%, lending further weight to the suggestion that these 
genes are native to A. baumannii (Bergogne-Berezin and Towner, 1996). 
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The contribution to resistance of these enzymes in A. baumannii has yet to be fully 
resolved. Kinetic analysis has only been performed on two enzymes – OXA-51 and 
OXA-69 (Brown et al., 2005, Heritier et al., 2005a). Both enzymes demonstrate poor 
hydrolysis of oxacillin and cloxacillin, a feature that has been observed in 
carbapenem-hydrolysing oxacillinases (Afzal-Shah et al., 2001, Bou et al., 2000b). 
High Km values for imipenem and meropenem in OXA-69 indicate a poor affinity for 
these substrates, but OXA-51 has a low Km for imipenem, suggesting a much higher 
affinity. However, OXA-69 weakly hydrolyses imipenem and meropenem, while 
OXA-51 weakly hydrolyses imipenem but not meropenem. The contribution of the 
enzymes to carbapenem resistance has been difficult to determine. Every member of 
the species possess a bl OXA-51-like gene, yet only a sub-set demonstrate carbapenem 
resistance. It has been suggested that the blaOXA-51-like genes are generally poorly 
expressed, and that they may only confer resistance when they have had their 
expression level increased with the insertion of a promoter on an ISAba1 insertion 
sequence element upstream of the gene (Turton et al., 2006a).   
 
There is a large degree of diversity within the OXA-51-like enzymes, with members 
differing by up to 16 amino-acids. Within the OXA-51-like enzymes there are 
subgroups or clusters of enzymes that are associated wi h certain epidemic lineages 
(Evans et al., 2008). The large group of enzymes clustered around the OXA-66 β-
lactamase are found in isolates belonging to an A. baumannii lineage including the 
prevalent European clone 2, while those clustered aound the OXA-69 enzyme are 
found in another lineage encompassing European clone 1. The OXA-71 enzyme is 
associated with European clone 3. The most commonly identified enzymes are those 
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of the OXA-66 cluster, which are particularly highly represented in South America 
and Asia (Merkier and Centron, 2006, Wang et al., 2007, Koh et al., 2007, Evans et 
al., 2008). Enzymes of the OXA-69 cluster are also comm n, particularly in eastern 
Europe (Evans et al., 2008). Additionally OXA-71 is regularly identified and due to 
its association with European clone 3, is often identifi d in isolates from the Iberian 
Peninsula (van Dessel t al., 2004, Evans et al., 2008). It is unknown whether 
sequence variations in the OXA-51-like enzymes contribute to increased resistance 
or an altered spectrum resulting in certain enzymes being selected thus altering allele 
frequencies, or if certain enzymes are more prevalent than others. 
 
1.5.4.4   The OXA-58-like enzymes 
The enzyme OXA-58 was first identified in an A. baumannii clinical isolate in 2003 
in France (Poirel et al., 2005b). The enzyme shares 48% and 49% amino-acid 
identity with OXA-23 and OXA-40 respectively, and was localised to a 30 kb 
plasmid. Two enzymes closely related to OXA-58 have since been identified. An A. 
baumannii isolated in 1996 from a hospital in Singapore contained a β-lactamase 
named OXA-96, which differs from the OXA-58 enzyme by a methionine 
substituting isoleucine at position 161 (Koh et al., 2007), and an enzyme named 
OXA-97 which differs from OXA-58 by a glycine substitu ing an alanine at position 
53 has been identified in A. baumannii solates in a hospital in Tunisia (Genbank 
accession number EF102240). These three enzymes constitute the OXA-58-like 
enzyme group (Table 2). 
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Kinetic analysis of OXA-58 has shown that it has similar properties to the other 
OXA-type carbapenemases of A. baumannii. The purified enzyme has weak activity 
against penicillins and imipenem, very weak activity against meropenem, and some 
activity against cephalothin and cefpirome, but not against ceftazidime or cefotaxime 
(Poirel et al., 2005b). However, OXA-58 hydrolyses imipenem twice as efficiently as 
OXA-40. When a plasmid carrying the blaOXA-58 gene was transformed into two 
susceptible A. baumannii reference strains, it resulted in greatly increase MICs of 
amoxicillin and ticarcillin but only very small increases in carbapenem MICs, to 
which the strains remained susceptible. However, when a plasmid containing the 
blaOXA-58 gene from a clinical isolate was transformed into the same reference strains, 
the MICs of carbapenems increased significantly in the strain over-expressing the 
AdeABC efflux pump (MICs of imipenem and meropenem of 32 mg L-1). In the 
second strain, MICs were higher than when the strain w s transformed with the 
artificial OXA-58 plasmid, though the strain remained sensitive (MICs = 2 mg L-1) 
(Heritier et al., 2005b). This demonstrates that isolates carrying a blaOXA-58-like gene 
may require a combination of factors to achieve high level carbapenem resistance. 
 
OXA-58-like enzymes have been found in a range of Acinetobacter species and are 
usually plasmid borne, though chromosomal location has been described (Bogaerts e  
al., 2006, Poirel et al., 2006). The G+C content of the blaOXA-58-like genes is 37.4-
37.5%, which is slightly lower than the A. baumannii genome content of 39-47% 
(Bergogne-Berezin and Towner, 1996), indicating that ese genes may have 
originated in another species. Isolates carrying blaOXA-58-like genes are most frequently 
reported from Europe, though the genes have been reported in isolates from South 
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America, North America, Asia Minor, Asia and Australia (Marque et al., 2005, Peleg 
et al., 2006, Coelho et al., 2006a, Koh et al., 2007, Wang et al., 2007, Lee et al., 
2009, Mendes et al., 2009b, Zarrilli et al., 2008, Castanheira et al., 2008).  
 
1.6 The role of mobile elements in resistance. 
1.6.1  Insertion sequences. 
1.6.1.1   ISAba1.  
The insertion sequence ISAba1 was first described in A. baumannii solates from 
2001, where it was found upstream of genes encoding the chromosomal class C β-
lactamases, the ADC enzymes (Corvec et al., 2003). However, it was noted that 
sequences with identity to this new insertion sequence had been identified upstream 
of the phaBAC gene encoding an acetoacetyl-CoA reductase, as well as upstream of 
the original blaARI-1 gene (now blaOXA-23) in A. baumannii solates previously. The 
element encodes two over-lapping open reading frames which, following a frame-
shift during translation, form a functional transpoase that is responsible for the 
transposition activity of the element (Mugnier et al., 2009). It has been demonstrated 
that when ISAba1 is found 9 base-pairs upstream of the blaADC gene in the opposite 
orientation to the β-lactamase gene it provides a promoter located between the 
transposase coding region and the inverted-repeat left that is responsible for 
increasing the expression of the blaADC gene (Heritier et al., 2006). 
 
It has been suggested that the insertion of ISAba1 upstream of the blaOXA-23 gene 
increases the level of blaOXA-23 expression in a similar manner to the role it plays in 
increasing blaADC expression, as the insertion sequence has been found upstream of 
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blaOXA-23 in >97% of carbapenem-resistant isolates (Zhou et al., 2007, Turton et al., 
2006a, Heritier et al., 2006). Recent studies have shown that ISAba1 inserted 25 bp 
upstream of the blaOXA-23 gene contains sequences which can act as promoters f r its 
expression (Corvec et al., 2007, Segal et al., 2007). As well as potentially increasing 
expression, the insertion sequence may explain the wid spread prevalence of blaOXA-
23 genes both in A. baumannii and in other Acinetobacter species as it can a form 
putative transposon named Tn2006 (Corvec et al., 2007). As shown in Figure 3, the 
blaOXA-23 gene can be flanked by two oppositely orientated ISAba1 sequences. The 
nine base-pair target site duplications after the inv rted-repeat right of the upstream 
insertion sequence, and after the inverted-repeat right of the downstream insertion 
sequence, suggest that the whole structure can be mo ilised through transposition 
events. 
 
Similarly to its association with blaADC and blaOXA-23 genes, it has also been 
suggested that ISAba1 increases the expression of the blaOXA-51-like genes (Turton et 
al., 2006a). Comparisons of imipenem-resistant and imipenem-susceptible isolates 
from Taiwan demonstrated that the resistant isolates (MICs of imipenem and 
meropenem of 8 and 32 mg L-1 respectively to >32 mg L-1 for both antibiotics) had 
increased expression levels of their blaOXA-51-like genes relative to the susceptible 
isolates (MICs of imipenem and meropenem of 1 and 0.38 mg L-1 to 3 and 1.5 mg L-1 
respectively), and that all of the resistant isolates were positive by PCR for an 
ISAba1 sequence 7bp upstream of the blaOXA-51-like gene while the sensitive isolates 
were not (Hu et al., 2007). Similar results were obtained in a study of Spanish 
isolates, where two isolates of the same pulsetype differed in blaOXA-51-like gene  
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Figure 3: The interaction of ISAba1 with resistance determinants. A, ISAba1 
twenty-one base-pairs upstream of the sulphonamide resistance gene sulII (Segal et 
al., 2005); B, the chromosomal class C β-lactamase of A. baumannii with ISAba1 
nine base-pairs upstream (Heritier et al., 2006); C, ISAba1 upstream of the 
aminoglycoside-modifying enzyme aac6’1b (Naas et al., 2007); D; the intrinsic 
blaOXA-51-like β-lactamase of A. baumannii with ISAba1 seven base-pairs upstream 
(Turton et al., 2006a); E, the gene for the outer-membrane porin CarO is disrupted by 
an ISAba1 insertion (Lu et al., 2009); F, ISAba1 disrupts the insertion sequence 
IS1133 upstream of the aminoglycoside-modifying enzyme aacC2 (Segal et al., 
2003); G, ISAba1 upstream of the blaOXA-58 β-lactamase gene (Poirel and Nordmann, 
2006); H, the composite transposon Tn2006 potentially responsible for the 
mobilisation of the blaOXA-23 β-lactamase gene (Corvec t al., 2007). DEAD, putative 
DEAD helicase; DNA methyl, DNA methylase; sulf, sulphonamide resistance gene. 
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expression with the isolate containing ISAba1 7bp upstream of the gene having a 
higher level of expression than the isolate with ISAba1 elsewhere in the genome 
(Ruiz et al., 2007). Recently, the insertion of ISAba1 upstream of blaOXA-66 was 
observed in vivo, and this resulted in a doubling of the MICs to imipenem (from 2 to 
4 mg L-1) and to meropenem (from 3 to 6 mg L-1) (Figueiredo et al., 2009). 
Additionally, measurement of the expression levels of the blaOXA-66 gene in the 
isolates demonstrated that the insertion of ISAba1 had resulted in a 50-fold increase 
in gene expression. However it is unclear whether up- egulation of the blaOXA-51-like 
gene alone can be sufficient or responsible for clinically significant levels of 
resistance to carbapenems in some isolates, and what the contribution may be of 
other resistance mechanisms working in concert, such as reduced outer membrane 
permeability (Hu et al., 2007). 
 
ISAba1 has also been found in association with a variety of other genes involved in 
antimicrobial resistance (Figure 3). These include the sulphonamide resistance gene 
sulII (Segal et al., 2005), genes encoding aminoglycoside-modifying ezymes such 
as aac6’1b and aacC2 (Naas et al., 2007, Segal et al., 2003), and the β-lactamase 
blaOXA-58 (Poirel and Nordmann, 2006). The element has also been implicated in 
decreased membrane permeability through insertional nactivation of the gene 
encoding the pore-forming CarO protein (Lu et al., 2009), and in over-expression of 
the AdeABC efflux pump through insertional inactivaon of the regulatory gene 




1.6.1.2   ISAba3. 
The insertion sequence ISAba3 was first identified bracketing a blaOXA-58 gene in an 
A. baumannii solate from 2003 (Poirel et al., 2005b). The element contains a single 
open reading frame that encodes its transposase. ISAba3 has been found to be 
commonly associated with blaOXA-58 genes (Poirel et al., 2006, Tsakris et al., 2008, 
Zarrilli et al., 2007). The element can be found upstream and in the opposite 
orientation to blaOXA-58, where it is able to provide a promoter which is thought to 
increase the expression of the β-lactamase. The element is also commonly found 
downstream of blaOXA-58, and it has been suggested that ISAba3 plays a role in the 
dissemination of this enzyme, though possibly through homologous recombination 
rather than through transposition (Poirel and Nordmann, 2006). 
 
1.6.1.3   Other insertion sequences. 
In addition to ISAba1 and ISAba3 which are commonly found in association with 
resistance determinants in A. baumannii, there are several other insertion sequences 
that have been identified in similar roles, though to be less abundant. 
 
The insertion sequence ISAba4 has been found 25 bp upstream of blaOXA-23 and to 
contain promoter sequences which again may play a role in increased gene 
expression (Corvec et al., 2007). Additionally, downstream of the blaOXA-23 gene 
there is a truncated ATPase gene, followed by a sequence identical to the sequence at 
the end of the right inverted-repeat of ISAba4. This was proposed as a potential 
transposon named Tn2007, and it was suggested that the transposon mobilised the 
blaOXA-23 gene through a one-ended transposition mechanism (Corvec et al., 2007). 
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ISAba2 is an insertion sequence that is usually identified in association with blaOXA-
58 genes. The element can insert into the ISAba3 element that is found upstream of 
blaOXA-58, in the same orientation as the β-lactamase gene. The formation of this 
chimeric element creates a hybrid promoter for blaOXA-58 expression, with the -35 
region being located within the right inverted repeat of ISAba2 and the -10 region 
located within the ISAba3 element (Poirel and Nordmann, 2006). The 
ISAba2/ISAba3 chimeric element has been identified associated with blaOXA-58 from 
different strains internationally and appears to be widespread (Zarrilli et al., 2007, 
Poirel et al., 2006, Bertini et al., 2007). Similarly, the insertion sequence IS18 has 
been described as forming a chimeric element by inserti g into ISAba3 and 
providing a hybrid promoter upstream of blaOXA-58, though this element has been 
identified rarely (Poirel and Nordmann, 2006). 
 
Insertion sequences in A. baumannii also appear to be involved in altering the copy 
number of the blaOXA-58 gene, as duplication of the gene mediated by IS26 elements 
has been observed. The study examined three clonal isol tes, one containing one 
copy of blaOXA-58, one containing two copies, and one containing three copies. The 
MICs of imipenem for the three isolates were 16, 32 and 128 mg L-1 respectively 
(Bertini et al., 2007). IS26 appears to be able to duplicate the entire ISAba2/ISAba3-
blaOXA-58-ISAba3 region. This demonstrates that as well as increased expression due 
to promoters provided by insertion sequences, duplication of the blaOXA-58 gene 




1.6.2  Integrons. 
Integrons are genetic elements that are able to capture and express multiple genes. 
They contain an integrase gene, intI, and an attI recombination site. Genes that are 
associated with an attC recombination site, called gene cassettes, that are recognised 
by the integrase can then be inserted into the integron. This can occur successively 
such that an integron carries multiple gene cassettes. Integrons are sorted into classes 
based upon the sequence of their integrase gene (Partridge et al., 2009). In A. 
baumannii, integrons are often identified with the majority being of the class 1 type. 
They commonly carry genes conferring resistance to the aminoglycosides, 
sulphonamides, chloramphenicol, trimethoprim and β-lactams (Ploy et al., 2000, 
Koeleman et al., 2001, Gombac et al., 2002, Kraniotaki et al., 2006, Fournier et al., 
2006). While genes conferring resistance to the carbapenems of the blaIMP and blaVIM  
types have been found in A. baumannii, they are not generally widespread as yet, 
except in the Far East (Poirel and Nordmann, 2002). Enzymes of the class D OXA 
type that are able to confer carbapenem resistance hav  not been found on integrons. 
 
1.6.3  Resistance Islands. 
The term resistance island (RI) in bacteria refers to a region in a genome containing a 
high concentration of genes that encode resistance to antimicrobials that has been 
inserted into the bacterial chromosome. The first RI to be discovered in A. baumannii 
was published in 2006, and contained 45 resistance gen s located within a ~96 kb 
region inserted into an ATPase gene (Fournier et al., 2006). Subsequently, five 
further variations of the RI have been identified, and it is thought that insertions of 
RIs of various sizes into the ATPase gene in A. baumannii s a relatively common 
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phenomenon (Iacono et al., 2008, Adams et al., 2008, Shaikh et al., 2009, Post and 
Hall, 2009). While these RIs carry genes conferring esistance to many classes of 
antibiotic, only the island named AbaR4 carries a gene that confers carbapenem 
resistance due to containing a bl OXA-23 gene flanked by two ISAba1 sequences 
(Adams et al., 2008). The size and variability of these RIs demonstrate the 
prodigious ability that A. baumannii has to acquire and maintain resistance 
determinants, and therefore the problems that this bacterium poses and will continue 




















• Only three species of Acinetobacter are regularly responsible for serious 
infection – A. baumannii, genospecies 3 and genospecies 13TU. 
 
• Acinetobacter species cause serious infections in immunocompromised hosts. 
 
• A. baumannii s a particular problem due to high levels of antimicrobial 
resistance encountered in this species. 
 
• The carbapenems are regarded as the last sustainable group of antibiotics for 
treating infections caused by A. baumannii due to their high activity and low 
toxicity. 
 
• Resistance to the carbapenems has been emerging in A. baumannii, mainly 
conferred by the class D OXA-type β-lactamases. 
 
• In addition to acquired OXA-type β-lactamases, increased expression of the 







1.8 Aims of this project. 
The recent emergence of carbapenem resistance in A. baumannii, the discovery of 
the blaOXA-51-like genes, and the observation that the presence of ISAba1 upstream of 
the blaOXA-51-like gene is associated with reduced susceptibility to he carbapenems led 
to the development of the following hypothesis that will be tested in this thesis: 
 
• All A. baumannii possess a blaOXA-51-like gene, and could become resistant to 
the carbapenems through expression of this gene. 
 
To test this hypothesis, a set of experiments were d signed to answer a series of 
questions: 
1. How prevalent are the blaOXA-51-like genes, and are all the different alleles 
distributed equally? 
2. Are particular blaOXA-51-like alleles associated with particular A. baumannii 
strains, and are some strains more resistant to the carbapenems than others? 
3. Can insertion sequences be found in association with all blaOXA-51-like alleles? 
4. Do carbapenem-susceptible A. baumannii acquire resistance conferred by the 
blaOXA-51-like gene under selective pressure? 
5. Do all of the OXA-51-like enzymes show structural similarities indicating a 








2. Materials and Methods. 
2.1 Bacterial isolates. 
Sixty-four A. baumannii solates that were collected between 1982 and 2006from 
hospitals worldwide were provided by Dr. Kevin Towner. Isolates were originally 
collected to monitor outbreaks of A. baumannii nfection. Isolates had been initially 
identified in the individual hospital laboratories u ing standard microbiological 
techniques, and then confirmed as members of the A. baumannii species by tRNA 
fingerprinting (Ehrenstein et al., 1996). For identification experiments the type strain 
ATCC 19606 was used as a species 2 control strain, alo g with isolates Ab40, Ab41 
and Ab191 previously identified as belonging to species 1, 3 and 13TU respectively. 
For minimum inhibitory concentration determination the control strains 
Staphylococcus aereus NCTC 6571, Escherichia coli NCTC 10418 and 
Pseudomonas aeruginosa NCTC 10662 were used, along with A. baumannii ATCC 
19606. For amplification of blaOXA genes, A. baumannii strains Ab33, Ab34 and 
Ab35, previously identified in our laboratory to bepositive for blaOXA-23-like, blaOXA-
40-like and blaOXA-58-like genes respectively, were utilised. For blaOXA-51-like 
amplification, the control strain ATCC 19606 was included. 
 
2.2 Identification. 
Isolates that were found to be laOXA-51-like-negative by either the OXA multiplex 
PCR or the blaOXA-51-like whole gene PCR described below had their species 
identification confirmed by restriction analysis with endonucleases AluI and NdeII of 
an amplified fragment of the 16S-23S intergenic rDNA sequence as described by 
Dolzani et al (1995). Following overnight culture at 37˚C on MacConkey agar plates, 
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one to two colonies of each isolate were inoculated into 5 mL of nutrient broth and 
incubated overnight at 37˚C and 180 rpm. DNA purification from these overnight 
liquid cultures was performed using a Puregene DNA Purification System Genomic 
DNA Purification Kit (Gentra Systems, Minneapolis, MN, USA). PCR amplification 
of the 16S-23S intergenic rDNA sequence was performed using primer 1 
(TTGTACACACCGCCCGTCA) and primer 2 (GGTACTTAGATGTTTCAGTTC) in 50 µL 
volumes containing 10 µL 5X Green GoTaq Flexi Buffer, 1.5 mM MgCl2, 800 µM 
PCR nucleotide mix, and 1.25 U GoTaq DNA polymerase (Promega, Southampton, 
UK). Reactions were carried out in a Px2 Thermal Cycler (Thermo Fisher Scientific, 
Waltham, MA, USA) using primer concentrations of 25 pmol µL-1 and 0.5 µL 
template DNA. PCR conditions were as follows: 94°C for 5 mins, followed by 35 
cycles of 94°C for 1 min, 55°C for 1 min and 72°C for 1 min, followed by 72°C for 5 
mins. PCR products were analysed on 1.5% w/v agarose gel  stained with ethidium 
bromide and scanned using the Diversity Database software image capturing system 
(Bio-Rad, Hemel Hempstead, UK). 
 
Following successful amplification, PCR products were digested independently with 
AluI and NdeII (Promega, Southampton, UK) at 37°C for 12 hours in 50µL volumes 
containing 23.5 µL distilled H2O, 5 µL of restriction buffer, 0.5 µL bovine serum 
albumin, 20 µL of PCR product, and 1 µL of enzyme. R stricted products were then 
analysed an 4% w/v agarose gels stained with ethidium bromide and scanned using 




2.3 Minimum inhibitory concentration determination. 
All isolates were tested for their susceptibility to imipenem and meropenem. 
Imipenem was utilised in the form of imipenem-cilastatin with a potency of 50% 
(Merck, Sharp & Dohme Ltd, Hertfordshire, UK), and meropenem with a potency of 
99.8% was obtained from AstraZeneca (Cheshire, UK). Following overnight culture 
on MacConkey agar plates, isolates were grown overnight at 37˚C and 180 rpm in 5 
mL of Iso-sensitest broth. Minimum inhibitory concetrations (MICs) were 
determined by doubling dilutions in Iso-sensitest agar, according to the British 
Society for Antimicrobial Chemotherapy (BSAC) methodology (British Society for 
Antimicrobial Chemotherapy, 1991). The antibiotic con entration range used was 
0.008 to 128 mg L-1. All agars and broths used during this project were obtained 
from Oxoid Ltd, Basingstoke, UK. The results were interpreted according to the 
guidelines of the BSAC (Andrews, 2007). Pseudomonas aeruginosa NCTC 10662, 
Escherichia coli NCTC 10418 and Staphylococcus aureus NCTC 6571 were used as 
quality control strains. 
 
To compare the difference between the MIC values of imipenem and meropenem for 
isolates with an acquired OXA-type carbapenemase gen and those with ISAba1 
element upstream of their blaOXA-51-like gene, a Mann-Whitney U test was conducted 
in the SPSS version 13 software (SPSS Inc, Chicago, Illin is, USA).  
 
2.4 Amplification of blaOXA genes and insertion sequences. 
Amplification of the blaOXA genes and insertion sequences of the isolates was 





















Table 3: Primers used for blaOXA and insertion sequence amplification. 
a, 
Woodford et al (2006); b, Poirel et al (2006); c, Heritier et al (2005a); d, Heritier et al 
(2006). 
 
groups of blaOXA genes was undertaken using a multiplex PCR by the method of 
Woodford et al (2006). Expected product sizes were 501 bp (blaOXA-23-like), 246 bp 
(blaOXA-40-like), 353 bp (blaOXA-51-like) and 599 bp (blaOXA-58-like). Amplification of 
fragments of the insertion sequences ISAba1, ISAba2 and ISAba3 was achieved 
using primers designed by Poirel et al (2006) with expected product sizes of 434 bp, 
1134 bp and 403 bp respectively. Following overnight culture at 37˚C on 
MacConkey agar plates, DNA extraction was performed by boiling up to three 
colonies in 50 µL sterile distilled water for 10 min. PCRs were performed in 50 µL 
volumes containing 10 µL 5X Green GoTaq Flexi Buffer, 1.5 mM MgCl2, 800 µM 
 39 
PCR nucleotide mix, and 1.25 U GoTaq DNA polymerase (Promega, Southampton, 
UK). All PCR conditions were as described by Woodfor  et al (2006). Reactions 
were performed under the following conditions: 94°C for 5 mins, then 30 cycles of 
94°C for 25 s, 52°C for 40 s and 72°C for 50 s, followed by 72°C for 5 mins. 
Reactions were carried out in a Px2 Thermal Cycler (Thermo Fisher Scientific, 
Waltham, MA, USA) using primer concentrations of 25 pmol µL-1 and 0.5 µL 
template DNA. PCR products were analysed on 1.5% w/v agarose gels stained with 
ethidium bromide and scanned using the Diversity Datab se software image 
capturing system (Bio-Rad, Hemel Hempstead, UK). 
 
To amplify the entire blaOXA-51-like gene the primers OXA-69A and OXA-69B 
designed by Heritier et al (2005a) which lie externally to the gene were used to 
amplify a 975 bp fragment in 50 µL volumes containing 20 mM Tris-HCL (pH 8.8), 
10 mM KCl, 10 mM (NH4)2SO4, 2 mM MgSO4, nuclease-free BSA 0.1 mg mL
-1, 
0.1% Triton X-100, 1.5 mM MgCl2, 800 µM PCR nucleotide mix, and 1.25 U of P u 
DNA polymerase (Promega, Southampton, UK). PCRs were p formed under the 
following conditions: 95°C for 2 min, followed by 30 cycles of 95°C for 1 min, 48°C 
for 40 s and 72°C for 3 min, followed by 72°C for 6 min. 
For isolates which produced a product larger than 975 bp because of the presence of 
ISAba1 upstream of the blaOXA-51-like gene, the primer preABprom+ (Heritier t al., 
2006) was used with OXA-69B to produce a 1189 bp product under the same cycling 
conditions, except that the annealing temperature was increased to 53°C. Reactions 
and gel staining were carried out as above. 
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2.5 blaOXA-51-like gene sequencing. 
PCR products generated using the primers OXA-69 A and B, or preABprom+ and 
OXA-69 B as described in section 2.4, were purified using a QIAquick PCR 
Purification Kit (Qiagen, Crawley, UK) and sequenced in both directions on a 3730 
DNA Analyzer (Applied Biosystems, Warrington, UK). Sequencing reactions were 
performed using 5 µL of purified DNA template and 1 µL of primer at a 
concentration of 3.2 pmol µL-1, and using the BigDye system. Sequencing was 
performed by technical staff at the Gene Pool, University of Edinburgh. Sequences 
were analysed using the BLAST (http://www.ncbi.nlm.nih gov/BLAST/) and 
MultAlin (http://bioinfo.genopole-toulouse.prd.fr/multalin/) software. Sequences 
which appeared to be novel were re-amplified and re-sequenced to confirm this. 
 
2.6 PCR walking. 
In order to sequence and identify the blaOXA-51-like gene in isolates that failed to give a 
PCR product using primers OXA-69 A and B as described above, a genome walking 
technique using nested PCRs with specific and partially degenerate primers was 
employed. Reactions were performed as described by Guo and Xiong (2006) using 
the primers listed in table 4. PCRs were performed using GoTaq DNA polymerase 
and reaction components were the same as described in s ction 2.4. Primers OXA-
51-OUT1 and -OUT2 were used in the initial touch-down PCR, which used cycling 
parameters of 95°C for 5 mins, followed by denaturing stages of 95°C for 45 s, 
annealing stages starting at 60°C and decreasing in a stepwise manner by 0.5°C per 
cycle, down to 47.5°C for 45 s, and elongation stages of 72°C for 2 mins. A final 
elongation of 72°C for 5 mins was performed at the end of the amplification cycle 
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block. Primers OXA-51-OUT3 and -OUT4 were used in the second stage 
amplification under the following conditions: 95°C for 5 mins, then 35 cycles of 
95°C for 45 s, 50°C for 45 s, and 72°C for 2 mins, then a final elongation of 72°C for 
5 mins. All specific primers were used in combination with the degenerate primers 
Semi-1, Semi-2 and Semi-3. PCR products were analysed, purified and sequenced as 












Table 4: Primers used for walking out from the blaOXA-51-like genes.  
Primers Semi-1,-2 and -3 were designed by Guo et al (2006). Degenerate primers 
contain non-standard bases with the following propeties: N, any base; Y, 
pyrimidine; K, keto; S, strong; R, purine; M, amino. 
 
 
2.7 Pulsed-field gel electrophoresis. 
Isolates were typed by pulsed-field gel electrophoresis (PFGE) as described by 
Miranda et al (1996), with the following modifications. Cultures for making plugs 
were cultivated in 5 mL of nutrient broth. Plug slices were equilibrated in 100 µL of 
restriction endonuclease buffer for one hour at 4˚C prior to restriction with 30 units 
of ApaI restriction endonuclease overnight at 37˚C. Digested plug slices were run on 
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a 1% pulsed-field-certified agarose gel (Bio-Rad, Hertfordshire, UK) in 0.5 X TBE 
buffer using a pulse time of 5 to 35 seconds over 24 hours at 6 V cm-1. A lambda 
ladder was used as a size standard (New England Biolabs, Hertfordshire, UK). Gels 
were run at 12˚C using CHEF DRII apparatus (Bio-Rad, Hertfordshire, UK), stained 
with ethidium bromide and scanned using the Diversity Database software image 
capturing system (Bio-Rad, Hertfordshire, UK). Gel analysis was performed using 
the BioNumerics v4.0 software (Applied Maths, Sint-Martins-Latem, Belgium). 
Banding pattern similarity was calculated using the un-weighted pair group method 
using arithmetic averages (UPGMA), with the Dice co-efficient at a tolerance of 
1.3%. 
 
2.8 Sequence group typing. 
Two multiplex PCRs for the amplification of regions of the ompA, csuE and blaOXA-
51-like genes for identifying sequence groupings were performed using consensus 
primers and amplification conditions as described by Turton et al (2007) and PCR 
components as described by Evans et al (2008). The sequences of the primers used in 
the multiplex PCRs are listed in table 5. PCRs were p rformed in 25 µL volumes 
using pre-formulated Ready-to-Go PCR beads (GE Healthcare Life Sciences, Little 
Chalfont, UK) containing PCR buffer, dNTPs and DNA polymerase. Primers were 
used at a final concentration of 400 nM. Reaction cditions were as follows: 94°C 
for 3 mins, then 30 cycles of 94°C for 45 s, 57°C for 45 s, and 72°C for 1 min, then a 
final elongation stage of 72°C for 5 mins. PCR products were visualised as described 
in section 2.4. 
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Table 5: Primers used for amplifying fragments for sequence group typing 
(Turton et al., 2007). 
 
2.9 Multi-locus sequence typing. 
Isolates were typed using a multi-locus sequence typing (MLST) scheme based upon 
that published by Bartual et al (2005) with modifications to the cycling parameters. 
Following overnight culture at 37˚C on MacConkey agar plates, one to two colonies 
of each isolate were inoculated into 5 mL of nutrient broth and incubated overnight 
at 37˚C and 180 rpm. DNA purification from these overnight liquid cultures was 
performed using a Puregene DNA Purification System Genomic DNA Purification 
Kit (Gentra Systems, Minneapolis, MN, USA). PCRs for the seven ‘housekeeping’ 
genes gltA, gyrB, gdhB, recA, cpn60, gpi and rpoD were performed in 50 µL 
volumes containing 10 µL 5X Green GoTaq Flexi Buffer, 1.5 mM MgCl2, 800 µM 
PCR nucleotide mix, 1.25 U GoTaq DNA polymerase (Promega, Southampton, UK), 
and 0.5 µL of DNA template. Primers described by Bartual et al (2005) were used at 
a final concentration of 0.25 µM under standard conditions with the annealing 
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temperatures described in Table 6. A Px2 Thermal Cyc er (Thermo Fisher Scientific, 
Waltham, MA, USA) was used to conduct PCRs. Analysis of PCR products, product 
purification and sequencing were performed as described previously. Primers used 
for product amplification were also used for sequencing, except for in the case of the 
gyrB, gdhB and rpoD products. Primer pair M13 [-21] (TGTAAAACGACGGCCAGT) and 
M13 F (CAGGAAACAGCTATGACC) were used in sequencing gyrB fragments, primer 
pair GDH SEC F (ACCACATGCTTTGTTATG) and GDH SEC R 
(GTTGGCGTATGTTGTGC) were used in sequencing gdhB fragments, and primer pair 
70FS (ACGACTGACCCGGTACGCATGTA) and 70RS (ATAGAAATAACCAGACGTAAGTT) 
were used in sequencing rpoD fragments. Resulting sequences were analysed using
the online BLAST (http://www.ncbi.nlm.nih.gov/BLAST/) and MultAlin 
(http://bioinfo.genopole-toulouse.prd.fr/multalin/) software, and isolates were 
assigned to sequence types using tools on the A. baumannii MLST webpage 
(http://pubmlst.org/abaumannii/).  
 
Concatenated sequences for all seven genes were used to estimate the phylogeny 
using the neighbour-joining method (Saitou & Nei, 1987) under the Jukes-Cantor 
genetic distance model (Jukes & Cantor, 1969), withstatistical support for the nodes 
assessed via the bootstrap re-sampling method, with 1000 re-samples, implemented 
in Geneious v4.6.5. The phylogenetic tree was drawn usi g FigTree v.1.1.2 
(http://tree.bio.ed.ac.uk/software/figtree/). Neighbour-joining trees for all identified 





gene Primers Primer Sequence (5' to 3') Annealing
Citrato F1 AATTTACAGTGGCACATTAGGTCCC 55°C for 1 min
Citrato R12 GCAGAGATACCAGCAGAGATACACG
APRU F TGTAAAACGACGGCCAGTGCNGGRTCYTTYTCYTGRCA 45°C for 1 min
UP1E R CAGGAAACAGCTATGACCAYGSNGGNGGNAARTTYRA
GDHB 1F GCTACTTTTATGCAACAGAGCC 55°C for 1 min
GDHB 775R GTTGAGTTGGCGTATGTTGTGC
RA1 CCTGAATCTTCYGGTAAAAC 56°C for 1 min
RA2 GTTTCTGGGCTGCCAAACATTAC
CPN 3F2 ACTGTACTTGCTCAAGC 58°C for 1 min
CPN R2 TTCAGCGATGATAAGAAGTGG
GPI F1 AATACCGTGGTGCTACGGG 58°C for 1 min
GPI R1 AACTTGATTTTCAGGAGC










Table 6: PCR primers and modified conditions for amplification of the seven MLST genes. Primer sequences were designed by 
Bartual et al (2005). Degenerate primers contain non-standard bases with the following properties: N, any base; Y, pyrimidine; S, strong; 
R, purine; M, amino. 
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Comparisons of tree topologies were conducted visually, and differences confirmed 
using the quartet measure of tree-to-tree distance (Estabrook et al, 1985) 
implemented in the COMPONENT 2.0 software 
(http://taxonomy.zoology.gla.ac.uk/rod/cpw/index.html).  
 
The START2 software (http://pubmlst.org/software/analysis/start2/) was also used to 
calculate the index of association standardised (IA
S) for the seven loci (Haubold et al, 
1998). Evolutionary relationships and clonal complexes within the isolates were 
investigated by eBURST analysis (Feil t al, 2004), using the software on the 
eBURST website (http://eburst.mlst.net/v3/enter_data/single/), with statistical 
support for the complexes assessed via the bootstrap re-sampling method, with 1000 
re-samples. The pairwise homoplasy index test (phi test) was applied to investigate 
the possibility of recombination between the alleles within the seven ‘housekeeping’ 
genes (Bruen et al., 2006), and was implemented in the SplitsTree4 software 
(http://www.splitstree.org/). 
 
To investigate the degree of selection acting upon the seven MLST loci, πN/πS ratios 
(Nei & Gojobori, 1986) were calculated in the START2 software and compared with 
those generated for blaOXA-51-like, blaTEM, blaSHV, blaCTX-M and blaCMY genes, using 
the Kruskal-Wallis one-way analysis of variance implemented in the Minitab15 





2.10 Dose response curves. 
Following overnight culture on MacConkey agar plates at 37˚C, one colony for each 
isolate was inoculated into 10 mL nutrient broth and incubated overnight at 37˚C and 
180 rpm. Volumes of 200 µL overnight broth culture w re added to nutrient broths 
containing doubling dilutions of meropenem (AstraZeneca, Cheshire, UK) between 
0.008 and 128 mg L-1 in a total volume of 9.8 mL. This was vortexed, then 100 µL of 
a 10-4 dilution was plated out onto a nutrient agar plate, to enable the number of cells 
at time = 0 hours to be determined. The antibiotic-containing cultures were incubated 
at 37˚C and 180 rpm for three hours, then 100 µL of 10-2, 10-4 and 10-6 dilutions were 
plated out onto nutrient agar plates. All plates were incubated overnight at 37˚C, and 
colony counts were made for the initial time = 0 hours plates, and the appropriate 
dilution that gave a countable number of colonies for the time = 3 hours plates. This 
allowed the percentage viability after 3 hours of growth to be obtained. 
 
2.11 Mutation study. 
After overnight growth at 37˚C on MacConkey agar, one colony for each isolate 
studied was inoculated into 10 mL nutrient broth and incubated overnight at 37˚C 
and 180 rpm. Volumes of 100 µL of 10-5, 10-6 and 10-7 dilutions of the overnight 
culture were plated out in triplicate onto nutrient agar plates, incubated overnight at 
37˚C, and then the number of colonies were counted to calculate the viable count for 
that culture. Simultaneously, 100 µL volumes of culture were plated onto nutrient 
agar containing meropenem (AstraZeneca, Cheshire, UK) at 0.5X, 1X, 2X and 4X 
the meropenem MIC for that isolate, that had been pr viously determined. These 
plates were incubated at 37˚C for 48 hours, and then t  numbers of colonies were 
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counted on all plates. One colony from the plate with the highest concentration of 
meropenem on which there was bacterial growth was inoculated into 10 mL of 
nutrient broth and incubated overnight at 37˚C and 180 rpm. Volumes of 100 µL of 
culture were plated out to determine viable counts as described above, and onto 
plates containing meropenem at 0.5X, 1X, 2X and 4X the concentration of 
meropenem from which the culture was derived. These plat s were then incubated at 
37˚C for 48 hours as before, and the whole process repeated until colonies were only 
being recovered at concentrations of meropenem equal to or less than that from 
which the culture was derived. These final stage mutants were screened for ISAba1 
upstream of the blaOXA-51-like gene and had their blaOXA-51-like gene sequenced as 
described previously. The MICs for the parent and mutant isolates of imipenem and 
meropenem were determined. Freezer stocks of the mutant isolates were used that 
were frozen eight months prior to conducting MIC testing.  
 
2.12 Growth study. 
Following overnight culture on MacConkey agar, one colony of isolate A418 was 
used to inoculate 10 mL of nutrient broth, and 10 mL of nutrient broth containing 0.5 
mg L-1 of imipenem (Merck, Sharp & Dohme Ltd, Hertfordshire, UK). Cultures were 
incubated for 24 hours at 37˚C and 180 rpm. Volumes of 100 µL of the cultures were 
then added to 9.9 mL nutrient broth or 9.9 mL nutrient broth containing 0.5 mg L-1 
imipenem respectively and incubated for a further 24 hours. This process was 
repeated for 100 days. Freezer stocks of the cultures were made every 5 days by 
adding 900 µL of culture to 100 µL of glycerol and storing at -80˚C. The initial A418 
isolate and the two 100 day-old isolates had their blaOXA-51-like gene amplified and 
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sequenced using primers OXA-69A-EXT (GGATTAAATTTAGTTGCGAAGC) and 
OXA-69B-EXT (AATGGTTTCCCTGTCATTGG) as described in section 2.4, and were 
also typed by PFGE as described previously. 
 
2.13 OXA-51-like functional map. 
All publicly available OXA-51-like amino-acid sequences were obtained from the 
National Center for Biotechnology Information (NCBI) website 
(http://www.ncbi.nlm.nih.gov/). Sequences were analysed using MultAlin software 
(http://bioinfo.genopole-toulouse.prd.fr/multalin/) and all amino-acid variations were 
recorded. OXA-69 was chosen as a starting point in constructing the map as this was 
the enzyme found in the oldest isolate in this study (A1 from 1982). The map was 
subsequently re-drawn with OXA-65 as a starting point (see Results). Branches were 
constructed for each enzyme by listing the amino-acid changes from OXA-65 from 
the most common across all enzymes first, to the least common last. The branches 
were drawn in order from the enzymes with the fewest differences from OXA-65 
first, through to the enzymes with the highest number of differences. Branches with 
the same changes within them were merged to produce the f west number of 
branches possible. Amino-acid changes were not revers d within the same branch. 
 
2.14 blaOXA-51-like sequence analysis. 
All available nucleotide sequences for blaOXA-51-like genes were downloaded from the 
National Centre for Biotechnology Information (NCBI) website 
(http://www.ncbi.nlm.nih.gov/). The gene phylogeny was estimated using the 
bayesian method under the general time reversal model of nucleotide substitutions 
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with gamma-distributed rates, implemented in MrBayes (Huelsenbeck & Ronquist, 
2001). The phylogenetic tree was drawn using FigTree v.1.1.2 
(http://tree.bio.ed.ac.uk/software/figtree/). 
 
To compare the diversity within the blaOXA-51-like genes and A. baumannii as a 
species, MLST data for the six available genome sequences (ACICU, AB0057, 
AB307-0294, AYE, SDF and ATCC17978) along with two Acinetobacter 
genospecies 13TU isolates (st11681 and st7961) was downloaded from the NCBI 
website and combined with MLST data generated in this project. These sequences 
were used to estimate a phylogeny for A. baumannii via the bayesian method as 
described previously. 
 
2.15 OXA-51-like structural models. 
Structural models of the OXA-51-like enzymes were created using the online protein 
homology/analogy recognition engine (phyre) (http://www.sbg.bio.ic.ac.uk/~phyre/), 
using the crystal structure for OXA-40 published by Santillana et al (2007) as a 
backbone. The OXA-40 structure was chosen for this purpose as it has the highest 
sequence homology to the OXA-51-like enzymes of all the published enzyme 
structures to date, at approximately 63% amino-acid identity (Peleg et al, 2008). 
Structures were viewed in the Swiss-PdbViewer DeepVi w version 4 
(http://spdbv.vital-it.ch/). Structures were compared with one-another to identify 
amino-acid differences that may affect enzyme functio . Additionally, to investigate 
the degree of selection acting upon certain regions of the OXA-51-like enzymes, 
πN/πS ratios were calculated in the program DnaSP version 5 
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(http://www.ub.edu/dnasp/), within consecutive 50 amino-acid-long windows of an 
alignment of the enzyme sequences, with each window shifting 10 amino-acids down 
the sequence from the previous window. This was plotted against the percentage 
amino-acid difference of OXA-51-like sequences to an OXA-51-like consensus 




























3.1 Characteristics of isolates analysed by sequence groups. 
3.1.1  Sequence group 1 isolates. 
Isolates were assigned to sequence groups (SGs) by the method of Turton et al 
(2007) by multiplex PCR performed by Dr. Kevin Towner. Sequence group 1 (SG1) 
formed the largest group, accounting for 44% of isolates. The second largest group 
was SG2, containing 28% of the isolates, and SG3 was the third largest group, 
representing 9% of the isolates. Representatives of the three European lineages were 
found in separate sequence groups, with European Clo e 1 (EC1) belonging to SG2, 
European Clone 2 (EC2) belonging to SG1, and European Clone 3 (EC3) belonging 
to SG3, as described previously (Turton et al., 2007). Twelve (19%) isolates did not 
belong to one of the three major sequence groups, and produced novel combinations 
of products in the two multiplex PCRs. 
 
Table 7 shows the isolates assigned to SG1, the blaOXA-51-like gene they possess, their 
carbapenem MICs and PCR screening results. There is no particular geographical 
focus for SG1 isolates, with isolates originating from countries across Europe as well 
as from Asia, Africa and South America. Of the 28 isolates, 22 (79%) possess the 
blaOXA-66 gene. The remaining six isolates carry one of five genes that are similar to 
blaOXA-66, differing by a maximum of three nucleotides (transl ting to one amino-
acid) from this gene, except for blaOXA-108, which is slightly farther removed and 
differs by seven nucleotides (translating to five amino-acids). Two of these genes, 
blaOXA-108 and blaOXA-109 were novel discoveries (for sequence alignments, see 
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Isolate Origin SG bla OXA-51-like ISAba1 bla OXA-23-like bla OXA-40-like bla OXA-58-like ISAba1 ISAba2 ISAba3
allele upstream allele allele allele
of bla OXA-51 IMP MER
A369 Oviedo, Spain 1 OXA-66 - - + - + + - >128 >128
A332 Bilbao, Spain 1 OXA-66 - - + - + + - 64 128
A401 Taiwan 1 OXA-82 + - - - + - - 16 16
A380 London, United Kingdom 1 OXA-66 - - - + + + + 16 16
A392 Freiburg, Germany 1 OXA-66 - - - + + + + 8 8
A473 Warsaw, Poland 1 OXA-108 + - - - + + - 8 4
A371 Prague, Czech Republic 1 OXA-83 + - - - + - - 8 32
A484 Nottingham, United Kingdom 1 OXA-83 + - - - + - - 8 64
A387 Ioannina, Greece 1 OXA-66 - - - + + + + 4 4
A397 Thessalonika, Greece 1 OXA-66 - - - + - + + 4 4
A474 Warsaw, Poland 1 OXA-66 - - - - + - - 4 2
A418 Wroclaw, Poland 1 OXA-66 - - - - + - - 4 8
A343 Chesterfield, United Kingdom 1 OXA-109 + - - - + - - 2 4
A4 Nottingham United Kingdom 1 OXA-66 - - - - + - - 0.5 0.5
A47 Berlin, Germany 1 OXA-66 - - - - + - - 0.5 1
A365 London, United Kingdom** 1 OXA-66 - - - - + - - 0.5 0.5
A480 Nottingham, United Kingdom 1 OXA-66 - - - - + - - 0.5 0.5
A481 Nottingham, United Kingdom 1 OXA-66 - - - - + - - 0.5 2
A482 Nottingham, United Kingdom 1 OXA-66 - - - - + - - 0.5 1
A216 Sheffield, United Kingdom 1 OXA-66 - - - - + - - 0.5 1
A25 Nottingham, United Kingdom 1 OXA-66 - - - - + - - 0.25 0.5
A6 Nottingham, United Kingdom 1 OXA-66 - - - - + - - 0.25 0.5
A230 Nottingham, United Kingdom 1 OXA-66 - - - - - - - 0.25 1
A60 Buenos Aires, Argentina 1 OXA-65 - - - - + - - 0.25 1
A186 Johannesburg, South Africa 1 OXA-66 - - - - + - - 0.25 0.5
A140 Cologne, Germany 1 OXA-66 - - - - - - - 0.25 0.5
A24 Nottingham, United Kingdom 1 OXA-66 - - - - + - - 0.12 0.25
A320 RUH 134 European clone II 1 OXA-66 - - - - + - - 0.12 0.5
MICs (mg/L)
 
Table 7: Isolates assigned to SG1. IMP, imipenem; MER, meropenem; SG, sequence group. **Isolate belonging to the South East clone. 
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appendix A). None of the isolates carry a bl OXA-23-like gene. Only two isolates, A369 
and A332 both from Spain, possess a blaOXA-40-like gene, and these two isolates also 
have the highest levels of resistance to both imipenem and meropenem. A blaOXA-58-
like gene was detected in four isolates, and these isolates also had intermediate to high 
levels of carbapenem resistance. ISAba1 was found in 25 isolates (89%). However it 
was only located upstream of the blaOXA-51-like gene in five isolates, and all five of 
these isolates possessed a blaOXA-66-like gene rather than blaOXA-66 itself. These isolates 
all had intermediate to high levels of resistance to the carbapenems. ISAba2 was 
amplified from seven isolates, all but one of which also harboured either a blaOXA-40-
like or blaOXA-58-like gene. ISAba3 was located in just four isolates, and were the same 
four isolates that possessed a bl OXA-58-like gene. 
 
An example gel showing results of the multiplex PCR screening for the presence of 
blaOXA-23-like, blaOXA-40-like, blaOXA-51-like and blaOXA-58-like genes is shown in figure 4. 
An example gel showing results of the PCR amplification of the entire blaOXA-51-like 
gene, also indicating the presence of ISAba1 upstream of the gene is shown in figure 
5. Examples of the results of PCR screening for ISAba1, ISAba2 and ISAba3 are 
shown in figures 6, 7 and 8 respectively. 
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Figure 4: Example gel for the OXA multiplex PCR. Lanes are labelled with 





Figure 5: Example gel for the amplification of the entire blaOXA-51-like gene. 
Larger band sizes represent the presence of ISAba1 upstream of the blaOXA-51-like 

























































































































Figure 6: Example gel for the ISAba1 PCR. Lanes are labelled with markers, 
controls or isolate names. 
 
 
Figure 7: Example gel for the ISAba2 PCR. Lanes are labelled with markers, 












































































































Figure 8: Example gel for the ISAba3 PCR. Lanes are labelled with markers, 
controls or isolate names. 
 
3.1.2  Sequence group 2 isolates. 
The isolates assigned to sequence group 2 (SG2) are shown in table 8. As with the 
SG1 isolates, there was no particular geographical grouping, with isolates identified 
from across Europe, Asia and South America. Of the 18 isolates in SG2, 12 carried 
the blaOXA-69 gene (67%). The remaining six isolates possess one of three genes that 
have a maximum of one nucleotide difference (translating to one amino-acid 
difference) to blaOXA-69. These three genes, blaOXA-107, blaOXA-110 and blaOXA-112, were 
novel discoveries (see appendix A for sequence alignments). Two isolates carry a 
blaOXA-23-like gene, none carry a blaOXA-40-like gene, and one isolate carries a bl OXA-58-
like gene. The three isolates encoding acquired carbapenemases are intermediately 
resistant or resistant to the carbapenems. ISAba1 was detected in 13 isolates (72%), 







































Isolate Origin SG bla OXA-51-like ISAba1 bla OXA-23-like bla OXA-40-like bla OXA-58-like ISAba1 ISAba2 ISAba3
allele upstream allele allele allele
of bla OXA-51 IMP MER
A424 Croatia 2 OXA-107 + - - - + - - 8 16
A479 UK import from Pakistan 2 OXA-69 - + - - + - - 8 8
A384 Oslo, Norway 2 OXA-69 - - - + + - + 4 2
A52 Freiburg, Germany 2 OXA-69 - - - - - - + 4 8
A472 Warsaw, Poland 2 OXA-107 + - - - + - - 4 8
A390 Pleven, Bulgaria 2 OXA-69 - + - - + + - 4 16
A404 Wroclaw, Poland 2 OXA-110 + - - - + - - 2 4
A443 Ljubljana, Slovenia 2 OXA-107 + - - - + - - 2 8
A442 Sofia, Bulgaria 2 OXA-69 - - - - + - - 1 2
A407 Wroclaw, Poland 2 OXA-110 + - - - + - - 1 8
A167 Bosnia 2 OXA-69 - - - - + - - 0.5 1
A15 Dordrecht, The Netherlands 2 OXA-69 - - - - + - - 0.5 0.5
A1 Nottingham, United Kingdom 2 OXA-69 - - - - - - - 0.25 0.5
A297 RUH 875 European clone I 2 OXA-69 - - - - + - - 0.25 0.5
A14 Venlo, The Netherlands 2 OXA-69 - - - - - - - 0.25 2
A63 Buenos Aires, Argentina 2 OXA-69 - - - - - - - 0.12 0.5
A335 Lincoln, United Kingdom 2 OXA-69 - - - - - - - 0.12 0.5
A368 Mansfield, United Kingdom 2 OXA-112 - - - - + - - 0.12 1
A329 Barcelona, Spain 3 OXA-71 - - + - - - - 64 >128
A94 Barcelona, Spain 3 OXA-71 - - - - - - - 8 4
A377 Regensburg, Germany 3 OXA-71 - - - + - + + 4 2
A13 Rotterdam, The Netherlands 3 OXA-71 - - - - - - - 1 2
A20 Paris, France 3 OXA-71 - - - - - - - 0.25 1
A478 LUH 5875 European clone III 3 OXA-71 - - - - - - - 0.25 2
MICs (mg/L)
 
Table 8: SG2 and SG3 isolates. IMP, imipenem; MER, meropenem; SG, sequence group. 
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was only detected upstream of the genes similar to blaOXA-69 rather than blaOXA-69 
itself. One isolate contains ISAba2, and this is one of the two isolates encoding a 
blaOXA-23-like gene, and two isolates contain ISAba3, one of which is the isolate 
positive for blaOXA-58. 
 
3.1.3  Sequence group 3 isolates. 
The isolates assigned to sequence group 3 (SG3) are listed in table 8. All of the SG3 
isolates were obtained from Europe, though the sample size of six is quite small. All 
isolates in this group possess a bl OXA-71 gene. None of the isolates possess a blaOXA-
23-like gene. One isolate, with the highest MICs of imipenem and meropenem, carries 
a blaOXA-40-like gene. One isolate carries a bl OXA-58-like gene, and this is also the only 
isolate in which ISAba2 and ISAba3 were detected. ISAba1 was not detected in any 
isolate. 
 
3.1.4  Isolates belonging to other sequence groups. 
A total of 12 isolates belonged to less well represented sequence groups, and are 
shown in table 9. Three isolates belonged to sequence group 4 (SG4) as defined by 
Towner et al (2008) and possessed the blaOXA-51 gene. ISAba1 was detected in all 
three isolates and was upstream of the blaOXA-51 gene.  Isolate A483 was also found 
to be positive for a blaOXA-58-like gene, ISAba2 and ISAba3, and had a high imipenem 
MIC and intermediate meropenem MIC. Isolate A374 carried a blaOXA-23-like gene and 




Isolate Origin SG bla OXA-51-like ISAba1 bla OXA-23-like bla OXA-40-like bla OXA-58-like ISAba1 ISAba2 ISAba3
allele upstream allele allele allele
of bla OXA-51 IMP MER
A483 UK import from Morocco 4 OXA-51 + - - + + + + 128 4
A374 Rotterdam, The Netherlands 4 OXA-51 + + - - + + - 16 32
A125 Belfast, Northern Ireland 4 OXA-51 + - - - + - - 2 4
A376 Feldkirch, Austria 5 OXA-68 - - + - - - - 0.5 0.5
A388 Ioannina, Greece 6 OXA-92 - - - + + + + 1 2
A457 Estonia 7 OXA-106 - - - - - - - 0.5 1
A95 Trieste, Italy 10 OXA-98 - - - - - - - 0.12 0.25
A37 Singapore 8 OXA-64 - - - - + - - 0.25 0.25
A135 Ghent, Belgium 8 OXA-111 - - - - - - - 0.12 0.25
A92 Barcelona, Spain 9 OXA-69* - - - - - - - 0.25 2
A187 Johannesburg, South Africa 9 OXA-68 - - - - + - - 0.12 1
A16 Leeds, United Kingdom 11 OXA-64 - - - - - - - 0.25 0.25
MICs (mg/L)
 
Table 9: Isolates assigned to sequence groups 4 to 11. IMP, imipenem; MER, meropenem; SG, sequence group. *Variant blaOXA-69 






There was one isolate representing each of sequence groups 5, 6 and 7, as defined by 
Towner et al (2008). The SG5 isolate carried blaOXA-68, and was positive only for a 
blaOXA-40-like gene, and no insertion sequences. The SG6 isolate con ained a blaOXA-92 
gene. It was also found to carry a bl OXA-58-like sequence as well as ISAba1, ISAba2 
and ISAba3, though ISAba1 was not upstream of the blaOXA-92 gene. The isolate 
belonging to SG7 possessed blaOXA-106, and was negative for all other acquired OXA-
type carbapenemases and insertion sequences. 
 
Four novel sequence groups were identified and named SG8, SG9, SG10 and SG11. 
The combination of amplicons defining these SGs is listed in table 10. Two 
representatives of SG8 were identified and they possess a blaOXA-64 gene and a 
blaOXA-111 gene. The blaOXA-111 gene was a novel discovery. Isolate A37 was positive 
for ISAba1, but otherwise both isolates were negative for all other OXA-type genes 
and insertion sequences. The two isolates belonging to SG9 were found to contain a 
blaOXA-69 gene and a blaOXA-68 gene. This was the only blaOXA-69 gene that was not 
associated with an isolate belonging to SG2, however it contained five silent 
nucleotide substitutions (G426→A, C474→A, C511→T, G540→A and T801→C) 
compared to the blaOXA-69 gene found in the SG2 isolates. A blaOXA-68 gene was also 
found in the single SG5 isolate in this study. As SG5 and SG9 only differ by the 
presence of a band for the blaOXA-51-like gene in the group 2 multiplex PCR, it is 
possible that this isolate is, in fact, another memb r of SG5. The blaOXA-68-containing 
isolate was positive for ISAba1, otherwise both isolates were negative for all other 
products. One isolate was found for each of SG10 and SG11. The SG10 isolate 
carries a blaOXA-98 gene, while the SG11 isolate carries a blaOXA-64 gene. A blaOXA-64  
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SG csuE bla OXA-51-like ompA csuE bla OXA-51-like ompA
1 + + + - - -
2 - - - + + +
3 + + - - - +
4 - + + - - -
5 - - + - - -
6 + - - - + +
7 - - + + - -
8 + + - - - -
9 - - + - + -
10 + - + - - -
11 - + - - - -
Group 1 Multiplex PCR Group 2 Multiplex PCR
 
Table 10: Sequence group designation by amplicons. SG, sequence group; csuE, 
gene encoding a product important in a pilus chaperone-usher secretion system; 
ompA, gene encoding the porin outer-membrane protein A. SG1, 2 and 3 definitions 
by Turton et al (2007), and SG4, 5, 6 and 7 definitions by Towner et al (2008). 
 
 
gene was also found in an isolate belonging to SG8, however SG8 and SG11 only 
differ in the amplification of a csuE product in the group 1 multiplex PCR, so are not 
that distantly related. No other OXA-type genes or insertion sequences were found in 
either isolate. 
 
It should be noted that while all isolates carried a blaOXA-51-like gene, they did not all 
give amplicons using the blaOXA-51-like primers used in the sequence grouping scheme. 
This is because the primers were designed to be specific for particular blaOXA-51-like 
subgroups. For example, the group 1 multiplex PCR primers for the blaOXA-51-like 
genes contain a total of four mismatches when compared to the sequence for blaOXA-
69, whereas they match completely with blaOXA-66. 
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3.2 Pulsed-field gel electrophoresis compared with sequence grouping and 
blaOXA- 51- like gene content. 
The 64 isolates in this study were analysed by PFGE, the majority of which was 
performed by Dr. Hamouda. PFGE profile analysis revealed that the isolates varied 
considerably, with very few distinct groups (figure 9). Six pairs of isolates and two 
groups of three isolates clustered at ≥87% similarity, which is a cut-off value that has 
been suggested for use in identifying isolates belonging to the same epidemic strain 
(Seifert et al., 2005). The first group of three isolates contains A24, A6 and A4, 
which were all isolated from Nottingham, UK, all possess a blaOXA-66 gene and 
belong to SG1. Similarly, the other group of three closely related isolates is 
composed of A13, A20 and A478, which all belong to SG3 and possess a blaOXA-71 
gene. However, their geographical distribution is more widespread, though still 
limited to mainland Europe. Three of the six closely-r lated pairs of isolates also 
carry the same blaOXA-51-like gene as one another and belong to the same SG. 
However, the other three pairs, while belonging to the same sequence group, possess 
different blaOXA-51-like genes. A480, A369 and A186 all carry blaOXA-66, while their 
closely related isolates A484, A401 and A343 carry blaOXA-83, blaOXA-82 and blaOXA-
109 respectively. However, these genes only differ from blaOXA-66 by one nucleotide 
(blaOXA-83 and blaOXA-109), or two nucleotides with one being a silent substitution 
(blaOXA-82), in all cases translating to one amino-acid difference in the enzyme (see 
appendix A). 
 
 The majority of isolates (53%) shared ≤80% similarity. Interestingly some isolates 
with different blaOXA-51-like sequences, and belonging to different sequence groups,  
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Figure 9: Pulsed-field gel electrophoresis analysis. OXA, blaOXA-51-like gene; SG, 
sequence group. A grey vertical line denotes relatedness of 87%. SG1 isolates are in 
red, SG2 isolates in blue and SG3 isolates in green. 
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were more similar to one another according to PFGE analysis than they were to 
isolates containing the same blaOXA-51-like gene and belonging to the same sequence 
group. Thus, isolate A186, which belonged to SG1 and contained a blaOXA-66 gene, 
shared 80% identity with isolate A335, which belonged to SG2 and contained a 
blaOXA-69 gene. Similarly, isolate A368, which belonged to SG2 and contained a 
blaOXA-112 gene, shared 80% identity with isolate A457, which contained a blaOXA-106 
gene and belonged to SG7. Conversely, isolates with the same blaOXA-51-like gene and 
SG were not all grouped together: for example, of the five isolates belonging to SG3 
encoding blaOXA-71, three are clustered together and related at 87%. The other two 
isolates are clustered nearest to some SG1 isolates in the case of A94 or a SG2 
isolate in the case of A329, are about 61% related to one another and <45% related to 
the other three SG3 isolates. When isolates were from the same location, contain the 
same blaOXA-51-like gene, and belong to the same sequence group, they tend to form 
more closely related clusters. This can be seen with isolates A480, A484, A481 and 
A482 from Nottingham, UK. These isolates represent a dominant lineage in the 
particular hospital from which the isolates were taken. In general, the mismatch 
between the PFGE profile on the one hand, and the blaOXA-51-like gene content and SG 
designation on the other, was considerable. 
 
 
3.3 Carbapenem susceptibility testing. 
Out of the 64 isolates included in the study, 36 (56%) were susceptible to both 
imipenem and meropenem according to BSAC criteria (MIC ≤2 mg L-1). Resistance 
to imipenem and meropenem (MIC ≥16 mg L-1) was seen in six isolates, four isolates 
were resistant to meropenem and intermediate (MIC of 4 t  8 mg L-1) for imipenem, 
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one isolate was resistant to imipenem and intermediat  to meropenem, nine isolates 
were intermediate for imipenem and meropenem, three isolates were intermediate for 
imipenem only, and five isolates were intermediate for meropenem only. Of the six 
imipenem- and meropenem-resistant isolates, four belong d to SG1, one to SG3 and 
one to SG4. These six isolates possessed a blaOXA-23-like gene (one isolate), a blaOXA-
40-like gene (three isolates), a blaOXA-58-like gene (one isolate) or carried ISAba1 
upstream of the blaOXA-51-like gene (two isolates). The four isolates that were rsistant 
to meropenem with intermediate susceptibilities to imipenem either had ISAba1 
upstream of the blaOXA-51-like gene (3 isolates) or carried a bl OXA-23-like gene (1 
isolate). The single isolate that was resistant to imipenem with intermediate 
resistance to meropenem possessed a blaOXA-58-like gene and ISAba1 upstream of the 
blaOXA-51-like gene. Of the 28 isolates that were resistant or ofintermediate resistance 
to one or both carbapenems, 13 belonged to SG1 (46%), 9 belonged to SG2 (32%), 3 
were from SG3 (11%), and SG4 accounted for the remaining 3 isolates (11%). 
Within the 36 isolates that were fully susceptible, only one carried an acquired OXA-
type β-lactamase (a blaOXA-58-like gene in A388), and none were positive for ISAba1 
upstream of the blaOXA-51-like gene. All isolates had previously been screened by Dr. 
Towner for the presence of blaIMP-like and blaVIM-like  metallo-β-lactamases, with only 
isolate A474 being positive, and was found to carry blaVIM-2. 
 
A total of 13 isolates possess an acquired OXA-type carbapenemase gene of either 
the blaOXA-23-like, blaOXA-40-like or blaOXA-58-like families that did not also possess an 
ISAba1 sequence upstream of their blaOXA-51-like gene. There are a total of 11 isolates 
for which the opposite is the case. In order to determine whether isolates encoding a 
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gene for an acquired OXA-type carbapenemase are associ ted with higher 
carbapenem MICs than isolates that contain an ISAba1 element upstream of their 
blaOXA-51-like gene, a Mann-Whitney U test was conducted on both the imipenem and 
meropenem MICs for these isolates, and the results are hown in table 11. The p 
values for both imipenem and meropenem are greater than 0.05, demonstrating that 
there is no statistical difference in the MICs of imipenem and meropenem for isolates 






Table 11: Summary of results for Mann-Whitney U test for the difference 
between the imipenem and meropenem MICs for isolates with an acquired 
OXA-type carbapenemase without an ISAba1 upstream of their blaOXA-51-like 
gene, and vice versa. Number, number of isolates; Mean rank, the mean rank v lue 
for the MICs for the isolates; Sum of Ranks, the sum of all of the ranks for the MICs 





Number Mean rank Sum of Ranks Probabilitya Probabilityb
Imipenem MICs Acquired OXA 13 13.73 178.5
ISAba1 -OXA-51 11 11.05 121.5
Total 24
Meropenem MICs Acquired OXA 13 11.92 155





3.4 OXA-51-like functional map. 
The OXA-51-like enzyme map revealed the enzymes formed distinct groupings 
(figure 10). Three very closely inter-related enzyme groups, with each member 
separated by one or two amino-acid differences were formed around OXA-66, OXA-
69 and OXA-98. These three enzymes appeared to form a hub from which the 
enzymes in their respective groups radiated. Outside of these major groups, four 
other enzymes had more than one enzyme that was closely related to them branching 
from them. Enzymes OXA-71, the enzyme representative of SG3, and OXA-51, the 
enzyme representative of SG4, both had two similar enzymes radiating from them. 
Enzymes OXA-106, found in the single representative of SG7, and OXA-90 both 
had three branches leading from them to similar enzymes. All other enzymes were 
linked in a chain-like manner rather than being clustered. The degree of variation 
within the OXA-51-like enzymes as a whole is considerable, with the two most 
distantly related enzymes, OXA-87 and OXA-75, differ ng by 16 amino-acids (for 
amino-acid sequences see appendix A). 
 
The three enzymes representative of SG1 (OXA-66), SG2 (OXA-69) and SG3 
(OXA-71) were not closely related, with differences at four amino-acid positions 
between OXA-66 and OXA-69, five amino-acid positions between OXA-66 and 
OXA-71, and seven amino-acid positions between OXA-69 and OXA-71. The OXA-
66 cluster was the largest group with 14 members (OXA-66, -65, -88, -76, -109, -82, 
-83, -84, -79, -80, -115, -131, -138 and –EU255296). The OXA-69 cluster had five 
members (OXA-69, -92, -107, -110 and -112), and 11 enzymes comprised the OXA-











































































































































































































































Figure 5: OXA-51-like enzyme map. Amino-acid substitutions are listed with respect to OXA-65. *PubMed accession number is listed 
for these enzymes as their official designation has yet to be publicly released. Grey circles represent hypothetical intermediate enzymes. 
Solid red, OXA-66; pale red, enzymes related to OXA-66; solid blue, OXA-69; pale blue, enzymes related to OXA-69; solid yellow, OXA-
98; pale yellow, enzymes related to OXA-98; green, OXA-71. 
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study, all isolates that were identified as belonging to SG1 carried genes for OXA-
66-like enzymes, except for isolate A473, which carries blaOXA-108. All isolates from 
SG2 had genes for OXA-69-like enzymes, and the genefor OXA-71 was identified 
in all SG3 isolates. 
 
Interestingly within different enzyme groups, the same amino-acid variations were 
observed. Changes at position 167 from a leucine residu  (with respect to OXA-65) 
to either a valine or a glutamine residue is seen three times within the OXA-66-like 
cluster, once in the OXA-69-like cluster, once between OXA-71 and OXA-113, and 
once between OXA-130 and OXA-108. Similarly, differences at position 129 
between an isoleucine and a leucine or valine are seen twice in the OXA-66-like 
cluster and once in the OXA-69-like cluster. The enzyme OXA-65 was chosen as the 
reference enzyme, which all amino-acid differences would be listed with respect to, 
as it appears to be the most central enzyme within the map. The central area of the 
map is bereft of enzymes, and it is possible that te ancestor of the OXA-51-like 
enzyme family would have taken up a position in this region. It is also of note that 
the enzymes that have been discovered more recently, identifiable by having the 
higher numerical designations or just the accession numbers, tend to be located on 
the fringes of the map rather than more centrally, indicating that in some cases we 






3.5 Multi-locus sequence typing. 
3.5.1  Analysis of concatenated sequences for all seven loci. 
A total of 44 isolates were chosen for analysis by MLST. Isolates were chosen such 
that at least one isolate with every different blaOXA-51-like gene identified in this study 
was included, and the more prevalent SGs were proporti nally represented. The 
designations of the alleles for the seven genes amplified for the 44 isolates along 
with their sequence type (ST) designation are shown in table 12. Provisional ST 
designations were assigned for novel allele combinatio s that were not found on the 
online A. baumannii MLST database.  
 
A total of 24 different STs were identified within the 44 isolates, with 19 of these 
being novel. Analysis of the data using the eBURST method, designed for examining 
evolutionary descent using MLST data (Feil et al, 2004), identified four clonal 
complexes along with nine singletons (figure 11). The largest clonal complex 
contained ST34 which was identified as a potential founder, with ST46, ST36, ST40, 
ST4 and ST22 radiating from it. A second major clona  complex contained ST49, 
ST51, ST47 and ST25 surrounding ST33, which was identifi d as a potential founder 
for the complex. The other two minor clonal complexes identified contained ST50 
and ST48, and ST35 and ST38 respectively. 
 
The index of association standardised (IA
S) was calculated to determine the linkage 
disequilibrium between the seven loci (Haubold et al, 1998). This measure calculates 
whether within a population, sets of alleles are linked together i.e. there is linkage 
disequilibrium, or if alleles are randomly distributed with respect to one another  
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Isolate gltA gyrB gdhB recA cpn60 gpi rpoD ST
A92 2 2 2 1 1 2 7 2
A230 1 12 3 2 2 7 3 4
A397 1 12 3 2 2 7 3 4
A187 1 15 13 12 4 12 2 20
A483 1 15 13 12 4 12 2 20
A371 1 3 3 2 2 7 3 22
A401 1 3 3 2 2 7 3 22
A484 1 3 3 2 2 7 3 22
A384 10 12 4 11 1 9 5 25
A1 10 12 4 11 4 9 5 33*
A297 10 12 4 11 4 9 5 33*
A368 10 12 4 11 4 9 5 33*
A442 10 12 4 11 4 9 5 33*
A63 10 12 4 11 4 9 5 33*
A216 1 12 3 2 2 3 3 34*
A24 1 12 3 2 2 3 3 34*
A25 1 12 3 2 2 3 3 34*
A320 1 12 3 2 2 3 3 34*
A392 1 12 3 2 2 3 3 34*
A4 1 12 3 2 2 3 3 34*
A6 1 12 3 2 2 3 3 34*
A20 1 1 1 1 1 9 6 35*
A329 1 1 1 1 1 9 6 35*
A377 1 1 1 1 1 9 6 35*
A478 1 1 1 1 1 9 6 35*
A387 1 12 3 2 2 4 3 36*
A388 10 26 4 11 4 11 5 37*
A13 1 27 1 1 1 9 6 38*
A37 1 15 2 15 1 16 18 39*
A47 1 12 3 2 2 19 3 40*
A60 1 15 18 10 14 12 18 41*
A473 1 24 22 12 17 20 4 42*
A457 1 25 13 6 4 25 22 43*
A135 1 28 21 10 1 24 4 44*
A95 14 23 20 16 1 11 20 45*
A343 1 3 3 2 2 3 3 46*
A479 10 12 4 11 4 22 5 47*
A125 12 18 12 1 15 3 19 48*
A404 10 12 4 11 4 4 5 49*
A407 10 12 4 11 4 4 5 49*
A443 10 12 4 11 4 4 5 49*
A472 10 12 4 11 4 4 5 49*
A374 12 18 12 1 15 26 19 50*
A424 10 12 4 11 4 19 5 51*  
Table 12: Multi-locus sequence typing alleles amplified for 44 isolates. ST, 
sequence type. * Provisional designation. 
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Figure 11: eBURST analysis of the 44 isolates. The size of the dot is proportional to the number of is lates within the sequence type. 
ST34 and ST33 are proposed clonal complex founders (blue). 
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throughout the population i.e. there is linkage equilibrium. Linkage disequilibrium 
arises through clonal spread in a population, while t e presence of frequent 
recombination will result in linkage equilibrium. Complete linkage equilibrium will 
result in IA
S = 0, while complete linkage disequilibrium will result in IA
S significantly 
greater than 0. An IA
S value that differs significantly from 0 is considered to 
represent linkage disequilibrium (Maynard Smith e  al, 1993). Analysis of the entire 
dataset of 44 isolates produced an IA
S value of 0.4907 (p = <0.001). This was 
decreased to 0.3569 (p = <0.001) when only one representative of each sequence 
type was included. Both values are significantly greater than 0, and indicate that the 
population is clonal. 
 
A Neighbour-joining tree was constructed using concatenated sequences for the 
seven genes for all 44 isolates, and is shown in figure 12, along with the OXA-51-
like enzyme carried by each isolate. The tree is spl t into two main clades. All of the 
isolates encoding genes for an OXA-66-like enzyme, and belonging to SG1, are 
grouped together in the top clade of the tree with reasonable support. Similarly, the 
five isolates encoding genes for OXA-71 from SG3 are grouped together in the 
bottom clade of the tree with a high degree of support. However, the isolates from 
SG2 that possess genes for OXA-69-like enzymes weresplit between the two clades. 
Eight of these isolates were grouped in the top clade with a good degree of support, 
while the other six isolates were found in the bottom clade, with a high level of 
support for their relatedness to the SG3 isolates. In order to determine the reason for 
the splitting of the SG2 isolates, neighbour-joining trees were constructed for each of 
the seven loci individually.
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Figure 12: Neighbour-joining tree for 44 isolates using concatenated sequences for the seven genes. Isolate names are followed by the 
OXA-51-like enzyme that they carry and their SG. Branches are labelled with % support. The tree is mid-po nt rooted. Red, SG1; blue, 
SG2; pink, SG3. 
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3.5.2  Analysis of each individual locus. 
The neighbour-joining trees for the seven MLST genes ar  shown in figures 13 to 19. 
Comparison of the tree topologies for all identified alleles of the seven genes 
revealed inconsistencies with the trees for gyrB and gpi in relation to one another and 
to the other five trees. Within the trees for the cpn60, rpoD, gltA, recA and gdhB 
alleles, isolates forming SG1, SG2 and SG3 generally cluster with the other isolates 
forming their SG. In some instances, for example in the gdhB tree (figure 16), the 
isolates from these three main SGs form their own discrete clades. In others, for 
example the gltA tree (figure 13), SG2 is in a distinct clade while SG1 and SG3 share 
one. Conversely, in the rpoD tree (figure 19) SG3 is found in its own clade, while 
SG1 and SG2 share one. While there is some variation within the phylogenies for 
these five genes, the data from these alleles do not result in a major splitting of 
members from the same sequence group across two clades. However, the 
phylogenies for the gyrB and gpi alleles are different. The tree showing the 
relationships between the gpi alleles (figure 14) shows a major split between isolates 
belonging to SG2. Isolates A424, A472, A443, A407, A404 and A479 are found in 
the top half of the tree, which they share with the SG1 isolates. However, isolates 
A63, A442, A384, A368, A297 and A1 are found in thelower half of the tree along 
with the SG3 isolates. The branches for both parts of he tree show strong support. 
This major split of the SG2 isolates did not match with the features observed for the 
first five genes mentioned above. Analysis of the tre  for the gyrB alleles (figure 18) 
revealed further inconsistencies. The majority of the isolates belonging to SG1 are 
found in the top half of the tree close to the SG2 isolates. However, four of the SG1 
isolates, A484, A401, A371 and A343, are in the lower region of the tree, with strong  
 77 
 
Figure 13: gltA neighbour-joining tree. Isolate names are followed by the OXA-51-like enzyme that they carry and their SG. Branches 
are labelled with % support. The tree is mid-point rooted. Red, SG1; blue, SG2; pink, SG3.
 78 
 
Figure 14: gpi neighbour-joining tree. Isolate names are followed by the OXA-51-like enzyme that they carry and their SG. Branches are 
labelled with % support. The tree is mid-point rooted. Red, SG1; blue, SG2; pink, SG3. 
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Figure 15: recA neighbour-joining tree. Isolate names are followed by the OXA-51-like enzyme that they carry and their SG. Branches 
are labelled with % support. The tree is mid-point rooted. Red, SG1; blue, SG2; pink, SG3. 
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Figure 16: gdhB neighbour-joining tree. Isolate names are followed by the OXA-51-like enzyme that they carry and their SG. Branches 
are labelled with % support. The tree is mid-point rooted. Red, SG1; blue, SG2; pink, SG3. 
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Figure 17: cpn60 neighbour-joining tree. Isolate names are followed by the OXA-51-like enzyme that they carry and their SG. Branches 
are labelled with % support. The tree is mid-point rooted. Red, SG1; blue, SG2; pink, SG3. 
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Figure 18: gyrB neighbour-joining tree. Isolate names are followed by the OXA-51-like enzyme that they carry and their SG. Branches 
are labelled with % support. The tree is mid-point rooted. Red, SG1; blue, SG2; pink, SG3. 
 83 
 
Figure 19: rpoD neighbour-joining tree. Isolate names are followed by the OXA-51-like enzyme that they carry and their SG. Branches 
are labelled with % support. The tree is mid-point rooted. Red, SG1; blue, SG2; pink, SG3. 
 84 
support shown for the splitting of the two groups. This phylogeny is inconsistent 
with that for gpi as well as those for the other five genes. These visual observations 
suggest that the gpi and gyrB loci may not be stable and suitable for use in an MLST 
scheme. 
 
The visual observations of the differences in the topologies for the gpi and gyrB 
phylogenies in relation to those for the other five genes was confirmed via the quartet 
measure of tree-to-tree distances (Estabrook et al, 1985). This method calculates the 
similarity of two tree topologies to one another by comparing for each possible set of 
four isolates, whether they are related to one another in the same manner in both 
trees, or not. Examining the phylogenies for the seven MLST genes demonstrated 
that for gyrB and gpi the number of differently resolved quartets was greater than the 
number of similarly resolved quartets, in contrast to the other five genes (table 13). 
This demonstrated that the visual observation of inconsistencies was correct. Alleles 
for all seven genes were analysed with the pairwise homoplasy index (phi) test 
(Bruen et al, 2006). This test compares sites at which there is variation with other 
‘nearby’ sites at which there is variation to determine whether sequences contain a 
consistent pattern of nucleotide variation. Sudden changes in one sequence from a 
pattern similar to its closely related sequences to one similar to a more distantly 
related sequence provides evidence for the sequence having undergone 
recombination. After analysing the sequences of the alleles for all seven genes the 
phi test detected statistically significant evidenc for recombination (p = 0.0036) 
within the alleles for gyrB, but not within the alleles for the other six genes. Together 
these observations suggest that the gyrB and gpi genes both have different  
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Tree comparisons        Q Same Different
gyrB cpn60 135751 48678 87073
gpi cpn60 135751 53525 82226
gyrB 135751 54176 81575
gltA cpn60 135751 72781 62970
gyrB 135751 48728 87023
gpi 135751 48678 87073
gdhB cpn60 135751 81976 53775
gyrB 135751 66570 69181
gpi 135751 64914 70837
gltA 135751 79804 55947
rpoD cpn60 135751 85972 49779
gyrB 135751 66667 69084
gpi 135751 62436 73315
gltA 135751 80324 55427
gdhB 135751 106700 29051
recA cpn60 135751 101700 34051
gyrB 135751 51342 84409
gpi 135751 57243 78508
gltA 135751 81937 53814
gdhB 135751 93872 41879
rpoD 135751 92481 43270  
Table 13: Quartet measures of tree-to-tree distances. Q, maximum number of 
resolved quartets; Same, number of quartets that were resolved and the same; 
Different, number of quartets that were resolved but different. 
 
 
evolutionary histories to the other five genes, ands such are not reliable or suitable 
for use within an MLST scheme. 
 
3.5.3  Analysis of concatenated sequences for five loci. 
Due to evidence that the gpi and gyrB loci are unreliable for use in an MLST scheme, 
further phylogenetic analysis of the isolates in this study was performed using 
concatenated sequences of the remaining five loci – gltA, recA, gdhB, cpn60 and 
rpoD. A neighbour-joining tree using these five loci is shown in figure 20. 
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Figure 20: Neighbour-joining tree for 44 isolates using concatenated sequences for five alleles. Isolate names are followed by the 
OXA-51-like enzyme that they carry and their SG. Branches are labelled with % support. The tree is mid-po nt rooted. Red, SG1; blue, 
SG2; pink, SG3. 
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The phylogeny of the 44 isolates was consistent with SG designations and blaOXA-51-
like gene content, and was very well supported. Of the 17 isolates belonging to SG1, 
15 were grouped together in the top-most clade. The two SG1 isolates that were not 
grouped there, A473 and A60, possessed a blaOXA-108 and a blaOXA-65 gene 
respectively. Analysis of the individual locus trees indicates that A60 differs from the 
other SG1 isolates at the rpoD, recA, gdhB and cpn60 loci, whereas A473 only 
differs at the gdhB and cpn60 loci. 
 
All of the isolates belonging to SG2 were found in the same clade. Isolate A384 is 
slightly removed from the other SG2 isolates due to variations within the cpn60 
locus. Isolate A92 that carries a blaOXA-69 gene with five silent substitutions 
compared with the other blaOXA-69 sequences, and that belongs to SG9, differed from 
the SG2 isolates at the gdhB, recA and cpn60 loci, and to a lesser extent at the gltA 
locus, confirming that this isolate is very different to the other SG2 isolates despite 
containing a gene that codes for OXA-69. 
 
The five SG3 isolates were all found together in one clade with 100% support, as 
these isolates are grouped together in all of the individual locus trees. Two of the 
SG4 isolates, A374 and A125, were grouped together with 100% support as they 
were also the same as one another across the five loci. However, the other SG4 
isolate, A483, was not grouped with the other two, as it has a different nucleotide 
sequence for all five loci. As the blaOXA-51-like gene is identical in all three isolates, 
but the sequences for the alleles at the other five loci are not, it is possible that the 
blaOXA-51 gene in isolate A483 may have been horizontally transferred. The two 
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isolates that represent SG8 are found on their own separate branches. The isolates 
differ at the recA, gdhB and rpoD loci, but also possess different OXA-51-like 
enzymes, OXA-111 and OXA-64, which differ by four amino-acids, and by eight 
nucleotides. The two isolates representing SG9 are also found on separate branches 
as they differ at all but the rpoD locus. The two OXA-51-like enzymes that these 
isolates contain, OXA-68 and OXA-69 (with five silent nucleotide substitutions), 
differ by eight amino-acids and by 12 nucleotides. The fact that some isolates that 
share a SG, but differ at several MLST loci and carry different blaOXA-51-like genes 
suggests that the SG typing scheme may only be of value in discriminating between 
the three main epidemic lineages containing European clones I, II and III. 
 
3.5.4  Comparisons within and between MLST and blaOXA-51-like alleles. 
To investigate whether the blaOXA-51-like locus is comparable in terms of diversity to 
the ‘housekeeping’ genes used in the MLST scheme, and to other families of β-
lactamase genes, the πN/πS measure of diversity was used. All alleles for all seven 
MLST loci and blaOXA-51-like genes available at the time were included. In addition, 
the first 52 different entries on the PubMed website following a search for ‘TEM’ 
and ‘SHV’, and all entries for blaCTX-M-1-like, blaCTX-M-9-like and blaCMY genes were 
included (excluding multiples of the same enzyme variant). The πN/πS ratios are 
shown in table 14. A πN/πS ratio greater than one indicates positive selection i.e. 
selection for an amino-acid substitution to change the enzyme variant, while a ratio 




Locus Alleles Pairwise comparisons πN πS πN/πS
gltA 14 91 0.0072 0.2487 0.0291
gyrB 28 378 0.0087 0.2580 0.0336
recA 16 120 0.0075 0.6157 0.0122
gdhB 20 190 0.0171 0.3049 0.0560
cpn60 17 136 0.0072 0.1657 0.0435
gpi 25 300 0.0093 0.3012 0.0380
rpoD 20 190 0.0146 0.2029 0.0720
bla OXA-51-like 52 1326 0.0108 0.0218 0.2460
bla TEM 52 1326 0.0069 0.0158 0.4357
bla SHV 52 1326 0.0061 0.0151 0.4069
bla CTX-M-1-like 24 276 0.0066 0.0396 0.1664
bla CTX-M-9-like 17 136 0.0048 0.0079 0.6152
bla CMY 20 190 0.0084 0.0480 0.1759  
Table 14: πN/πS ratios for MLST genes, blaOXA-51-like genes, and other selected 
β-lactamase genes. 
 
The πN/πS ratios for the seven MLST ‘housekeeping’ genes were all very low, and 
did not differ from one another by more than a factor of 6. However, the blaOXA-51-like 
alleles produced a πN/πS ratio that was significantly higher than those for the MLST 
genes (p < 0.001), though still considerably less than one, and differed from them by 
a factor of between 3.4 and 20. This suggests that the blaOXA-51-like genes are under 
less purifying selection than is seen for purely ‘housekeeping’ genes (Nei & 
Gojobori, 1986). 
 
The πN/πS ratios for the selected β-lactamases were also less than one, but again 
were much greater than those of the ‘housekeeping’ genes, as expected. Interestingly, 
the values obtained ranging between 0.16 and 0.62 are in the same range as that 
obtained for the blaOXA-51-like alleles, suggesting that the blaOXA-51-like genes are under 
a similar level of selection to other major groups of β-lactamase genes. 
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3.6 Dose response curves. 
To determine if the presence of the intrinsic blaOXA-51-like genes in A. baumannii 
increased the ability of the species to survive carbapenem pressure, even if the 
isolates themselves are not resistant, dose response curves were calculated. The 
comparison of curves for three A. baumannii solates, two genospecies 13TU isolates 
and one genospecies 3 isolate is shown in figure 21. The A. baumannii solate ATCC 
19606 was used as a sensitive reference strain, while isolates A24 and A343 were 
chosen as they are sensitive representatives of the hig ly prevalent sequence group 1. 
For A. baumannii solates ATCC19606, which has no ISAba1 elements, and A24 
which has ISAba1 elements but not upstream of the blaOXA-51-like gene, there was no 
major difference in their ability to survive meropenem challenge compared with the 
genospecies 3 and 13TU isolates. This indicates that the presence of the blaOXA-51-like 
gene alone, without the presence of the ISAba1 sequence to potentially enhance its 
expression, does not greatly affect the survivability of the isolate. In contrast isolate 
A343, which has an ISAba1 sequence upstream of its blaOXA-51-like gene, is much 
better able to survive meropenem challenge than the other isolates. Despite the fact 
that the meropenem MIC for this isolate is only 4 mg L-1 (table 1), considered of 
intermediate susceptibility by BSAC 2008 criteria and susceptible by Clinical and 
Laboratory Standards Institute (CLSI) 2006 criteria, the isolate still maintains ≥100% 
viability at a meropenem concentration of 14.6 mg L-1 (equation of the line between 
points at 8 and 16 mg L-1 is y = -37.202x + 645.89), and is not reduced to a viability 
of less than 10% until the meropenem concentration reaches 45.8 mg L-1 (equation of 
the line between points at 32 and 64 mg L-1 is y = -0.5158x + 33.633). This suggests 
















ATCC19606 (sp.2) Ab191 (sp.13TU) Ab192 (sp.13TU) Ab41 (sp.3) A24 (sp.2) A343 (sp.2)
 
Figure 21: Percentage viability of Acinetobacter species after 3 hours challenge with meropenem. 
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A343 may allow it to survive meropenem challenge much better than the other 
isolates, with viability of ≥100% maintained at a concentration approaching 4-fold 
the isolates MIC value. However, it should be noted that due to the limitations of the 
isolate collection available, the three A. baumannii solates included in this 
experiment all possess different blaOXA-51-like genes (ATCC 19606 carries blaOXA-98, 
A24 carries blaOXA-66 and A343 carries blaOXA-109), and it is possible that these 
different enzyme variants may be contributing to the different responses to 
meropenem that were observed. 
 
3.7 Mutation study. 
In order to determine whether sensitive A. baumannii can acquire resistance to the 
carbapenems conferred by the blaOXA-51-like genes under selective pressure, a mutation 
study was conducted. Isolates were grown under increasing concentrations of 
meropenem, and mutants examined for changes to the gene sequence, or for the 
insertion of ISAba1 upstream of the gene. 
 
The increasing concentrations of meropenem that growth was detected on for the five 
studied isolates are shown in figure 22. Isolate ATCC 19606 was included as the 
sensitive type strain, and the other four isolates w re included to represent each of 
the three major sequence groups, as well as an isolate carrying blaOXA-65, encoding 
the enzyme that appears to be the closest to the centre of the OXA-51-like functional 
map (see section 3.4) and therefore present the greatest potential to acquire 


















































Figure 22: The highest concentrations of meropenem on which successive cultures of isolates were able to grow. Concentrations are 
in mg L-1. 
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Isolate A1 (representing SG2 carrying blaOXA-69) demonstrated the greatest fold-
increase in the concentration of meropenem which it ould grow on, increasing from 
1 mg L-1 to 128 mg L-1. The type strain ATCC19606 and isolate A24 (representing 
SG1 carrying blaOXA-66) showed the next greatest increase, going from 0.25 mg L
-1 to 
4 mg L-1, a 16-fold increase. Isolates A60 (representing SG1 carrying blaOXA-65) and 
A20 (representing SG3 carrying blaOXA-71) produced an 8-fold increase, going from 2 
and 4 mg L-1 to 16 and 32 mg L-1 respectively. Sequencing of the blaOXA-51-like genes 
of the mutant isolates demonstrated that there wereno nucleotide changes in any of 
the genes in relation to their parent isolates, and in the isolates that possess ISAba1 
(A60 and A24), the insertion sequence had not moved to insert upstream of the 
blaOXA-51-like gene. 
 
Analysis of MIC data obtained for the parent and mutant isolates eight months after 
their isolation is shown in table 15. The meropenem MICs for the A1 mutant and  
A20 mutant are 8-fold lower than the concentration of meropenem on which they 
were isolated. However, the MICs for four of the parent isolates (ATCC19606, A1, 
A20, and A60) had also decreased from those shown in tables 7 and 8, and 
previously determined for ATCC19606. This suggests that the mechanism of 
increased resistance in these isolates is transient and gradually decreases over time 
that the isolate is stored. However, the MICs for the mutants of isolates ATCC19606, 
A24 and A60 are at the same concentration as that of the meropenem plate they were 
isolated from. Interestingly, the increases in resistance to imipenem in the mutant 




MIC Fold-increase MIC Fold-increase
ATCC19606 0.06 0.12
ATCC19606 M 0.5 8 4 32
A1 0.12 0.25
A1 M 0.5 4 16 64
A20 0.12 0.5
A20 M 0.5 4 4 8
A24 0.12 0.25
A24 M 1 8 4 16
A60 0.25 0.5
A60 M 1 4 16 32
Imipenem Meropenem
 
Table 15: MICs of imipenem and meropenem for parent and mutant isolates. 
M, mutant isolate. MICs are in mg L-1. 
 
that the mechanism of increased resistance that was being selected by meropenem 
was not as effective at providing resistance to imipenem. 
 
3.8 Growth study. 
In order to investigate the degree of heterogeneity that can occur in A. baumannii 
pulsed-field gel electrophoresis patterns and the blaOXA-51-like gene over a medium-
term period of time, a growth study was conducted. Isolate A418 was studied as it 
represents the most prevalent sequence group, SG1, and carries the most prevalent 
blaOXA-51-like gene, blaOXA-66. Additionally, this isolate possess ISAba1, though it is 
not found to be present upstream of the blaOXA-66 gene. Therefore this experiment 
would also examine whether long-term exposure to sub-inhibitory concentrations of 
meropenem could induce the movement of the insertion sequence to insert upstream 
of the blaOXA-66 gene.  
Isolate A418 was grown for 100 days continually in nutrient broth, and for 100 days 
continually in nutrient broth containing imipenem at 1/8th of the isolate’s MIC. 
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Analysis of the PFGE patterns generated for the parnt isolate and for the two 100 
day-old isolates, shown in figure 23, shows that the isolate grown in nutrient-rich 
conditions without any pressures had an identical PFGE pattern to the parent isolate. 
However, the isolate grown under a sub-inhibitory concentration of imipenem had a 
slightly different pattern with 88% similarity to the parent isolate, and differing by 
three bands. These differences are not major, and the isolates would all be considered 
members of the same epidemic strain using a cut-off of ≥87%, though only 
marginally (Seifert et al., 2005). These data demonstrate that the PFGE pattern for 
isolate A418 can vary by almost enough for the isolate to be classified as a different 
epidemic strain after only 100 days growth in stressful conditions, and this may 
explain why PFGE analysis in section 3.2 was unable to group isolates in agreement 
with other typing methods. Sequencing of the blaOXA-51-like genes of the two 100 day-
old isolates revealed identical sequences to the parent isolate, and in neither isolate 





Figure 23: Pulsed-field gel electrophoresis analysis of the original parent isolate, 




3.9 blaOXA-51-like sequence analysis. 
3.9.1  Bayesian analysis of the species A. baumannii. 
Analysis of the blaOXA-51-like genes of the 64 isolates included in this study has shown 
that certain groups of closely related genes are associated with particular lineages 
within the species. Investigation of the phylogeny of the blaOXA-51-like genes and how 
this relates to that of the isolates that carry them was conducted through bayesian 
analysis of the nucleotide sequences. 
 
A phylogeny for A. baumannii was constructed using the sequences for the four 
‘housekeeping’ genes gltA, recA, cpn60 and rpoD previously amplified for the 44 
isolates in this study. Additionally, the sequences for these genes were downloaded 
from the PubMed website for the six published A. baumannii genome sequences 
(ACICU, AB0057, AB307-0294, AYE, SDF and ATCC17978), and for two 
genospecies 13TU isolates which were used as outgroups. The gpi and gyrB genes 
that it was previously shown demonstrated evidence for horizontal gene transfer were 
not used, and neither was gdhB as this gene was not found in isolate SDF, and 
therefore it can not be relied upon as a conserved ‘housekeeping’ gene. The resulting 
phylogeny is shown in figure 24. As was observed previously with the MLST data, 
all of the isolates with similar blaOXA-51-like genes were grouped together, with isolates 
belonging to SG1 found in the top clade of the tree, all of the SG2 isolates in the 
large central clade of the tree, and the five SG3 isolates in the bottom half of the tree, 
with all clades diverging independently from a common root for the species. 
Interestingly the main clades are not all found at the same distance from the common 
root. For example, the SG1 isolate A397 is at a distance of 0.2146 from the root,  
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Figure 24: Bayesian phylogeny of A. baumannii. Branch tips are labelled with isolate names and the OXA-51-like enzyme they contain. 
Branches are labelled with posterior probabilities. The tree is rooted to sp.13TU strain st7961. Red, SG1; blue, SG2; pink, SG3. 
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indicating a sequence divergence of 21% from the root. On the other hand, a branch 
length of 0.1906 for the SG2 isolate A479 represents 19% sequence divergence, and 
the length of 0.0183 for the SG3 isolate A13 represents 1.8% sequence divergence 
from the root. 
 
3.9.2  Bayesian analysis of blaOXA-51-like genes. 
To estimate the phylogeny of the blaOXA-51-like genes, all available allele variants were 
downloaded from the PubMed website. Added to these wer  allele variants identified 
from isolates from Pakistan not included in this study, and variants identified by Dr. 
Alsultan in our laboratory (personal communication). A bayesian analysis of all of 
these alleles is shown in figure 25. 
 
The blaOXA-51-like genes are believed to be intrinsic and ubiquitous in A. baumannii, 
and this study has shown the close relationship between groups of similar blaOXA-51-
like genes and certain lineages within the species. The hypothesis that the blaOXA-51-like 
genes have been co-evolving with the A. baumannii solates that carry them with 
little horizontal gene transfer was used as a basis for rooting the blaOXA-51-like 
phylogeny in the absence of an outgroup for these enzymes. Therefore the blaOXA-51-
like tree was rooted at the same position as that in the A. baumannii species tree in 
figure 24. 
 
The tree is split into seven main clades, with the different groups of blaOXA-51-like 
genes clustered in separate clades. All of the clades that carry the different enzyme 
groups diverge independently from a common root. However, the different clades do  
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Figure 25: Bayesian phylogeny of all available blaOXA-51-like allele variants. Branch tips are labelled with the enzyme name. For un-
named enzymes the PubMed accession number is used. For variants of named enzymes the enzyme name is followed by an accession 
number or isolate name as appropriate. Branches are labelled with posterior probabilities. The tree is rooted in concordance with figure 15. 
Red, blaOXA-66-like genes; blue, blaOXA-69-like genes; pink, blaOXA-71-like genes. 
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not all extend the same distance from the root. The enzyme OXA-66 extends a 
distance of 0.6674 from the root, representing a sequence divergence of 67%. The  
enzyme OXA-69 has a shorter branch length of 0.5152 translating to 52% sequence 
divergence, while OXA-71 is at a distance of only 0.3255, diverging 33% from the 
root. 
 
The top-most clade of the tree contains blaOXA-66 and related genes at its tip, and 
extends the furthest from the root. The ladder-like topology of the clade is indicative 
of recurrent selective sweeps over a period of time, a classic example of which is 
seen in the topology of trees examining the haemagglutinin gene in human influenza 
A virus strains (Cobey and Koelle, 2008). A similar p ttern is seen in the clade 
encompassing blaOXA-69 and similar genes. Other smaller clades that don’t extend as 
far from the root also show a topology indicative of selective sweeps. However, this 
is not so evident in the clade containing blaOXA-98. This clade is much more compact 
with many of the genes emerging from the same node. Th  two clades in which the 
ladder-like topology is most pronounced (the OXA-66-like and OXA-69-like 
enzymes) are also the two clades with the longest branch lengths. 
 
3.9.3  Comparison of A. baumannii and blaOXA-51-like phylogeny. 
A direct comparison of the phylogenies for the blaOXA-51-like genes and A. baumannii 
is shown in figure 26. There is a large degree of similarity in the topologies of the 
two trees, which would be expected if the blaOXA-51-like genes have been evolving 
within A. baumannii for a long period of time. The concordance of the two trees is 
good evidence for the co-evolution of the blaOXA-51-like genes and the ‘housekeeping’  
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Figure 26: Comparison of bayesian phylogenies for blaOXA-51-like genes and A. baumannii. Boxes encompass blaOXA-51-like genes 
associated with SG1 (red), SG2 (blue) and SG3 (pink) o  the left, and isolates allocated to SG1, 2 and 3 on the right.
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genes. However, there are some notable exceptions. As previously noted in the 
MLST analysis in section 3.5.3, the three isolates that contain a blaOXA-51 gene 
(A483, A125 and A374) are separated in the A. baumannii tree. Additionally, isolate 
A135 is not clustered with the SG4 isolates, despit the fact that the blaOXA-111 gene 
that it possesses is found within the same clade as blaOXA-51. Isolate A60 that belongs 
to SG1 and carries blaOXA-65 is separated from the other SG1 isolates, and is grouped 
with A37, which carries blaOXA-64. 
 
The similarities in the two phylogenies are most clearly demonstrated when 
examining the clusters of enzymes and isolates associated with the three major 
epidemic lineages associated with SG1, 2 and 3. Measur ments of the branch lengths 
for blaOXA-66, blaOXA-69 and blaOXA-71, along with those for three representative 
isolates that carry these genes are shown in table 16. For both the blaOXA-51-like genes 
and for A. baumannii as a species, SG1-associated blaOXA-51-like genes and isolates are 
evolving at the fastest rate, SG2-associated genes a d isolates are evolving at the 
second fastest rate, with SG3-associated genes and i olates evolving most slowly of 
the three groups. Interestingly, in all cases the blaOXA-51-like genes are evolving at a 
faster rate than the isolates that possess them. This demonstrates that the blaOXA-51-like 
genes are evolving faster than the rest of the A. baumannii genome, as would be 
expected if the ‘housekeeping’ genes were under a higher degree of purifying 
selection than the blaOXA-51-like genes, as demonstrated by the πN/πS ratios calculated 
in section 3.5.4. 
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SG OXA Branch length Rate Isolate Branch length Rate
1 66 0.6674 36.47 A230 0.2146 11.73
2 69 0.5152 28.15 A479 0.1906 10.42
3 71 0.3255 17.79 A13 0.0183 1
 
Table 16: Branch lengths and mutation rates for blaOXA-51-like genes and isolates 
that possess them. Rate, the relative evolutionary rate as a function of the shortest 
branch length of A13. 
 
3.10 OXA-51-like structural models. 
3.10.1  Identification of regions of variance. 
While there is a significant degree of sequence divrs ty within the blaOXA-51-like 
genes, the majority of nucleotide changes are likely to be synonymous, or to result in 
an amino-acid change that has little impact on enzyme function. In order to identify 
regions of the OXA-51-like enzymes where variation may affect the enzyme 
function, the percentage amino-acid variation at all sites within the enzymes was 
compared with the πN/πS ratios across 50-nucleotide-wide windows within te gene 
sequences (figure 27). 
 
The data in figure 27 was used to identify a number of sites at which there was a one 
or more of the following criteria: a large amount of amino-acid variation (>10%), a 
πN/πS ratio greater than one, and proximity to a region ide tified from the OXA-40 
crystal structure as being involved in enzyme activity or carbapenem specificity. 
These residues would be taken forward for further investigation. Due to the 
limitations of the structural models produced for the OXA-51-like enzymes, only 
residues from number 30 onwards could be investigated. This process resulted in the 
identification of 12 sites of interest: positions 36, 57, 107, 117, 129, 130, 146, 156, 
167, 168, 194 and 225. For each of these sites, two structural models that vary at the 
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Figure 27: OXA-51-like % amino-acid differences to consensus sequence compared with blaOXA-51-like πN/πS ratios. 
Blue boxes indicate regions thought to be active site elements and yellow boxes indicate regions thougt to be involved in carbapenem 
specificity, based upon the OXA-40 crystal structure.
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appropriate position were examined to identify the potential impact of the amino-acid 
changes. 
 
3.10.2  Examination of structural models. 
3.10.2.1  Positions 36, 57, 107, 117, 146, 156 and 194. 
Of the 12 sites that were examined, 7 contained amino-acid changes the effects of 
which could not be determined from the structural models available. Positions 36, 57, 
107, 117, 146, 156 and 194 were not found near the active site cleft, and were found 
on, or in the case of position 57 very near, the enzyme surface. In most cases the 
different amino-acids found at each site did confer different properties, as shown in 
table 17. The majority of these enzyme variations did not appear to have an effect on 
the structure of the enzyme. 
 
Amino-acid position Amino-acid Properties
36 Glutamate Negative, polar




Histidine Positive, aromatic, hydrophobic, polar
Arginine Positive, polar
107 Lysine Positive, hydrophobic, polar
Glutamine Polar
Glutamate Negative, polar
117 Aspartate Negative, polar
Asparagine Polar






Leucine hydrophobic aliphatic  
Table 17: Properties of amino-acids found at seven positions. 
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In addition to the different properties of the various enzymes, at position 57 the 
histidine that is found in enzymes such as OXA-69 forms a hydrogen bond with the 
glutamine at position 62. In enzymes such as OXA-66 that have a glutamine at 
position 57, this hydrogen bond does not exist. This may have a subtle effect of the 
structure of the enzyme. At position 194 enzymes such as OXA-51 have a proline 
residue, whereas enzymes such as OXA-66 and OXA-69, from the successful SG1 
and SG2 lineages, have a glutamine residue (see appendix A for alignments). 
Position 194 is found just at the start of helix α8 and forms part of the loop between 
helix α7 and helix α8 that turns the latter helix back into the enzyme structure (figure 
28). Due to the properties of proline and its ability to form stable tight direction 
changes in molecular structures, it is likely that v riation between proline and 
glutamine at position 194 has a significant effect on enzyme structure, though this 
could not be visualised due to the limitations of the models based upon the OXA-40 
backbone. 
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Figure 28: Proline residue at position 194 within the turn between helices α7 
and α8 in OXA-51. α-helices are in green, β-sheets are in blue, loops are in yellow. 
Structure was visualised in DeepView. 
 
 
3.10.2.2  Position 129. 
Residues at position 129 are found at the end and bottom of the active site cleft, not 
too far from the active site serine at position 80. Enzymes such as OXA-66 have an 
isoleucine at position 129, which sits just to the side of the base of the cleft, 5.73 Å 
distant from the active site serine (figure 29). In some enzymes such as OXA-83, one 
of the potential more recently evolved SG1 enzymes, the isoleucine is substituted for 
a leucine residue. The leucine residue sits slightly closer to the active site serine at a 
distance of 5.48 Å, and takes up more space along the bottom of the active site cleft 
than the isoleucine residue does (figure 25). This c ange in shape within the active  
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Figure 29: Molecular surface diagram showing view down the active site cleft of 
OXA-66 (grey) with the active site serine 80 (red) and an isoleucine at position 
129 (blue) indicated. Structure was visualised in DeepView. 
 
 
Figure 30: Molecular surface diagram showing view down the active site cleft of 
OXA-83 (grey) with the active site serine 80 (red) and a leucine at position 129 
(blue) indicated. Structure was visualised in DeepView. 
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site cleft reduces the amount of space for substrate molecules, and as such may affect 
the substrate profile or rate of hydrolysis of the enzymes. Amino-acid substitutions at 
position 129 occur independently in the blaOXA-66 and the blaOXA-69 clades of the 
blaOXA-51-like phylogeny, suggesting that there is a degree of positive selection for this 
variation. 
 
3.10.2.3  Position 130. 
Variations in the amino-acid at position 130 adjacent to those that occur at position 
129 are also observed. Enzymes such as OXA-66 have a proline residue that is likely 
to provide stability for the isoleucine residue at position 129, as well as for the 
hydrogen bond between residues alanine 128 and valine 131 (figure 31). In other 
enzymes such as OXA-115, a potential more recently volved SG1 enzyme, the 
proline at position 130 is substituted for a leucine residue (figure 32). This change is 
likely to result in movement of the isoleucine residue at position 129, and may also 
affect the hydrogen bond between alanine 128 and valine 131, resulting in an altered 
shape at the end of the active site cleft. Changes at position 130 are observed three 
times within the blaOXA-66 gene group, with the proline residue being replaced by a 
leucine, serine or a glutamine residue (see appendix A), indicating that there is 
selection for the loss of proline at this site. 
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Figure 31: OXA-66 structure showing the residues proline 130 (blue), the 
hydrogen bond between alanine 128 and valine 131 (green dashed line), and 
leucine 167 (yellow), in relation to the active site serine 80 (red). Structure was 
visualised in DeepView. 
 
 
Figure 32: OXA-115 structure showing the residues leucine 130 (blue), the 
hydrogen bond between alanine 128 and valine 131 (green dashed line), and 
valine 167 (yellow), in relation to the active site serine 80 (red). Structure was 
visualised in DeepView. 
 112 
3.10.2.4  Position 167. 
Another position within the active site cleft at whic  there is amino-acid variation is 
position 167. A view down the active site cleft shown in figure 33, from the opposite 
direction as that shown in figures 29 and 30, reveals that enzymes such as OXA-66 
have a leucine residue at position 167 that sits at the base and end of the cleft. The 
leucine residue is 5.25 Å from the active site serine 80, and only 3.70 Å from the 
isoleucine residue at position 129, which forms the other side of the base of the cleft, 
as shown in figure 29. However, other enzymes such as OXA-82, potential more 
recently evolved SG1 enzymes, have a valine residue at position 167 in place of the 
leucine. As shown in figure 34, this alters the shape of the end of the active site cleft. 
The valine residue sits further away from both the active site serine, 7.28 Å distant, 
as well as from the isoleucine residue at position 129, now at a distance of 6.12 Å. 
The presence of a valine residue at position 167 in place of a leucine residue 
increases the amount of space between the active site ser ne 80 and the end of the 
cleft, and also changes the shape of the end of the cleft. Changes at this position have 
occurred independently at least twice in the blaOXA-66 clade, and once in the blaOXA-69 
and blaOXA-71 clades of the blaOXA-51-like phylogeny, indicating that there is a 
significant degree of selection for this change. In OXA-115, a valine at position 167 
combines with the loss of proline at position 130, which is likely to significantly alter 
the shape of the cleft in this enzyme (figure 32). 
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Figure 33: Molecular surface diagram showing view down the active site cleft of 
OXA-66 (grey) with the active site serine 80 (red) and a leucine at position 167 
(blue) indicated. Structure was visualised in DeepView.  
 
 
Figure 34: Molecular surface diagram showing view down the active site cleft of 
OXA-82 (grey) with the active site serine 80 (red) and a valine at position 167 
(blue) indicated. Structure was visualised in DeepView. 
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3.10.2.5  Position 168. 
Variation at position 168 is observed in two enzymes, OXA-84 and the enzyme with 
accession number EU255295. While the changes from a valine to an alanine or 
methionine respectively do not appear to cause any major structural changes within 
the models constructed, the proximity of this residue to the important position 167, 
and the fact that the changes at position 168 appear to have occurred independently 
within these two enzymes suggests that they may have an effect on the end of the 
active site cleft to which they are adjacent. 
 
3.10.2.6  Position 225. 
The final position that was investigated was 225. Residues at position 225 are on the 
surface of the enzyme and close to the entrance to the active site cleft. Some isolates 
such as OXA-66 have an asparagine residue at this pos tion (figure 35). The 
structural models show this residue to form a hydrogen bond 3.17 Å long with the 
adjacent proline 226. Other enzymes such as OXA-71 have a aspartate residue at 
position 225, which while being slightly closer to the proline at position 226 (2.93 Å 
away) is twisted round, and a hydrogen bond is not formed (figure 36). The loss of a 
hydrogen bond at this position may allow more flexibility in these residues that are 
close to the active site cleft entrance, which may h ve implications for the 
conformation of the cleft. However, no structural changes were evident, which may 
be due to the limitations of the structural models ba ed on the OXA-40 backbone. 
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Figure 35: OXA-66 structure (grey) showing the asparagine at position 225 
(green) hydrogen-bonding with the adjacent proline 226 (purple). Structure was 
visualised in DeepView. 
 
 
Figure 36: OXA-71 structure (grey) showing the aspartate at position 225 
(green) no longer hydrogen-bonding with the adjacent proline 226 (purple). 
Structure was visualised in DeepView. 
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4. Discussion. 
The data presented in this thesis were obtained in order to answer questions about the 
nature of the blaOXA-51-like genes in A. baumannii. Within the literature, study of the 
blaOXA-51-like genes is very sparse, and combined with the relativ y recent 
development of the sequence grouping scheme (Turton et al., 2007), this results in 
there being very few other data available with which the work presented here can be 
put into context. In fact, there is very few data av ilable from large studies of 
chromosomally-located β-lactamases in any species, with the possible exception of 
the AmpC enzymes in Citrobacter freundii (Barlow and Hall, 2002). It is for these 
reasons that where there is discussion of other data here, the inability to make direct 
comparisons limits the conclusions that can be drawn from them. 
 
4.1 Sequence grouping, insertion sequences and OXA-type β-lactamases. 
The initial focus of this study was a phenotypic and genotypic analysis of a group of 
64 A. baumannii solates in order to compare the OXA-type β-lactamase gene and 
insertion sequence content of these isolates with their susceptibility to the 
carbapenems and the relatedness of the isolates. In the first instance the properties of 
the isolates were examined in relation to their categorisation by the sequencing 
grouping technique of Turton et al (2007), performed by Dr. Towner. 
 
Within the isolates examined there was clearly a high representation of SG1 and SG2 
isolates, which together accounted for 72% of all iso ates. The isolates largely 
originate from Europe, and it may be that this biases the data set towards SG1 and 
SG2, as the lineages of European clones 2 and 1 (EC2 and EC1) which belong to 
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SG1 and SG2 respectively are known to be widespread in Europe, and to be 
responsible for many of the outbreaks of infection in this region (Towner et al., 
2008). However, globally, reports of isolates relatd o EC2 (SG1) are widespread. In 
particular, reports from East Asia often find isolates related to EC2 to account for 
almost all A. baumannii that are identified (Kim et al., 2008, Cho et al., 2009). 
Analysis of isolates in our laboratory from Saudi Arabia and Pakistan has also 
identified 55% and 47% of isolates respectively to possess blaOXA-51-like genes that are 
associated with EC2 (Alsultan et al., 2009, and unpublished data). The reasons for 
the apparent global success of isolates belonging to the EC2 lineage, and the success 
of isolates belonging to EC1 in Europe, particularly countries in Eastern Europe, are 
unknown. It has been suggested that the reason for the success of A. baumannii as a 
species is due to the presence of the insertion sequence ISAba1 that is able to provide 
a promoter to increase gene expression levels as well as mobilise genes (Mugnier t
al., 2009). It is interesting to note that ISAba1 is highly represented in the isolates 
belonging to SG1 and SG2 in this study, and this may be a contributing factor to their 
success. In contrast, isolates belonging to SG3 did not carry an ISAba1 element, and 
isolates from this sequence group are generally onl identified in large numbers in 
studies examining outbreaks on the Iberian peninsula (van Dessel et al., 2004). It is 
possible that the lack of an ISAba1 element in SG3 isolates has prevented them from 
establishing themselves over a more widespread geographical area, as they lack the 
genetic flexibility provided by the insertion sequenc . While the other sequence 
groups identified in this study contain too few representatives to support any reliable 
statements with regards to the prevalence of ISAba1 within them, it is interesting to 
note that ISAba1 is not widely found in the other sequence groups, with the 
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exception of SG4, which is associated with the blaOXA-51 gene. Isolates encoding a 
blaOXA-51 gene are reportedly widespread in South America, and it may be that SG4 
represents another successful lineage similar to the SG1 and SG2 lineages in this 
geographic area (Merkier and Centron, 2006). 
 
Within SG1 and SG2, the majority of blaOXA-51-like genes were found to be laOXA-66 
and blaOXA-69 respectively, with the remainder comprising genes very closely related 
to these. The reasons for these differences in frequency of blaOXA-51-like genes are 
unknown, but there are some interesting points to no e. Within both SG1 and SG2, 
only isolates encoding blaOXA-66 or blaOXA-69 were also found to possess an acquired 
OXA-type β-lactamase gene of the blaOXA-23-like, blaOXA-40-like or blaOXA-58-like families. 
Conversely, only isolates with blaOXA-51-like genes that were closely related to the 
blaOXA-66 and blaOXA-69 genes, rather than these genes themselves, were found t  
contain an ISAba1 element upstream of the blaOXA-51-like gene. This trend can be seen 
in data from studies such as that by Turton et al (2006a). In this study, of the nine 
isolates that had their blaOXA-51-like gene sequenced, the four isolates that carried a 
blaOXA-66-like gene all carried an ISAba1 element upstream of the gene, while the 
remaining five isolates that possessed blaOXA-66 itself, or blaOXA-69, were negative for 
ISAba1 upstream of the gene. As all but 4 of the 28 resistant or intermediately 
resistant isolates possessed either an acquired OXA-type β-lactamase or ISAba1 
upstream of their blaOXA-51-like gene, it suggests that these two mechanisms represent 
two main paths that isolates within sequence groups can initially take in order to 
increase their resistance to the carbapenems, and th t subsequently isolates may 
contain both, as seen in the two SG4 isolates A483 and A374.  
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Analysis of the OXA-51-like functional map demonstrates that while there is a 
reasonable degree of variation within the enzyme family as a whole, enzymes from 
isolates belonging to the same sequence group are typically only one or two amino-
acids different to one another. Within the three main enzyme clusters surrounding 
OXA-66, OXA-69 and OXA-98, there is a trend for the most recently identified 
enzymes to be found at the edges of these clusters, uggesting that they may have 
evolved more recently. Additionally, the same amino-acid variations resulting in the 
more recently identified enzymes occur multiple times within and between the 
enzymes clusters, suggesting that these enzymes hav come under a common 
selective pressure. It could be speculated that much of the amino-acid variation seen 
within the centre of the map is ancient and the result of chance mutations, whereas 
the more recently identified enzymes have arisen due to a common selective pressure 
such as antibiotic use. This would also explain why in this study the genes for 
‘founder’ enzymes OXA-66 and OXA-69 were identified most frequently, as these 
enzymes would be older and so more widespread than the more recently evolved 
OXA-66-like and OXA-69-like enzymes, which have not had sufficient time to fix 
themselves in the A. baumannii population. 
 
While the sequence grouping technique appears to be successful in classifying 
isolates, there are limitations to it that must be borne in mind. As the technique works 
through scoring isolates on whether or not there is a visible PCR amplification 
product within six separate multiplex PCRs it requires that a negative PCR result is 
interpreted as the absence of a particular allele. While generally this assumption is 
universally applied to PCR results, it has the potential to lead to the misclassification 
 120 
of isolates into the wrong sequence group. In the present study, it is possible that this 
has happened with isolates A376 and A187. Isolate A376 is classified as belonging 
to SG5, while A187 belongs to SG9. The difference between these two sequence 
groups is within the blaOXA-51-like gene in the group 2 multiplex PCR. However, 
sequencing of the blaOXA-51-like gene from these two isolates identified a bl OXA-68 
sequence in both instances, suggesting that the isolate  should both give the same 
result in any PCR that amplifies any region of thisgene. In this case, it is likely that a 
false-negative result has caused these two isolates to be assigned to different 
sequence groups when they are in fact members of the same sequence group. 
 
The current sequence grouping technique correlates well with specific blaOXA-51-like 
gene carriage, and the representative isolates of Eur pean clones 1, 2 and 3 (EC1, 
EC2 and EC3) are separated into SG2, SG1 and SG3 respectively. Due to this, 
throughout this study it is assumed, for example, that for all intents and purposes the 
terms EC1 and SG2, or the carriage of a blaOXA-69-like gene are effectively 
interchangeable. The same is true for EC2, SG1 and blaOXA-66-like gene carriage, and 
EC3, SG3 and blaOXA-71 gene carriage. However, it should be noted that there as not 
been a study that assess in detail whether this is indeed the case. Such a study could 
be of great use, as at present it requires the use of s veral complementary typing 
techniques that are not routinely available in reference laboratories to determine 
whether isolates belong to one of the European clonal lineages. If it is found that 
identification of the blaOXA-51-like gene of an isolate is a proxy for these typing 
techniques, it would represent a much more simple, rapid and affordable method for 
determining the lineage that an isolate belongs to. 
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4.2 Carbapenem susceptibility. 
Of the 64 isolates included in this study, 28 (44%) were resistant or of intermediate 
resistance to one or both of imipenem and meropenem, and all of these isolates 
belonged to SG1, SG2, SG3 or SG4. Generally imipenem was a more effective drug 
than meropenem, with MICs for isolates often being o e to two-fold lower than those 
for meropenem. The reason for this difference is unknown. It may be that 
mechanisms such as the multidrug efflux pumps of the RND type which are found in 
A. baumannii, such as the AdeABC pump, that contribute to the resistance phenotype 
observed, have a better affinity for meropenem as a substrate than for imipenem.  
 
A lot of attention has been focussed in the literature on the acquired OXA-type 
β-lactamases of A. baumannii and their contribution to carbapenem resistance in this 
species. Less attention has been focussed on the contribution of the blaOXA-51-like 
genes to carbapenem resistance, and how the over-expression of the blaOXA-51-like 
gene caused by the insertion of an ISAba1 element upstream of it compares with the 
resistance conferred by the acquired enzymes. In this s udy, a comparison of the 
imipenem and meropenem MICs for isolates with an acquired OXA-type 
β-lactamase only, with those with ISAba1 upstream of their blaOXA-51-like gene only, 
resulted in the rejection of the null hypothesis that t e MICs for these two groups are 
different. This is an important finding, as it indicates that within the isolates in this 
study, the presence of an ISAba1 element upstream of the blaOXA-51-like gene has the 
same implications for carbapenem resistance as the pres nce of an acquired OXA-
type β-lactamase. This is of great concern, as all A. baumannii carry a blaOXA-51-like 
gene, and within the most prevalent sequence groups the ISAba1 element is found at 
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a high frequency. If ISAba1 is able to mobilise itself to insert upstream of theblaOXA-
51-like gene in most isolates, then this presents the worrying scenario whereby the 
majority of A. baumannii solates could have MICs of the carbapenems at the same 
level as that which they would demonstrate if they possessed an acquired OXA-type 
β-lactamase. 
 
An investigation of the effect of low-level expression of the blaOXA-51-like genes on an 
isolate’s survivability to meropenem challenge compared with that seen in other 
Acinetobacter species through the measurement of dose response curves 
demonstrated that in the isolates examined without an ISAba1 element inserted 
upstream of the blaOXA-51-like gene there is no difference between the response of A. 
baumannii to meropenem challenge compared with other Acinetobacter species. A 
similar effect can be seen with regard to the blaOXA-23-like genes (Poirel et al., 2008). 
The blaOXA-23-like gene family is believed to have originated in the sp cies 
Acinetobacter radioresistens. However, in this species the blaOXA-23-like genes are not 
associated with ISAba1 and isolates encoding the genes are fully susceptibl  to the 
carbapenems, suggesting that it is only when there is an association with ISAba1 and 
the resulting increased expression levels of the gen  due to this that the blaOXA-23-like 
genes confer carbapenem resistance. Similarly, in this s udy it was only in isolate 
A343, which has an ISAba1 element upstream of the blaOXA-51-like gene, that the 
survivability to meropenem was much greater than tht for the other A. baumannii 
isolates as well as the other Acinetobacter species tested. It is possible that it is 
through increased expression of the blaOXA-51-like gene in this isolate mediated by the 
ISAba1 sequence that is the cause for the increase in resistance level. However it 
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should be noted that the blaOXA-51-like genes that the isolates used for the dose 
response study carry are different, and it may be that the OXA-109 enzyme produced 
by isolate A343 has an increased ability to hydrolyse meropenem over the OXA-51-
like enzymes produced by the other isolates, and that it is this difference that is 
responsible for the variation in resistance. Studies in which isogenic isolates either 
possessing ISAba1 upstream of the blaOXA-51-like gene or not, along with isogenic 
isolates carrying different blaOXA-51-like genes would allow these confounding factors 
to be separated.  
 
Significantly, the MIC of meropenem to A343 suggests the isolate is of intermediate 
susceptibility, or fully susceptible depending on the criteria utilised, yet the isolate is 
able to survive meropenem concentrations at which isolates would be considered 
resistant while maintaining a high level of viability. This is an important point, as it 
means that data for isolates that are currently return d by hospital reference 
laboratories as being susceptible may be misleading, because if the isolate has an 
ISAba1 element upstream of its blaOXA-51-like gene it may be able to survive much 
higher concentrations of a carbapenem than the MIC suggests. 
 
4.3 Pulsed-field gel electrophoresis. 
Analysis of the PFGE profiles of the 64 isolates in this study was not able to group 
isolates in concordance with the blaOXA-51-like gene that they possess, unlike the 
sequence grouping technique. Not only were isolates with the same blaOXA-51-like gene 
not grouped together by PFGE, but isolates with different blaOXA-51-like genes from 
different sequence groups were clustered more closely to one another than they were 
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to the other isolates from their sequence group. The technique of PFGE can be very 
useful for examining the relatedness of isolates colle ted over a reasonably long 
period of time for which there is little lateral gene transfer and low mutation rates, as 
changes in the restriction sites in such isolates will accumulate slowly. The technique 
can also be applied to isolates within which the rat of lateral gene transfer and 
mutation may be higher, as long as the isolates repres nt a much shorter timeframe, 
within which there has not been sufficient time for a large number of changes at 
restriction sites to occur. The 64 isolates examined  this study were collected over a 
period of 25 years between 1982 and 2006. The failure of PFGE to group isolates 
together as might be expected from the sequence grouping results suggests that either 
the degree of lateral gene transfer, the mutation rates, or both, are high enough that 
PFGE is unable to cluster isolates in a manner that is representative of their 
relatedness. Alternatively, it is possible that the blaOXA-51-like, csuE and ompA genes 
that are used for the sequence grouping scheme, which are all implicated in 
antimicrobial resistance or virulence in A. baumannii, may have been subject to 
horizontal gene transfer. As such the PFGE profiles would present a more 
representative picture of the relatedness of the whole genomes of the isolates 
examined. In order to determine whether the sequence grouping technique or PFGE 
was more representative of the relatedness of the isolates, a subset of the isolates 
were typed by MLST. 
 
4.4 Multi-locus sequence typing. 
MLST is a technique which is commonly used in bacteria to determine the 
phylogenetic relationships of isolates. It is based upon sequencing regions of a 
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number of genes that are chosen based upon being relatively conserved within the 
species under examination. Often, genes for essential cellular functions, so-called 
‘housekeeping’ genes, are used. This makes MLST an excellent method for 
analysing longer-term evolution within and even between species, but will not be 
able to distinguish between recently diverged isolates. There are many different 
schemes for many different bacterial species, each with their own selection of 
‘housekeeping’ genes that are amplified. For A. baumannii there is an MLST scheme 
published by Bartual et al (2005), as well as an online scheme 
(http://www.pasteur.fr/recherche/genopole/PF8/mlst/Abaumannii.html). In this study 
the scheme of Bartual et al was used, which utilises the sequences from seven genes. 
 
Analysis of the allelic profiles of the representative subset of 44 isolates by eBURST 
grouped the isolates into four clonal complexes, with the remainder of the isolates 
represented as singletons. All of the sequence types (STs) that are linked with ST34, 
which together form the largest clonal complex, are from isolates that belong to SG1. 
The STs associated with ST33, the second largest clonal complex, are all from 
isolates belonging to SG2. The remaining two clonal complexes that consist of two 
STs each (ST50 and ST48, and ST35 and ST38) belong to isolates assigned to SG4 
and SG3 respectively. Combined with the index of association value calculated that 
is significantly greater than zero, this demonstrates that SG1, SG2, SG3 and SG4 are 
indeed discrete lineages that are quite different to one another. However, when the 
actual nucleotide sequences for the alleles were used to construct a more accurate 
phylogeny, the resulting tree had split the SG2 isolates into separate clades. 
Following a more detailed analysis, two of the alleles, gyrB and gpi, showed 
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significant evidence for recombination. As the MLST method rests upon the 
assumption that in the majority of isolates for the majority of the time the alleles 
under investigation are stable, then alleles that appe r to be undergoing a significant 
amount of horizontal gene transfer are unsuitable. As such, the gyrB and gpi loci 
should not be considered suitable for use in an MLST scheme. The only study to 
have published an in-depth analysis of results using the MLST scheme of Bartual et
al (2005) appears to have the same problems as were encountered here, with the trees 
for gyrB and gpi being non-concordant with those for the other loci(Park et al., 
2009). Interestingly, there was a reasonable degree of discordance with the tree for 
the gdhB alleles and the trees for the other six alleles as well, which was not 
observed in our data. Unfortunately neither this study nor the other published studies 
that have utilised the Bartual et al MLST scheme presented sequence grouping or 
blaOXA-51-like allele data that could be used to compare with the data generated here 
(Bartual et al., 2005, Wisplinghoff et al., 2008, Park et al., 2009). 
 
Analysis of the data using the remaining five loci produced a phylogeny that is far 
more concordant with sequence grouping, blaOXA-51-like gene content, and the 
population structure suggested by the eBURST analysis. However, there are a few 
notable exceptions, with two SG1 isolates separated from each other and from the 
main SG1 clade, one SG2 isolate separated from the ain SG2 clade, and one SG4 
isolate separated from the other two SG4 isolates. In all of these cases there is a 
common feature, in that these isolates differed from the other isolates in their 
sequence groups at the gdhB and cpn60 loci. While some of these isolates differed at 
more than just these two loci, this common feature s ggests that these two loci are 
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more variable than the gltA, rpoD and recA loci. However, in the case of the SG4 
isolate A483, which differed from the other two SG4 isolates at all five MLST loci, it 
is possible that it is the blaOXA-51-like gene that has been horizontally transferred, 
though due to the results of the eBURST analysis indicating that the sequence types 
of the SG4 isolates are related it is perhaps more likely that isolate A483 has a much 
higher mutation rate than the other SG4 isolates and as such has one or two 
nucleotide changes in each of its ‘housekeeping’ genes. While the isolates share the 
same sequence group, this does not necessarily mean that the ompA and csuE genes 
in these three isolates are identical or very similar, as they may vary considerably 
outside of the regions in which the multiplex primers bind. Fully sequencing the 
ompA and csuE genes in the three SG4 isolates would indicate whether it was more 
likely that the blaOXA-51-like gene had been horizontally transferred, whether there as 
been a significant degree of horizontal gene transfer involving many loci, or there is 
a higher rate of mutation in isolate A483. While it is generally assumed that the 
blaOXA-51-like genes are immobile and maintained on the A. baumannii chromosome, 
there has been a brief mention in the literature of potential horizontal transfer of the 
genes (Pournaras et al., 2006), and very recently the sequence of a blaOXA-51-like gene 
from a genospecies 13TU isolate in association withan upstream ISAba1 element 
has been deposited in GenBank (accession number EU670845.2), indicating that 
there is potential for these genes to be horizontally transferred.  
 
Currently the evidence for horizontal transfer of theblaOXA-51-like genes is sparse. As 
the genes can be associated with an ISAba1 element located upstream, which has 
been implicated in the mobility of the blaOXA-23-like genes (Poirel et al, 2008; Corvec 
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et al, 2007), it is conceivable that the blaOXA-51-like genes could also be mobilised in 
this manner. Whether the reports of mobilised blaOXA-51-like genes represent the start 
of the ‘escape’ of these enzymes from the A. baumannii chromosome, or whether 
they represent infrequent spontaneous recombination eve ts with plasmids already 
carrying an ISAba1 sequence remains to be seen. Should the blaOXA-51-like genes 
confer an advantage to the isolates that acquire them in terms of increased antibiotic 
resistance, then it is likely that these genes will join the ever-increasing group of 
mobile antibiotic resistance determinants. Interestingly, the only blaOXA-51-like gene 
described to have been horizontally transferred, blaOXA-138 found in an Acinetobacter 
species 13TU isolate, is the gene at the very tip of the blaOXA-66 clade in the blaOXA-51-
like gene tree (figure 25), potentially representing one f the most recently evolved 
blaOXA-51-like genes. It contains the leucine to valine substitution at position 167, 
presenting the possibility that this gene has recently volved with altered kinetic 
characteristics, which may have resulted in the mobilised gene being selected for as 
it conferred an advantage to the recipient isolate. 
 
It should be noted that as the sequence grouping was performed by Dr. Towner in 
Nottingham, and the blaOXA-51-like gene sequencing and MLST was conducted in 
Edinburgh, it is possible that isolate mix-up, resulting in the two laboratories 
working on different isolates but believing them to be the same one, could explain 
discrepancies between the MLST and SG results. However, within the isolates where 
such discrepancy was noted in this study, the SG and blaOXA-51-like identification were 
concordant, while the MLST was not. As the MLST and blaOXA-51-like sequencing 
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were both done in Edinburgh, it is highly unlikely that an isolate mix-up between the 
two laboratories explains the discrepancy between MLST and SG designation. 
 
It has been suggested that the blaOXA-51-like genes of A. baumannii are themselves 
‘housekeeping’ genes akin to those that would be used in an MLST scheme 
(Whitman et al., 2008). This study demonstrates that the degree of diversity within 
the blaOXA-51-like alleles as measured by the πN/πS ratios is far greater than that seen 
within the seven ‘housekeeping’ genes from the MLST scheme, with the ratio a 
minimum of 3.4-fold higher. When compared with a range of other β-lactamase 
genes that are widely accepted as arising through antibiotic selection, the πN/πS ratio 
for the blaOXA-51-like genes sits within the range of 0.1664 - 0.4357 that is calculated 
for the ratios for these genes, suggesting that the blaOXA-51-like genes are under a 
similar level of positive selection as these other β-lactamase genes. However, all of 
the loci tested gave ratios that were less than one. Th  likely explanation for this is 
that the ratios were calculated across the whole allele sequence. The structures of the 
β-lactamase enzymes are highly conserved, with enzymes from classes A, B, C and 
D demonstrating a remarkable similarity in tertiary structure. As was shown in figure 
27 in the results section, using a sliding window across the blaOXA-51-like allele 
sequences to calculate πN/πS ratios demonstrates that the majority of the enzyme 
sequence is under purifying selection, with only a few ‘hotspots’ where the πN/πS 
ratio was greater than one. The effect of this is that while the majority of the 
sequence is under purifying selection such that the general structure of the 
β-lactamase is maintained, any non-synonymous nucleotide changes that occur in or 
around the active site region due to positive selection are in the minority compared to 
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the synonymous changes across the rest of the sequence. As mentioned above, when 
ratios were calculated for different regions across the enzyme sequence, it was 
demonstrated that some regions of the enzyme are und r a higher level of positive 
selection than others. Ideally, the most precise analysis to detect which sites were 
under a greater degree of positive selection than others would be obtained by 
measuring the πN/πS ratios across smaller regions between enzymes. However, with 
the β-lactamase enzymes, in many cases this will not be possible, as the only 
difference between two enzymes is one amino-acid substit tion as a result of a single 
nucleotide substitution. In these cases a ratio could not be calculated as the value for 
πS would be zero. It should also be noted that the or β-lactamase families that 
were used for comparison with the OXA-51-like enzymes were comprised entirely of 
alleles that are believed to have arisen due to antibiotic selection. For example, with 
the blaSHV genes, a range of ancestral sequences from Klebsiella pneumoniae that 
were in existence before the advent of antibiotics were not included. This inherently 
biases the πN/πS ratio towards a higher value. As was discussed prviously, it is 
possible that a large number of the OXA-51-like enzymes are not enzymes that have 
recently evolved in response to antibiotic use, but rather are much older enzymes. If 
this is the case, then a πN/πS ratio for these enzymes that is calculated using the 
sequences for all of the group members will inevitable be lower than one calculated 
using enzymes that are thought to have arisen throug  antibiotic selection alone. 
Unfortunately there is not enough information available at present to determine 
which of the OXA-51-like enzymes are likely to have arisen due to recent antibiotic 
selection in the same manner as the other β-lactamase families, but it is likely that if 
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such a like-for-like comparison of πN/πS could be made then the ratios for the 
blaOXA-51-like genes would be even higher than those calculated in this study. 
 
4.5 A. baumannii mutability. 
Two experiments were undertaken in this study to examine the degree of genetic 
variability in A. baumannii over time. While the mutation study was able to obtain 
isolates that were able to grow at repeatedly higher concentrations of meropenem, no 
nucleotide changes were seen in the blaOXA-51-like genes. This is perhaps not 
surprising, as the bacteria are able to rapidly adapt to an increasing concentration of 
antibiotic by regulating the expression of efflux systems such as the AdeABC pump, 
and outer membrane porins. Changes in gene regulation re able to occur far more 
rapidly than mutations, as mutations are random events that occur at a relatively low 
frequency.  
 
Additionally, ISAba1 elements were not found to have inserted upstream of the 
blaOXA-51-like genes. However, this has been observed in a clinical isolate from France 
in which the isolate, following treatment of the patient with imipenem, gained an 
ISAba1 element upstream of its blaOXA-51-like gene that was not present prior to 
treatment (Figueiredo et al., 2009). This process does not seem to have been 
observed frequently, which may be for a number of reasons. Firstly, it may be that it 
is only within certain isolates that ISAba1 elements are able to move frequently. 
Certainly it has been shown that different A. baumannii lineages are not equal in the 
frequency that they carry ISAba1, and so it may be the case that there is additional 
variation within the species in the degree to which isolates facilitate the mobilisation 
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of the element once it is present. Secondly, if the ISAba1 elements are not stable, 
then the removal of the antibiotic pressure may result in the element excising from 
the upstream region of the blaOXA-51-like gene. In our laboratory we have observed that 
isolates initially reported as encoding ISAba1 upstream of their blaOXA-51-like genes 
can later be found to be negative, following a period of time in which the isolates 
were stored at -80°C. Additionally, during a sequencing project of A. baumannii 
genomes problems were encountered due to ISAba1 elements moving between 
sequencing runs (Mark Adams, personal communication). It may be that in many 
cases an ISAba1 element is not identified upstream of blaOXA-51-like genes as in the 
period between retrieving the isolate from the patient and a study being conducted 
the element has moved. 
 
In addition to increased expression of the blaOXA-51-like gene mediated by an ISAba1 
sequence, it is possible that carbapenem MICs for isolates could be increased through 
duplication of the blaOXA-51-like gene. Such a phenomenon has been observed with the 
blaOXA-58 gene, where duplication of the gene mediated by IS26 elements resulted in 
isolates with one, two or three copies of the gene. Th  increase in copy number was 
seen to be associated with a step-wise increase in th  MICs of meropenem and 
imipenem (Bertini et al, 2007). In the isolates studied here, while the presence of 
ISAba1 upstream of the blaOXA-51-like genes was analysed, the presence of other 
insertion sequences was not, and it is possible that the blaOXA-51-like genes in some of 
the isolates were being duplicated by an unknown mechanism. Sequencing the 
surrounding genetic environment of the blaOXA-51-like genes in the isolates with raised 
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carbapenem MICs combined with southern analysis of restricted DNA would 
determine if this were the case. 
 
In the second experiment where an A. baumannii solate was grown continuously for 
100 days under both nutrient-rich conditions and sub-inhibitory concentrations of 
imipenem, there were again no differences observed in the sequence of the blaOXA-51-
like gene, and the ISAba1 element did not insert upstream of the blaOXA-51-like gene. 
Additionally, the sequences of the MLST alleles were identical in both the parent and 
the 100-day-old isolates. This was as expected following the results of the previous 
mutation study, and the fact that the ‘housekeeping’ genes are, due to their nature, 
relatively highly conserved. However, analysis of the PFGE patterns of the isolates 
showed that there was a small difference in the banding pattern of the isolate that had 
been grown under sub-inhibitory concentrations of imipenem compared to the parent 
isolate. After 100 days of growth at a sub-inhibitory concentration of imipenem the 
isolate demonstrated only 88% relatedness with its parent isolate. The reason for the 
alterations in the restriction sites and therefore the banding patterns is unknown, but 
it is interesting that the differences were only observed in the isolate that was under 
selective pressure and not the isolate grown in non-selective nutrient-rich conditions. 
This result is consistent with the PFGE data obtained for the 66 isolates in this study 
where isolates that are shown to belong to the same lineage by sequence grouping 
and MLST techniques were completely unrelated by PFGE. In the hospital, bacteria 
are exposed to much higher concentrations of antibiotic than were used here, as well 
as a range of other selective pressures such as expo ure to biocides. The results of the 
growth study indicate that over a relatively short period of time under little selective 
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pressure the PFGE profile of an isolate can vary, and that for A. baumannii care 
should be taken in interpreting PFGE data if isolates have been obtained over a 
period of more than a few months, particularly if the isolates originated from 
environments in which there is considerable selectiv  pressure. 
 
4.6 Sequence analysis. 
Analysis of the phylogeny of A. baumannii as a species and of the blaOXA-51-like genes 
provides substantial evidence that within the species there are discrete lineages that 
have been evolving independently of one another for a significant period of time, and 
that the blaOXA-51-like genes associated with these lineages have been co-volving 
within them. 
 
The species tree for A. baumannii s intriguing as the different clades extend varying 
distances from the root. Two explanations for this opology are that the different 
branch lengths represent differences in time, with the isolates closest to the root 
being the oldest and those furthest away the youngest, or that they represent 
differences in mutation rate, with those isolates clo est to the root evolving more 
slowly and those furthest from the root evolving more rapidly. As the isolates used in 
this study, and all of the sequenced isolates that were downloaded from PubMed, 
were all isolated relatively recently, particularly in evolutionary terms, then the 
differences in branch lengths that are observed are likely to represent differences in 
the rates of evolution of different clades. This is an interesting finding as the 
identification of different lineages within a bacterial species evolving at markedly 
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different rates is unusual and suggests a significat degree of heterogeneity within A.
baumannii as a species. 
 
The conclusions that can be drawn from the topology of the A. baumannii species 
tree are reinforced when the phylogeny of the blaOXA-51-like genes is examined. As 
with the species tree, the sequences of the blaOXA-51-like genes have all been identified 
from isolates that are recent in origin, therefore the variations in branch length are 
likely as the result of varying rates of mutation. However, in the blaOXA-51-like tree the 
variation in the branch lengths of the different clades is even more pronounced than 
in the species tree. Importantly, there is a correlation in the lengths of the branches 
between the isolates and blaOXA-51-like genes of the three main sequence groups, with 
SG1 isolates and blaOXA-66-like genes on the longest branches of the three groups, SG3 
isolates and blaOXA-71 genes on the shortest branches, and SG2 isolates and blaOXA-69-
like genes on branches of an intermediate length. Additionally the three groups of 
enzymes that are associated with the three main sequence groups are found in 
discrete clades that all diverge from the root, in he same manner as the clades for the 
isolates belonging to the different sequence groups. These observations support the 
suggestion that the different sequence groups have been evolving independently and 
at different rates. However, it should be noted that only four alleles were used to 
construct the A. baumannii species tree. While the overall topology of the spcies 
tree is unlikely to be substantially altered with the inclusion of a greater number of 
reliable ‘housekeeping’ genes, due to the concordance with the blaOXA-51-like tree and 
with the sequence grouping data, the relationships between some of the branches 
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belonging to isolates that are not from the main sequence groups may be subtly 
altered. 
 
An interesting feature of the blaOXA-51-like tree is its ladder-like topology seen in some 
branches. Such topologies are usually seen in trees for rapidly evolving organisms 
such as the influenza A virus, where the topology is indicative of repeated selective 
sweeps of the population (Cobey and Koelle, 2008). Interestingly it is the branches 
that are thought to be evolving more quickly and that are associated with the major 
epidemic lineages of SG1 and SG2 that show the mostpr nounced ladder-like 
topology, though most of the branches do to some ext nt. This suggests that the 
blaOXA-51-like genes, and in particular those belonging to SG1 and SG2 isolates, have 
been periodically subjected to positive selection that has served to reduce the 
variation within the clades of this enzyme family. Due to the assumed intrinsic nature 
of the blaOXA-51-like genes to A. baumannii, it is likely that much of the positive 
selection resulting in the topology seen in the gene tree was acting upon the isolate 
genomes as a whole rather than upon the blaOXA-51-like genes themselves, and this 
corresponds with the fact that the basic topology of the A. baumannii species tree is 
concordant with the blaOXA-51-like tree. 
 
Comparisons of the phylogenies for isolates from the three main sequence groups 
and the blaOXA-51-like genes associated with them demonstrate not only a correlation 
between the branch lengths of the sequence groups and their blaOXA-51-like genes, but 
in each case the relative evolutionary rate of the blaOXA-51-like genes is considerably 
higher than the rate for the isolates from the sequence group that contain them. This 
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suggests that the blaOXA-51-like genes are consistently evolving at a faster rate than he 
A. baumannii core genome, as represented by the ‘housekeeping’ ge es. This is in 
agreement with the πN/πS ratios calculated for the blaOXA-51-like genes and the MLST 
alleles. As the blaOXA-51-like genes are under less purifying selection than the 
‘housekeeping’ genes they will have a faster rate of fixation of mutations generated 
by random genetic drift, and therefore greater variation. This results in their rate of 
evolution being closer to the mutation rate, while th rate of evolution of the 
‘housekeeping’ genes is far slower than the mutation rate, as purifying selection 
removes the majority of deleterious mutations that arise. 
 
Analysis of the blaOXA-51-like phylogeny confirms some of the observations made with 
regards to the OXA-51-like enzyme functional map. Firstly, as mentioned above the 
distinct clades within the blaOXA-51-like tree all diverge from the root, with the vast 
majority of enzymes being located at a distance from the root. This correlates with 
the splitting of the enzymes into cluster in the functional map, and a lack of enzymes 
in the central region. Additionally, the enzymes that are found at the edges of the 
three main clusters surrounding OXA-66, OXA-69 and OXA-98 in the functional 
map tend to be found at the extremities of their clades in the blaOXA-51-like tree. It is 
likely that the blaOXA-51-like genes that are found at the tips of their clades ar  the 
sequences that have evolved most recently. However, since the discovery of the 
existence of the blaOXA-51-like genes was only published in 2005 (Brown et al., 2005), 
combined with the fact that A. baumannii has only been recognised as an important 
pathogen for a few decades, means that almost all of the blaOXA-51-like sequences that 
are now known are from relatively recent isolates. Therefore there is no historical 
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timeline that can be followed for the evolution of these enzymes as there is for 
enzymes such as the TEM and SHV families. However, th  blaOXA-51-like tree gives a 
well supported estimation of the evolutionary history f the genes, and is backed up 
by the frequency of identification of different blaOXA-51-like genes. For example, in the 
top-most clade of the tree, the genes that are positioned closer to the root of the tree 
have only been identified on one occasion, demonstrating that while they are still in 
existence, they are at a low frequency, as would be exp cted had these genes been 
the ones that were severely depleted in frequency during a selective sweep. On the 
other hand, the gene blaOXA-66 is found towards the tip of the clade in a region of the 
tree where the ladder-like topology is no longer evid nt. The blaOXA-66 gene is the 
most frequently identified blaOXA-51-like gene in A. baumannii, and it is likely that this 
gene is currently the most successful within this clade. The shape of the tree at this 
point, where the genes are all diverging from the same node as blaOXA-66, suggests 
that these other genes have all arisen recently from blaOXA-66. This is supported by 
the fact that these other genes have only been found in low numbers. If further 
selective sweeps occur in this clade as appear to have done previously, this will 
greatly reduce the frequency of most of the genes i this grouping, with the 
successful gene going on to found the next grouping of closely related enzymes, as 
blaOXA-66 is currently doing. The same process appears to behappening in the blaOXA-
69 clade and the blaOXA-98 clade, though is less evident in the other clades. 
 
The structure of the blaOXA-51-like tree indicates, as suggested by the OXA functional 
map, that blaOXA-98 and similar genes form a distinct clade. Unfortunaely, within the 
64 isolates included in this study only 3 possessed blaOXA-51-like genes that are found 
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in the blaOXA-98 clade, and so an analysis of whether isolates that carry this group of 
genes form a major sequence group cannot be made. However, it should be noted 
that the three isolates that were identified with blaOXA-98-like genes in this study were 
all assigned to separate lesser sequence groups. The isolate that were used in the 
development of the sequence grouping scheme almost all carried a blaOXA-66-like, 
blaOXA-69-like, or blaOXA-71 gene, and none carried a blaOXA-98-like gene. Therefore, it is 
perhaps unsurprising that the scheme is able to easily as ign isolates encoding 
blaOXA-66-like, blaOXA-69-like and blaOXA-71 genes to SG1, SG2 and SG3 respectively, but 
when isolates encoding other blaOXA-51-like genes are encountered, the scheme does 
not group together isolates that might be expected to be of the same sequence group 
based upon their blaOXA-51-like genes. Further development of the sequence grouping 
scheme to include a wider range of isolates encoding a greater variety of blaOXA-51-like 
genes may result in the identification of further major sequence groups similar to 
SG1, SG2 and SG3. 
 
The conclusion that the blaOXA-51-like genes have been evolving within A. baumannii 
for a significant period of time raises the question of why these genes have been 
maintained in this species. It has been known for some time that many bacteria 
possess a chromosomal class C β-lactamases, the expression of which is able to 
confer resistance to the cephalosporin β-lactams (Jacoby, 2009). The cephalosporins 
are derived from molecules that are produced naturally by a number of soil bacteria 
and fungi, and the class C beta-lactamases are likely to have evolved in response to 
the presence of these antibiotics in the environment (Brakhage et al., 2005). A. 
baumannii is one of many species that possess a class C enzym , which in the case of 
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A. baumannii are referred to as ADC enzymes (for Acinetobacter-derived 
cephalosporinase) (Hujer t al., 2005). In contrast to the class C enzymes, molecular 
class D enzymes such as the OXA-51-like family are much more efficient at 
hydrolysing the penicillins than the cephalosporins (Bush et al., 1995). Like the 
cephalosporins, the penicillins are also derived from naturally-produced molecules 
from soil bacteria, and similarly the evolution of penicillinases is thought to have 
occurred in response to this (Brakhage et al., 2005). Recent discoveries of 
chromosomally-located class D β-lactamases in many bacterial species (table 18) 
indicate that like the class C enzymes, the presence of a gene encoding a class D 
β-lactamase within certain bacterial classes is not a  uncommon occurrence. In the 
evolutionary arms race that bacterial species are engaged in both with other bacteria 
and with other domains of life, bacterial species have evolved multiple antibiotic 
defences, and in the case of A. baumannii t is possible that the blaOXA-51-like genes 





Enzyme Species Class Order
OXA-12 Aeromonas jandaei Gamma-Proteobacteria Aeromonadales
OXA-22 Ralstonia pickettii Beta-Proteobacteria Burkholderiales
OXA-23 Acinetobacter radioresistens Gamma-Proteobacteria Pseudomonadales
OXA-29 Legionella gormanii Gamma-Proteobacteria Legionellales
OXA-50 Pseudomonas aeruginosa Gamma-Proteobacteria Pseudomonadales
OXA-51 Acinetobacter baumannii Gamma-Proteobacteria Pseudomonadales
OXA-54 Shewanella oneidensis Gamma-Proteobacteria Alteromonadales
OXA-55 Shewanella algae Gamma-Proteobacteria Alteromonadales
OXA-60 Ralstonia pickettii Beta-Proteobacteria Burkholderiales
OXA-61 Camylobacter jejuni Epsilon-Proteobacteria Campylobacterales
OXA-62 Pandoraea pnomenusa Beta-Proteobacteria Burkholderiales
OXA-63 Brachyspira pilosicoli Spirochaetes Spirochaetales  
Table 18: Selected chromosomally-located class D OXA-type β-lactamases. Data 
for OXA-12 from Rasmussen et al (1994), OXA-22 and OXA-60 from Girlich et al 
(2004b), for OXA-23 from Poirel et al (2008), for OXA-29 from Franceschini et al 
(2001), for OXA-50 from Girlich et al (2004a), for OXA-51 from Brown et al 
(2005), for OXA-54 from Poirel et al (2004), for OXA-55 from Heritier et al (2004), 
for OXA-61 from Alfredson and Korolik (2005), for OXA-62 from Schneider et al 
(2006), and for OXA-63 from Meziane-Cherif et al (2008). 
 
 
4.7 OXA-51-like structural analysis. 
Despite that fact that all of the blaOXA-51-like genes have been identified recently, it is 
likely that it is the genes that are found towards the tips of the various clades in the 
blaOXA-51-like phylogeny that have evolved most recently. Therefore, any evolution 
within the blaOXA-51-like family that has taken place due to carbapenem selective 
pressure is likely to be manifest in these tip-located genes. However, in order not to 
bias the identification of important structural changes by this assumption, an analysis 
of variance across all of the blaOXA-51-like genes was conducted. 
 
The analysis of πN/πS ratios and percentage amino-acid variation from a consensus 
sequence identified 12 amino-acid positions which would be examined in detail 
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using structural models. However, for seven of these positions no structural changes 
were observed. The reason for this may be due to the limitations of the method used 
to construct the structural models. As there is no crystal structure available for any of 
the OXA-51-like enzymes, the structure for the OXA-40 enzyme had to be used 
(Santillana et al., 2007). The OXA-51-like models were constructed by the 
sequences for these enzymes being super-imposed on the OXA-40 backbone. While 
this approach is useful in allowing the positions that the different amino-acids 
occupy to be visualised, it is not able to model major changes to the protein 
backbone that may be caused by the differences in the amino-acid sequences 
between OXA-40 and the OXA-51-like enzymes. It is likely that it is limitations in 
the structural models that have resulted in no structu al changes being identified for 
some of the 12 amino-acid positions investigated. For example, the change at 
position 194 from a proline in enzymes such as OXA-51 to a glutamine in enzymes 
such as OXA-66 and OXA-69 is likely to have a significant structural impact, 
particularly considering its position in a loop that joins two central α helices. 
However, as the structural models are not able to model such major structural 
changes, no differences are seen between the structures of OXA-51, OXA-66 and 
OXA-69 due to changes at position 194. To enable the actual effects that these 
amino-acid variations have on the structures of the OXA-51-like enzymes requires a 
crystal structure to be determined for one of them that can then be used as a basis for 
more reliable models of the other enzymes to be detrmined. 
 
Another reason that differences at some of the amino-acid positions investigated did 
not show any structural variation in the structural models is that these amino-acids 
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are not involved in actual structural changes in the enzyme itself, and vary for 
another reason that cannot be determined with the models available. For example, the 
β-lactamases OXA-2, OXA-10 and OXA-13 exist in the form of dimers when at high 
enough concentrations (Paetzel et al., 2000, Pernot et al., 2001, Maveyraud et al., 
2002), such as might be found in the bacterial periplasmic matrix. There has also 
been a suggestion that OXA-69 may also exist in a dimerised form (Heritier et al., 
2005a). If the OXA-51-like enzymes exist in the form of dimers when expressed at a 
high enough level, then there is the potential for amino-acid variation to arise on the 
surface of the proteins that results in variation in properties such as the binding 
affinity of the two monomers to one another. It is interesting to note that of the seven 
amino-acid positions that appeared to show no structu al changes in the enzyme, six 
are positioned on the enzyme surface, with the seventh just below the surface of the 
enzyme. However, none of these amino-acid positions are located within the end of 
the β3 strand or the α9 helix, which are implicated in dimerisation in the other class 
D enzymes. It is possible that some of these amino-acid variations are responsible for 
changes in how the protein interacts with other molecules, rather than having a direct 
affect on the protein structure itself. 
 
The final reason for why variation at some amino-acid positions appears to have no 
structural effect may be because the variation is due to stochastic effects. For 
example, an amino-acid change that occurred far back in the evolutionary history of 
the OXA-51-like enzymes simply due to a chance mutation, that has no effect on 
enzyme function and is not deleterious, could be passed on to all of the OXA-51-like 
enzymes that have since evolved from this ancestral sequence. This would result in a 
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large percentage of OXA-51-like enzymes differing from the consensus sequence at 
that particular amino-acid position without this position playing any role in the 
activity of the enzyme. It is possible that variation at amino-acid positions at which a 
high percentage of OXA-51-like enzymes differ from the consensus sequence, such 
as at positions 36 and 107, is due to such stochasti  effects. 
 
Despite the limitations of the structural models, variations at five amino-acid 
positions were identified that may have an effect on he activity of the OXA-51-like 
enzymes. These five amino-acid positions are all found within or very near to the 
active site cleft of the enzyme. Firstly, amino-acid variation is seen at positions 129 
and 130. Analysis of the crystal structure of OXA-40 suggested that the binding of 
carbapenems was assisted through van der Waals interactions between the methyl 
group of the carbapenem and the non-polar valine residu  at position 130. 
Additionally it has been suggested that the presence of the non-polar side chain of 
the valine residue at position 130, which is found in many class D β-lactamases, may 
be a contributory factor to the broad substrate specificity of these enzymes 
(Santillana et al., 2007). In the OXA-51-like structural models the residues that take 
up the synonymous position to valine-130 are at position 129. The variations seen at 
position 129 within the OXA-51-like enzymes are betw en a valine, leucine or 
isoleucine residue. These three residues all have non-polar side chains, and so their 
substitutions are unlikely to have a role in changing the chemistry of the enzyme-
substrate interaction. However, the side chains of the three residues do have different 
sizes and conformations which may play a role in altering substrate specificity or 
affinity through changing the shape and size of the end of the cleft. 
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The effect of changes at position 130 in the OXA-51-like enzymes is less clear. In 
the OXA-40 structure, there is a proline residue at the synonymous 131 position. The 
enzyme OXA-66 also has a proline at this position, but some of the other OXA-66-
like enzymes have substituted it for a leucine, serine or glutamine residue. Due to the 
relative inflexibility of proline residues, it is likely that the loss of a proline at this 
position will allow greater movement of the surrounding residues. This includes the 
important residue at position 129 discussed above. As the properties of the residues 
that replace the proline are varied, it is likely that it is the loss of the proline residue 
to increase branch flexibility, rather than the gaining of a particular property from 
another residue, that is the reason for the changes. 
 
The third amino-acid position within the active site where variation is seen is 
position 167. The most common variation at this site is between a leucine and a 
valine. In the OXA-40 model, there are interactions in the active site whereby the 
active site serine at position 81 (synonymous with serine 80 in the OXA-51-like 
enzymes) forms a weak hydrogen bond with a lysine residue at position 84 (position 
83 in OXA-51-like enzymes), which itself forms a hydrogen bond with the side chain 
of a tryptophan residue at position 167 (position 166 in OXA-51-like enzymes) 
(Santillana et al., 2007). As the chemical properties of leucine andvaline are not 
dissimilar, variation between these two residues in the OXA-51-like enzymes at 
position 167 is likely to have an effect on the activity of the enzyme through 
changing the shape of the active site cleft, rather t an through biochemical means. It 
may also have effects such as disrupting the hydrogen bond between the lysine 83 
and tryptophan 166 residues. In one enzyme, currently u named with the accession 
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number EU255296, the leucine 167 is replaced with a glutamine residue. The 
substitution of a hydrophobic amino-acid for a polar one within the active site is 
likely to have a significant effect on the substrate profile and activity of the enzyme. 
 
The final two of the five amino-acid positions that were identified as potentially 
affecting the active site of the enzyme are position 168 and 225. The effects of the 
variations at these positions are difficult to tellfrom the structural models as there is 
little actual structural variation evident. Changes at position 168 are between valine, 
alanine and methionine, which are all hydrophobic (though alanine only slightly), 
and as such variation between them is unlikely to result in any major changes in the 
chemical interactions surrounding them. However, they are adjacent to the active site 
residue 167, and it may be that changes at position 168 alter the conformations that 
the residue at position 167 is able to adopt. At position 225 residues vary between 
asparagine and aspartate. In the OXA-40 model shown in figure 37, the loop 
connecting the β4 and β5 strands is closer to the active site cleft than in the other 
OXA-type enzymes that have had their structure solved, and it is thought that the 
stability of the β4-β5 loop is contributed to by a hydrophobic core formed by valine 
residues at positions 78, 225 and 229, and a tryptophan at 231 (positions 77, 224, 228 
and 230 in the OXA-51-like enzymes) (Santillana et al., 2007). In the OXA-51-like 
enzymes, at the end of the β4 strand a much bulkier tryptophan at position 222 
replaces the methionine at the synonymous position in OXA-40, and next to this in 
the β4-β5 loop a much bulkier aspartate residue at position 223 replaces the glycine 
found in OXA-40 (figure 38). The large differences in the size and conformation of 
the residues at the end of the β4 strand and the start of the β4-β5 loop between OXA- 
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Figure 37: OXA-40 structure showing the β4 and β5 strands and their 
connecting loop. Residues forming hydrophobic core are blue. Dashed lin s are 
hydrogen bonds. Structure was visualised in DeepView. 
 
 
Figure 38: OXA-66 structure showing the β4 and β5 strands and their 
connecting loop. Residues forming hydrophobic core are blue. Dashed lin s are 
hydrogen bonds. Structure was visualised in DeepView. 
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40 and the OXA-51-like enzymes is likely to result in differences in the activities of 
the enzymes. Interestingly it should be noted that in OXA-79, the tryptophan at 
position 222 has been substituted for a glycine, which is likely to have an effect on 
the function of the active site. In some of the OXA-51-like enzymes, an asparagine 
residue is found at position 225, and this may form a hydrogen bond with the 
adjacent proline 226 that may assist in stabilising the loop. Other OXA-51-like 
enzymes have an aspartate residue at position 225, which is not shown in the model 
to form any hydrogen bonds which may make the loop m re flexible. The limitations 
of the models are such that no major structural changes are seen due to differences at 
position 225. However, it has been suggested that changes in the shape and 
orientation of the β4-β5 loop may contribute to determining the specificity of the 
OXA-type β-lactamases for various different β-lactam antibiotics. It is likely that the 
differences between OXA-40 and the OXA-51-like enzymes in this region of the 
structure will explain differences in the substrate profiles of the two enzyme groups. 
Differences at position 225 within the OXA-51-like enzymes may result in subtle 
differences in the enzyme structure but an accurate crystal structure for this enzyme 
family is required to examine more closely the effects of this variation. 
 
It is interesting to note that of the five amino-acid positions examined in this study at 
which variation is thought may have an effect on the activity of the OXA-51-like 
enzymes, all the variation except that at position 225 is found to occur between 
enzymes whose genes are at the very tip of their respective branches in the blaOXA-51-
like gene tree. For example, variation at position 129 is seen in OXA-83 and OXA-
131, branch-tip enzymes in the blaOXA-66 clade, and OXA-110, at the tip of the 
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blaOXA-69 clade (figure 39). This suggests that much of this variation has arisen 
recently and that this may have been in response to antibiotic pressure. Therefore it is 
possible that these more recently evolved enzymes represent either altered or 
extended-spectrum variants of the OXA-51-like enzymes. An analogous situation 
appears to be occurring with the chromosomal class C AmpC enzymes in 
Escherichia coli and Pseudomonas aeruginosa. Chromosomal AmpC enzymes from 
isolates that predate the antibiotic era are able to hydrolyse the early-generation 
cephalosporins and appear to have evolved in response t  the naturally-occurring 
cephalosporins produced by environmental organisms (Barlow and Hall, 2002). 
However, recently variants of the AmpC enzymes in both E. coli and P. aeruginosa 
have been detected that appear to have broadened their spectrum of activity to 
include the later-generation cephalosporins and in some cases the carbapenems 
(Mammeri et al., 2008, Mammeri et al., 2006, Rodriguez-Martinez et al., 2009). 
These enzymes have been named extended-spectrum AmpCs (ESACs). It is tempting 
to speculate that similar antibiotic pressures have resulted in evolution in A. 
baumannii to form extended-spectrum OXA-51-like enzymes. Continued work to 
analyse the different kinetic properties of these enzymes is required to determine if 
this is the case. 
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Figure 39: blaOXA-51-like genes encoding enzymes with amino-acid substitutions likely to effect enzyme activity. Bayesian blaOXA-51-like 
phylogeny is as described in figure 25. Blue arrows, enzymes varying at position 129; orange arrows, enzymes varying at position 130; red 
arrows, enzymes varying at position 167; pink arrows, enzymes varying at position 168.
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In contrast, the origin of variation at position 225 appears to be found much further 
towards the root of the blaOXA-51-like gene tree, with certain clades containing genes 
for enzymes with an asparagine, while others have an aspartate. If there is an effect 
on enzyme function due to variation at this position it is likely to be one with a 
broader scope than one such as increased carbapenem hydrolysis.   
 
4.8 Summary. 
This study aimed to investigate in detail the OXA-51-like enzymes of A. baumannii: 
how they are related to carbapenem resistance within isolates, how isolate 
epidemiology corresponds with blaOXA-51-like gene content, and how the OXA-51-like 
enzymes have evolved and what the possible consequences of the variation within 
their sequences may be. During the course of the study several interesting and 
important results have been found. Firstly, isolates b longing to SG1 and SG2 appear 
to be the most successful, certainly across Europe, and within these isolates it is the 
blaOXA-66 and blaOXA-69 genes that are most regularly identified. Most of these isolates 
possess an ISAba1 element, which lends weight to the suggestion that the presence of 
ISAba1 within an isolate is a large contributing factor t increased success. For the 
main sequence groups, SG1, SG2 and SG3, the blaOXA-51-like gene that an isolate 
carries correlates with the sequence group they belong to. This means that for these 
sequence groups, identification of the blaOXA-51-like gene an isolate carries is sufficient 
to determine which lineage the isolate belong to. There is also evidence that there 
may be further large sequence groups of isolates. Further development of the 
sequence grouping scheme that confirmed this would mean that many if not all A. 
baumannii could be assigned to an epidemic lineage based upon the blaOXA-51-like 
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gene they contain. While PFGE has been shown to be inappropriate for use with A. 
baumannii isolates collected over more than a short period of time, MLST has been 
shown to correlate both with the sequence grouping results and with blaOXA-51-like 
gene content, assuming appropriate ‘housekeeping’ alleles are utilised. This further 
strengthens the argument that the determination of the blaOXA-51-like gene of an isolate 
could serve as a useful epidemiological tool. 
 
It had been argued that the blaOXA-51-like genes of A. baumannii are ‘housekeeping’ 
genes (Whitman et al., 2008). This has been shown to be incorrect, as the variation 
seen within the genes and their evolution is akin to other well-known β-lactamases 
such as the TEM, SHV and CTX-M families than to ‘housekeeping’ genes. It has 
been shown that isolates in this study that possess an ISAba1 element upstream of 
their blaOXA-51-like gene have carbapenem MICs that are not statistically significantly 
different to those of isolates that possess an acquired OXA-type β-lactamase of the 
OXA-23, OXA-40 or OXA-58 families. Additionally, the presence of ISAba1 
upstream of a blaOXA-51-like gene is correlated with a greatly increased ability of the 
isolate to survive carbapenem challenge, even at concentrations far above the 
carbapenem MIC for the isolate. These findings indicate that in the isolates in this 
study the expression of certain OXA-51-like enzymes is as important a threat to 
carbapenem use as the acquired OXA enzymes. This is of great concern, as it 
presents the scenario that all A. baumannii have the potential to become resistant to 
the carbapenems without needing to acquire additional β-lactamases. 
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Analysis of the sequences of ‘housekeeping’ genes ad bl OXA-51-like genes shows that 
the species A. baumannii consists of several phylogenetically distinct lineag s that 
appear to be evolving at different rates. Additionally there is evidence that the 
species has undergone successive selective sweeps during the past. Within the major 
enzyme groups, the enzymes that are closely related to OXA-66, OXA-69 and OXA-
98 seem to have evolved most recently, and it is within such enzymes that amino-
acid variation at positions 129, 130 and 167 occur, which may have an affect on the 
activity of the enzyme, with the possibility that the variation has arisen in response to 
antibiotic use. 
 
In order to test the hypothesis posed for this project, a series of five questions were 
asked. The first question asked: 
• How prevalent are the blaOXA-51-like genes, and are all of the various alleles 
distributed equally?  
This has been answered by showing that the blaOXA-51-like genes appear to be 
universal within A. baumannii, but that there are distinct biases in the distribu ion of 
the alleles. The reason for this answers the second question, which asked: 
• Are particular blaOXA-51-like alleles associated with certain strains, and are 
certain strains more resistant to the carbapenems than others?  
It has been demonstrated that certain successful lineages of A. baumannii are 
associated with particular groups of closely related blaOXA-51-like genes. This study did 
not find that particular lineages of A. baumannii were likely to be significantly more 
resistant to the carbapenems than others. However, the third question asked: 
• Can insertion sequences be found in association with all blaOXA-51-like genes? 
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The data show that it is isolates that carry a blaOXA-66-like, blaOXA-69-like, or blaOXA-51 
gene that are associated with an ISAba1 element, and the ISAba1 element could not 
be induced to insert upstream of the blaOXA-51-like genes, suggesting that under the 
conditions tested, not all A. baumannii are conducive to ISAba1 insertion. This also 
partially relates to question four, which asked: 
• Can susceptible A. baumannii acquire carbapenem resistance conferred by the 
blaOXA-51-like alleles under selective pressure?  
For the isolates studied here this was shown not to be the case, either by ISAba1-
conferred increased expression or changes in the blaOXA-51-like genes themselves. The 
final question asked: 
• Do all of the OXA-51-like enzymes show structural similarities indicating a 
shared ability to hydrolyse similar substrates?  
The answer to this is that while many of the OXA-51-like enzymes appear to have 
similar structures, the recently evolved enzymes have amino-acid changes that may 
affect the hydrolytic properties of the enzymes, altering their substrate profiles. 
 
Together the results of this study demonstrate that the OXA-51-like enzymes are an 
important feature to consider when studying A. baumannii. The ability to use their 
identification as a proxy for more expensive or time-consuming typing techniques 
shows great potential for their utilisation in epidemiological studies. Additionally, 
the presence of some of the enzymes is correlated wi h clinically significant levels of 
resistance to the carbapenems, and association with epidemic lineages. Therefore the 
identification of the blaOXA-51-like gene that an isolate carries provides important 
information indicating the likelihood of whether treatment with a carbapenem will be 
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successful. Finally, the blaOXA-51-like genes appear to be continually evolving, and the 
monitoring of this process to identify enzyme variants with increased substrate 
spectrums or higher levels of activity is crucial if we are to preserve and use 
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1. Nucleotide alignment for all 60 blaOXA-51-like genes. Substitutions are labelled 
 with respect to blaOXA-65. 
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                 5          15         25         35         45         55                      
OXA-65       ATGAACATTA AAGCACTCTT ACTTATAACA AGCGCTATTT TTATTTCAGC CTGCTCACCT  
OXA-82       .......... .......... .......... .......... .......... ..........  
OXA-138      .......... ..A.C..... .......... .......... .......... ..........  
OXA-115      .......... .......... .......... .......... .......... ..........  
OXA-109      .......... .......... .......... .......... .......... ..........  
OXA-80       .......... .......... .......... .......... .......... ..........  
OXA-66       .......... .......... .......... .......... .......... ..........  
OXA-83       .......... .......... .......... .......... .......... ..........  
EU255296     .......... .......... .......... .......... .......... ..........  
OXA-79       .......... .......... .......... .......... .......... ..........  
OXA-76       .......... .......... .......... .......... .......... ..........  
OXA-131      .......... .......... .......... .......... .......... ..........  
OXA-84       .......... .......... .......... .......... .......... ..........  
OXA-90       .......... ....C..... .......... .......... .......... ..........  
OXA-130      .......... .......... .......... .......... .......... ..........  
EU255295     .......... .......... .......... .......... .......... ..........  
OXA-108      .......... .......... .......... .......... .......... ..........  
OXA-95       .......... .......... C......... .......... .......... ..........  
OXA-88       .......... .......... .......... .......... .......... ..........  
OXA-94       .........C .......... .......... .......... .......... ..........  
OXA-104      .......... .......... .......... .......... .......... ...T......  
OXA-107      .......... .......... .......... .......... .......... ..........  
OXA-69       .......... .......... .......... .......... .......... ..........  
OXA-110      .......... .......... .......... .......... .......... ..........  
OXA-112      .......... .......... .......... .......... .......... ..........  
OXA-92       .......... .......... .......... .......... .......... ..........  
EU255289     .......... .......... .......... .......... .......... ..........  
EU255293     .......... .......... .......... .......... .......... ..........  
OXA-89       .......... ..A....... .......... .......... .......... ........A.  
OXA-149      .......... ....C..... .......... .......... .......... ..........  
OXA-77       .......... .......... ......C... .......... .......... ..........  
OXA-128      .......... .......... .......... .......... .......... ..........  
OXA-68       .......... .......... .......... .......... .......... ..........  
OXA-144      .......... .......... .......... .......... .......... ..........  
OXA-117      .......... .......... .......... .......... .......... ..........  
OXA-98       .......... .......... .......... .......... .......... ..........  
OXA-78       .......... .......... .......... .......... .......... ..........  
OXA-91       .......... .......... .......... .......... .......... ..........  
OXA-116      ---------- --------.. .......... .......... .......... ..........  
OXA-150      .......... .......... .......... .......... .......... ..........  
OXA-75       .........C .......... .......... .......... .......... ..........  
OXA-93       .......... ....C..... .......... ...A...... .......... ..........  
OXA-71       .......... ....C..... .......... .......... .......... ..........  
EU255290     .......... .......... .......... .A........ .......... ..........  
OXA-113      .......... ....C..... .......... .......... .......... ..........  
EU255291     .......... .......... .......... .......... .......... ..........  
OXA-51       .......... ..A....... .......... .......... .......... ..........  
OXA-132      .......... ..A....... .......... .......... .......... ..........  
OXA-99       .......... ..A....... .......... .......... .......... ..........  
OXA-64       .......... .......... .......... .......... .......... ..........  
OXA-111      .......... ..A....... .......... .......... .......... ..........  
OXA-106      .......... .......... .......... .......... .......... ..........  
OXA-70       .......... .......... .......... .......... .......... ..........  
EU255294     .......... .......... .......... .......... .......... ..........  
OXA-148      .......... .......... .......... .......... .......... ..........  
EU255292     .......... .......... .......... .......... .......... ..........  
OXA-86       .......... ..A....... .......... ...A...... .......... ..........  
OXA-87       .......... ..A....... .......... ...A...... .......... ..........  
OXA-67       .......... .......... .......... ...A...... .......... ..........  









             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                 65         75         85         95        105        115                    
OXA-65       TATATAGTGA CTGCTAATCC AAATCACAGT GCTTCAAAAT CTGATGAAAA AGCAGAGAAA  
OXA-82       .......... .......... .........C .......... ......T... ..........  
OXA-138      .......... .......... .........C .......... ......T... ..........  
OXA-115      .......... .......... .........C .......... ......T... ..........  
OXA-109      .......... .......... .........C .......... ......T... ..........  
OXA-80       .......... .......... .........C .......... ......T... ..........  
OXA-66       .......... .......... .........C .......... ......T... ..........  
OXA-83       .......... .......... .........C .......... ......T... ..........  
EU255296     .......... .......... .........C .......... ......T... ..........  
OXA-79       .......... .......... .........C .......... ......T... ..........  
OXA-76       .......... .......... .........C .......... ......T... ..........  
OXA-131      .......... .......... .........C .......... ......T... ..........  
OXA-84       .......... .......... .........C .......... ......T... ..........  
OXA-90       .......... .......... .........C .......... .......... ..........  
OXA-130      .......... ..A....... .........C .......... .......... ..........  
EU255295     .......... ..A....... .........C .......... .......... ..........  
OXA-108      .......... ..A....... .........C .......... .......... ..........  
OXA-95       .......... .......... .........C .......... .......... ..........  
OXA-88       .......... .......... .........C .......... .....A.... ..........  
OXA-94       .........T .......... .......... .......... .......... ..........  
OXA-104      .......... .......... .........C .......... .......... ..........  
OXA-107      .......... .......... .......... .......... .......C.. ..........  
OXA-69       .......... .......... .......... .......... .......C.. ..........  
OXA-110      .......... .......... .......... .......... .......C.. ..........  
OXA-112      .......... .......... .......... .......... .......C.. ..........  
OXA-92       .......... .......... .......... .......... .......C.. ..........  
EU255289     .......... .......... .......... .......... .......C.. ..........  
EU255293     .......... .......... .......... .......... .......C.. ..........  
OXA-89       .........T .......... .......... .......... .......... ..........  
OXA-149      .........T .......... .......... .......... .......... ..........  
OXA-77       .........T .......... .......... .......... .......... ..........  
OXA-128      .........T .......... .......... .......... .......... ..........  
OXA-68       .........T .......... .......... .......... .......... ..........  
OXA-144      .........T .......... .......... .......... .......... ..........  
OXA-117      .........T .......... .......... .......... .......... ..........  
OXA-98       .........T .......... .......... .......... .......... ..........  
OXA-78       .........T .......... .......... .......... .......... ..........  
OXA-91       .........T .......... .......... .......... .......... ..........  
OXA-116      .........T .......... .......... .......... .......C.. ..........  
OXA-150      .........T .......... .......... .......... .......... ..........  
OXA-75       .......... .......... ....T..... .......... .......... ..........  
OXA-93       .......... .......... .........C .......... .......... ..........  
OXA-71       .......... .......... .........C .......... .......... ..........  
EU255290     .......... .......... .........C .......... .......... ..........  
OXA-113      .......... .......... .........C .......... .......... ..........  
EU255291     .......... .......... .........C .......... .......... ..........  
OXA-51       .......... .......... .........C .......... .......... ..........  
OXA-132      .......... .......... .........C .......... .......... ..........  
OXA-99       .......... .......... .........C .......... .......... ..........  
OXA-64       .......... .......... .........C .......... .......... ..G.......  
OXA-111      .........T .......... .......... .......... .......... ..........  
OXA-106      .......... .......... .........C .......... .....A.... ..........  
OXA-70       .......... .......... .........C .......... .....A.... ..........  
EU255294     .......... .......... .........C .......... .....A.... ..........  
OXA-148      .......... .......... .........C .......... .....A.... ..........  
EU255292     .......... .......... .........C .......... .....A.... ..........  
OXA-86       .......... .......... .........C A......... .......... ..........  
OXA-87       .......... .......... .........C A......... .......... ..........  
OXA-67       .......... .......... .........C A......... .......... ..........  














             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                125        135        145        155        165        175                
OXA-65       ATTAAAAATT TATTTAACGA AGCACACACT ACGGGTGTTT TAGTTATCCA ACAAGGCCAA  
OXA-82       .......... .......... .......... .......... .......... ..........  
OXA-138      .......... .......... .......... .......... .......... ..........  
OXA-115      .......... .......... .......... .......... .......... ..........  
OXA-109      .......... .......... .......... .......... .......... ..........  
OXA-80       .......... .......... .......... .......... .......... ..........  
OXA-66       .......... .......... .......... .......... .......... ..........  
OXA-83       .......... .......... .......... .......... .......... ..........  
EU255296     .......... .......... .......... .......... .......... ..........  
OXA-79       .......... .......... .......... .......... .......... ..........  
OXA-76       .......... .......... .......... .......... .......... ..........  
OXA-131      .......... .......... .......... .......... .......... ..........  
OXA-84       .......... .......... .......... .......... .......... ..........  
OXA-90       .......... .......... .......... .......... .......... ..........  
OXA-130      .......... .......... .......... .......... .......... ..........  
EU255295     .......... .......... .......... .......... .......... ..........  
OXA-108      .......... .......... .......... .......... .......... ..........  
OXA-95       .......... .......... .......... .......... .......... ..........  
OXA-88       .......... .......... .......... .......... .......... ..........  
OXA-94       .......... .......... .......... .......... .......... ..........  
OXA-104      .......... .......... .......... .......... .......... ..........  
OXA-107      .......... .......... .......... .......... .......... T.....T...  
OXA-69       .......... .......... .......... .......... .......... T.....T...  
OXA-110      .......... .......... .......... .......... .......... T.....T...  
OXA-112      .......... .......... .......... .......... .......... T.....T...  
OXA-92       .......... .......... .......... .......... .......... T.....T...  
EU255289     .......... .......... .......... .......... .......... T.....T...  
EU255293     .......... .......... .......... .......... .......... T.....T...  
OXA-89       .......... .......... .......... .......... .......... ..........  
OXA-149      .......... .......... .......... .......... .......T.. ..........  
OXA-77       .......... .......... .......... .......... .......... ..........  
OXA-128      .......... .......... .......... .......... .......... ..........  
OXA-68       .......... .......... .......... .......... .......... ..........  
OXA-144      .......... .......... .......... .......... .......... ..........  
OXA-117      .......... .......... .......... .......... .......... ..........  
OXA-98       .......... .......... .......... .......... .......... ..........  
OXA-78       .......... .......... .......... .......... .......... ..........  
OXA-91       .......... .......... .......... .......... .......... ..........  
OXA-116      .......... .......... .......... .......... .......... ..........  
OXA-150      .......... .......... .......... .......... .......T.. ..........  
OXA-75       .......... .......... .......... .......... .......... ..........  
OXA-93       .......... .......... .......... ........C. .......... ..........  
OXA-71       .......... .......... .......... ........C. .......... ..........  
EU255290     .......... .......... .......... ........C. .......... ..........  
OXA-113      .......... .......... .......... ........C. .......... ..........  
EU255291     .......... .......... ..T....... .......... .......... ..........  
OXA-51       .......... .......... ..T....... .......... .......... ..........  
OXA-132      .......... .......... ..T....... .......... .......... ..........  
OXA-99       .......... .......... ..T....... .......... .........G ..........  
OXA-64       .......... .......... .......... .......... .......... ..........  
OXA-111      .......... .......... .......... .......... .......... ..........  
OXA-106      .......... .......... .......... .......... .......... ..........  
OXA-70       .......... .......... .......... .......... .......... ..........  
EU255294     .......... .......... .......... .......... .......... ..........  
OXA-148      .......... .......... .......... .......... .......... ..........  
EU255292     .......... .......... .......... .......... .......... ..........  
OXA-86       .......... .......... .......... .......... .......... ..........  
OXA-87       .......... .......... .......... .......... .......... ..........  
OXA-67       .......... .......... .......... .......... .......... ..........  














             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                185        195        205        215        225        235                
OXA-65       ACTCAACAAA GCTATGGTAA TGATCTTGCT CGTGCTTCGA CCGAGTATGT ACCTGCTTCG  
OXA-82       .......... .......... .......... .......... .......... ..........  
OXA-138      .......... .......... .......... .......... .......... ..........  
OXA-115      .......... .......... .......... .......... .......... ..........  
OXA-109      .......... .......... .......... .......... .......... ..........  
OXA-80       .......... .......... .......... .......... .......... ..........  
OXA-66       .......... .......... .......... .......... .......... ..........  
OXA-83       .......... .......... .......... .......... .......... ..........  
EU255296     .......... .......... .......... .......... .......... ..........  
OXA-79       .......... .......... .......... .......... .......... ..........  
OXA-76       .......... .......... .......... .......... .......... ..........  
OXA-131      .......... .......... .......... .......... .......... ..........  
OXA-84       .......... .......... .......... .......... .......... ..........  
OXA-90       .......... .......... .......... .......... .......... ..........  
OXA-130      .......... .......... .......... .......... .......... ..........  
EU255295     .......... .......... .......... .......... .......... ..........  
OXA-108      .......... .......... .......... .......... .......... ..........  
OXA-95       .......... .......... .......... .......... .......... ..........  
OXA-88       .......... .......... .......... .......... .......... ..........  
OXA-94       .......... .......... .......... .......... .......... ..........  
OXA-104      .......... .......... .......... .......... .......... ..........  
OXA-107      .......... .......... .......... .......... .......... ..........  
OXA-69       .......... .......... .......... .......... .......... ..........  
OXA-110      .......... .......... .......... .......... .......... ..........  
OXA-112      .......... .......... .......... .......... .......... ..........  
OXA-92       .......... .......... .......... .......... .......... ..........  
EU255289     .......... .......... .......... .......... .......... ..........  
EU255293     .......... .......... .......... .......... .......... ..........  
OXA-89       .......... .......... .......... .....A.... .......... ..........  
OXA-149      .......... .......... .......... .......... .......... ..........  
OXA-77       .......... .......... .......... .......... .......... ..........  
OXA-128      .......... .......... ..T....... .......... .......... ..........  
OXA-68       .......... .......... .......... .......... .......... ..........  
OXA-144      .......... .......... .......... .......... .......... ..........  
OXA-117      .......... .......... .......... .......... .......... ..........  
OXA-98       .......... .......... .......... .......... .......... ..........  
OXA-78       .......... .......... .......... .......... .......... ..........  
OXA-91       .......... .......... .......... .......... .......... ..........  
OXA-116      .......... .......... .......... .......... .......... ..........  
OXA-150      .......... .......... .......... .......... .......... ..........  
OXA-75       .......... .......... .......... .......... .......... ..........  
OXA-93       .......... .......... .......... .......... .......... ..........  
OXA-71       .......... .......... .......... .......... .......... ..........  
EU255290     .......... .......... .......... .......... .......... ..........  
OXA-113      .......... .......... .......... .......... .......... ..........  
EU255291     .......... .......... .......... .......... .......... ..........  
OXA-51       .......... .......... .......... .......... .......... ..........  
OXA-132      .......... .......... .......... .......... .......... ..........  
OXA-99       .......... .......... .......... .......... .......... ..........  
OXA-64       .......... .......... .......... .......... .......... ..........  
OXA-111      .......... .......... .......... .....A.... .......... ..........  
OXA-106      .......... .......... .......... .......... .......... ..........  
OXA-70       .......... .......... .......... .......... .......... ..........  
EU255294     .......... .......... .......... .......... .......... ..........  
OXA-148      .......... .......... .......... .......... .......... ..........  
EU255292     .......... .......... .......... .......... .......... ..........  
OXA-86       .......... .......... .......... .......... T......... ..........  
OXA-87       .......... .......... .......... .......... T......... ..........  
OXA-67       .......... .......... .......... .......... .......... ..........  














             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                245        255        265        275        285        295                
OXA-65       ACCTTCAAAA TGCTTAATGC TTTGATCGGC CTTGAGCACC ATAAGGCAAC CACCACAGAA  
OXA-82       .......... .......... .......... .......... .......... ..........  
OXA-138      .......... .......... .......... .......... .......... ..........  
OXA-115      .......... .......... .......... .......... .......... ..........  
OXA-109      .......... .......... .......... .......... .......... ..........  
OXA-80       .......... .......... .......... .......... .......... ..........  
OXA-66       .......... .......... .......... .......... .......... ..........  
OXA-83       .......... .......... .......... .......... .......... ..........  
EU255296     .......... .......... .......... .......... .......... ..........  
OXA-79       .......... .......... .......... .......... .......... ..........  
OXA-76       .......... .......... .......... .......... .......... ..........  
OXA-131      .......... .......... .......... .......... .......... ..........  
OXA-84       .......... .......... .......... .......... .......... ..........  
OXA-90       .......... .......... .......... .......... .......... ..........  
OXA-130      .......... .......... .......... .......... .......... ..........  
EU255295     .......... .......... .......... .......... .......... ..........  
OXA-108      .......... .......... .......... .......... .......... ..........  
OXA-95       .......... .......... .......... .......... .......... ..........  
OXA-88       .......... .......... .......... .......... .......... ..........  
OXA-94       .......... .......... .......... .......... .......... ..........  
OXA-104      .......... .......... .......... .......... .......... ..........  
OXA-107      .......... .......... .......... .......... .......... ..........  
OXA-69       .......... .......... .......... .......... .......... ..........  
OXA-110      .......... .......... .......... .......... .......... ..........  
OXA-112      .......... .......... .......... .......... .......... ..........  
OXA-92       .......... .......... .......... .......... .......... ..........  
EU255289     .......... .......... .......... .......... .......... ..........  
EU255293     .......... .......... .......... .......... .......... ..........  
OXA-89       .......... .......... .......... .......... .......... ...T......  
OXA-149      .......... .......... .......... .......... .......... ...T......  
OXA-77       .......... .......... .......... .......... .......... ...T......  
OXA-128      .......... .......... .......... .......... .......... ...T......  
OXA-68       .......... .......... .......... .......... .......... ...T......  
OXA-144      .......... .......... .......... .......... .......... ...T......  
OXA-117      .......... .......... .......... .......... .......... ...T......  
OXA-98       .......... .......... .......... .......... .......... ...T......  
OXA-78       .......... .......... .......... .......... .......... ...T....C.  
OXA-91       .......... .......... .......... .......... .......... ...T......  
OXA-116      .......... .......... .......... .......... .......... ...T......  
OXA-150      .......... .......... .......... .......... .......... ...T......  
OXA-75       .......... .......... ......A... .......... .......... ...T......  
OXA-93       .......... .......... .......A.. .......... .......... ..........  
OXA-71       .......... .......... .......... .......... .....A.... ..........  
EU255290     .......... .......... .......... .......... .....A.... ..........  
OXA-113      .......... .......... .......... .......... .....A.... ..........  
EU255291     .......... .......... .......... .......... .......... ..........  
OXA-51       .......... .......... .......... .......... .......... ..........  
OXA-132      .......... .......... .......... .......... .......... ..........  
OXA-99       .......... .......... .......... .......... .......... ..........  
OXA-64       .......... .......... .......... .......... .......... ..........  
OXA-111      .......... .......... .......... .......... .......... ..........  
OXA-106      .......... .......... .......... .......... .......... ..........  
OXA-70       .......... .......... .......... .......... .......... ..........  
EU255294     .......... .......... .......... .......... .......... ..........  
OXA-148      .......... .......... .......... .......... .........G ..........  
EU255292     .......... .......... .......... .......... .......... ..........  
OXA-86       .......... .......... .......... .......... .......... ..........  
OXA-87       .......... .......... .......... .......... .......... ..........  
OXA-67       .......... .......... .......... .......... .......... ..........  














             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                305        315        325        335        345        355                
OXA-65       GTATTTAAGT GGGATGGTAA AAAAAGGTTA TTCCCAGAAT GGGAAAAGGA CATGACCCTA  
OXA-82       .......... .......... .......... .......... .......... ..........  
OXA-138      .......... .......... .......... .......... .......... ..........  
OXA-115      .......... .......... .......... .......... .......... ..........  
OXA-109      .......... .......... .......... .......... .......... ..........  
OXA-80       .......... .......... .......... .......... .......... ..........  
OXA-66       .......... .......... .......... .......... .......... ..........  
OXA-83       .......... .......... .......... .......... .......... ..........  
EU255296     .......... .......... .......... .......... .......... ..........  
OXA-79       .......... .......... .......... .......... .......... ..........  
OXA-76       .......... .......... .......... .......... .......... ..........  
OXA-131      .......... .......... .......... .......... .......... ..........  
OXA-84       .......... .......... .......... .......... .......... ..........  
OXA-90       .......... .......... .......... .......... .......... ..........  
OXA-130      .......... .......... .......... .......... .......... ..........  
EU255295     .......... .......... .......... .......... .......... ..........  
OXA-108      .......... .......... .......... .......... .......... ..........  
OXA-95       .......... .......... .......C.. .......... .......... ..........  
OXA-88       .......... .......... .......... .......... .......... ..........  
OXA-94       .......... .......... .......... .......... .......... ..........  
OXA-104      .......... .......... .......C.. .......... ........A. ..........  
OXA-107      ........A. .......GG. .......C.. .......... ........A. ..........  
OXA-69       ........A. .......GG. .......C.. .......... ........A. ..........  
OXA-110      ........A. .......GG. .......C.. .......... ........A. ..........  
OXA-112      ........A. .......GG. .......C.. .......... ........A. ..........  
OXA-92       ........A. .......GG. .......C.. .......... ........A. ..........  
EU255289     A......... ....C..GC. .......C.G .......... .......... ..........  
EU255293     .......... ..A.C..GC. .......C.G .......... .......... ..........  
OXA-89       .......... ....C..GC. .......C.. .......... ........A. ..........  
OXA-149      .......... ....C..GC. .......C.. .......... ........A. ..........  
OXA-77       .......... ....C..GC. .......C.. .......... ........A. ..........  
OXA-128      .......... ....C..GC. .......C.. .......... ........A. ..........  
OXA-68       .......... ....C..GC. .......C.. .......... ........A. ..........  
OXA-144      .......... ....C..GC. .......C.. .......... ........A. ..........  
OXA-117      .......... ....C..GC. .......C.. .......... ........A. ..........  
OXA-98       .......... ....C..GC. .......C.. .......... ........A. ..........  
OXA-78       .......... ....C..GC. .......C.. .......... ........A. ..........  
OXA-91       .......... ....C..GC. .......C.. .......... ........A. ..........  
OXA-116      .......... ....C..GC. .......C.. .......... ........A. ..........  
OXA-150      .......... ....C..GC. .......C.. .......... ........A. ..........  
OXA-75       .......... ....C..GC. .......C.. .......... ........A. ..........  
OXA-93       .......... ....C..GC. .......C.. .......... .......... ..........  
OXA-71       .......... ....C..GC. .......C.. .......... .......... ..........  
EU255290     .......... ....C..GC. .......C.. .G........ .......... ..........  
OXA-113      .......... ....C..GC. .......C.. .......... .......... ..........  
EU255291     .......... ....C..GC. .......C.. .......... .......... ..........  
OXA-51       .......... ....C..GC. .......C.. .......... .......... ..........  
OXA-132      .......... ....C..GC. .......C.. .......... .......... ..........  
OXA-99       .......... ....C..GC. .......C.. .......... .......... ..........  
OXA-64       .......... ....C..GC. .......C.. .......... .......... ..........  
OXA-111      .......... ....C..GC. .......C.. .......... .......... ..........  
OXA-106      .......... ..A.C..GC. .......C.G .......... .......... ..........  
OXA-70       .......... ..A.C..GC. .......C.G .......... .......... ..........  
EU255294     .......... ..A.C..GC. .......C.G .......... .......... ..........  
OXA-148      .......... ..A.C..GC. .......C.G .......... .......... ..........  
EU255292     .......... ..A.C..GC. .......C.G .......... .......... ..........  
OXA-86       A......... ....C..GC. .......C.G .......... .......... ..........  
OXA-87       A......... ....C..GC. .......C.G .......... .......... ..........  
OXA-67       A......... ....C..GC. .......C.G .......... .......... ..........  














             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                365        375        385        395        405        415                
OXA-65       GGCGATGCCA TGAAAGCTTC CGCTATTCCA GTTTATCAAG ATTTAGCTCG TCGTATTGGA  
OXA-82       .......... .......... .......... .......... .......... ..........  
OXA-138      .......... .......... .......... .......... .......... ..........  
OXA-115      .......... .......... ........T. .......... .......... ..........  
OXA-109      .......... .......... ........A. .......... .......... ..........  
OXA-80       .......... .......... ........T. .......... .......... ..........  
OXA-66       .......... .......... .......... .......... .......... ..........  
OXA-83       .......... .......... ....C..... .......... .......... ..........  
EU255296     .......... .......... .......... .......... .......... ..........  
OXA-79       .......... .......... .......... .......... .......... ..........  
OXA-76       .......... .......... .......... .......... .......... ..........  
OXA-131      .......... .......... ....G..... .......... .......... ..........  
OXA-84       .......... .......... .......T.. .......... .......... ..........  
OXA-90       .......... .......... .......... .......... .......... ..........  
OXA-130      .......... .......... .......... .......... .......... ..........  
EU255295     .......... .......... .......... .......... .......... ..........  
OXA-108      .......... .......... .......... .......... .......... ..........  
OXA-95       .......... .......... .......... .......... .......... ..........  
OXA-88       .......... .......... .........G .......... .......... ..........  
OXA-94       .......... .......... .........G .......... .......... ..........  
OXA-104      ........T. .......... .........G .......... .......... ..........  
OXA-107      ........T. .......... .........G .......... .......... ..........  
OXA-69       ........T. .......... .........G .......... .......... ..........  
OXA-110      ........T. .......... ....C....G .......... .......... ..........  
OXA-112      ........T. .......... .........G .......... .......... ..........  
OXA-92       ........T. .......... .........G .......... .......... ..........  
EU255289     ..T.....T. .......... .........G .......... .......... ..........  
EU255293     ........T. .......... .........G .......... .......... ..........  
OXA-89       ........T. .......... .........G .......... .......... ..........  
OXA-149      ........T. .......... .........G .......... .......... ..........  
OXA-77       ........T. .......... .........G .......... .....C.... ..........  
OXA-128      ........T. .......... .........G .......... .......... ..........  
OXA-68       ........T. .......... .........G .......... .......... ..........  
OXA-144      ........T. .......... .........G .......... .......... ..........  
OXA-117      ........T. .......... .........G .......... .......... ..........  
OXA-98       ........T. .......... .........G .......... .......... ..........  
OXA-78       ........T. .......... .........G .......... .......... ..........  
OXA-91       ........T. .......... .........G .......... .......... ..........  
OXA-116      ........T. .......... .........G .......... .......... ..........  
OXA-150      ........T. .......... .........G .......... .......... ..........  
OXA-75       ........T. .......... .........G .......... .......... ..........  
OXA-93       .....C..T. .......... .........G .......... .......... ..........  
OXA-71       .....C..T. .......... .........G .......... .......... ..........  
EU255290     .....C..T. .......... .........G .......... .......... ..........  
OXA-113      .....C..T. .......... .........G .......... .......... ..........  
EU255291     ........T. .......... .........G .......... .......... ..........  
OXA-51       ........T. .......... .........G .......... .......... ..........  
OXA-132      ........T. .......... .........G .......... .......... ..........  
OXA-99       ........T. .......... .........G .......... .......... ..........  
OXA-64       ........T. .......... .........G .......... .......... ..........  
OXA-111      ........T. .......... .........G .......... .......... ..........  
OXA-106      ........T. .......... .........G .......... .......... ..........  
OXA-70       ........T. .......... .........G .......... .......... ..........  
EU255294     ........T. .......... .........G .......... .......... ..........  
OXA-148      ........T. .......... .........G .......... .......... ..........  
EU255292     ........T. .......... .........G .......... .......... ..........  
OXA-86       ..T.....T. .......... .........G .......... .......... ..........  
OXA-87       ..T.....T. .......... .........G .......... .......... ..........  
OXA-67       ..T.....T. .......... .........G .......... .......... ..........  














             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                425        435        445        455        465        475                
OXA-65       CTTGAGCTCA TGTCTAAGGA AGTGAAGCGT GTTGGTTATG GCAATGCAGA TATCGGTACC  
OXA-82       .......... ....A..... .......... .......... .......... ..........  
OXA-138      .......... .......... .......... .......... .......... ..........  
OXA-115      .......... .......... .......... .......... .......... ..........  
OXA-109      .......... .......... .......... .......... .......... ..........  
OXA-80       .......... .......... .......... .......... .......... ..........  
OXA-66       .......... .......... .......... .......... .......... ..........  
OXA-83       .......... .......... .......... .......... .......... ..........  
EU255296     .......... .......... .......... .......... .......... ..........  
OXA-79       .......... .......... .......... .......... .......... ..........  
OXA-76       .......... .......... .......... .......... .......... ..........  
OXA-131      .......... .......... .......... .......... .......... ..........  
OXA-84       .......... .......... .......... .......... .......... ..........  
OXA-90       .......... .......... .......... .......... .......... ..........  
OXA-130      .......... .......... .......... .......... .....A.... ..........  
EU255295     .......... .......... .......... .......... .....A.... ..........  
OXA-108      .......... .......... .......... .......... .....A.... ..........  
OXA-95       .......... .......... .......... .......... .......... ..........  
OXA-88       .......... .......... .......... .......... .......... ..........  
OXA-94       .......... .......... .......... .......... .......... ..........  
OXA-104      .....A.... .......T.. .......... .......... .......... ..........  
OXA-107      .......... .......... .......... .......... .......... ..........  
OXA-69       .......... .......... .......... .......... .......... ..........  
OXA-110      .......... .......... .......... .......... .......... ..........  
OXA-112      .......... .......... .......... .......... .......... ..........  
OXA-92       .......... .......... .......... .......... .......... ..........  
EU255289     .....A.... .......... .......... .......... .......... ..........  
EU255293     .....A.... .......T.. .......... .......... ........C. ..........  
OXA-89       .....A.... .......T.. .......... .......... .......... ..........  
OXA-149      .....A.... .......T.. ........A. .......... .......... ..........  
OXA-77       .....A.... .......T.. .......... .......... .......... ..........  
OXA-128      .....A.... .......T.. .......... .......... .......... ..........  
OXA-68       .....A.... .......T.. .......... .......... .......... ..........  
OXA-144      .....A.... .......T.. .......... .......... .......... ..........  
OXA-117      .....A.... .......T.. .......... .......... .......... ..........  
OXA-98       .....A.... .......T.. .......... .......... .......... ..........  
OXA-78       .....A.... .......T.. .......... .......... .......... ..........  
OXA-91       .....A.... .......T.. .......... .......... .......... ..........  
OXA-116      .....A.... .......T.. .......... .......... .......... ..........  
OXA-150      .....A.... .......T.. ........A. .......... .......... ..........  
OXA-75       .....A.... .......T.. .......... A......... .......... ..........  
OXA-93       .....A.... .......T.. .......... .......... .......... ..........  
OXA-71       .....A.... .......... .......... .......... .......... ..........  
EU255290     .....A.... .......... .......... .......... .......... ..........  
OXA-113      .....A.... .......... .......... .......... .......... ..........  
EU255291     .....A.... .......... .......... .......... .......... ..........  
OXA-51       .....A.... .......... .......... .......... .......... ..........  
OXA-132      .....A.... .......... .......... .......... .......... ..........  
OXA-99       .....A.... .......... .......... .......... .......... ..........  
OXA-64       .....A.... .......... .......... .......... .......... ..........  
OXA-111      .....A.... .......... .......... .......... .......... ..........  
OXA-106      .....A.... .......T.. .......... .......... .......... ..........  
OXA-70       .....A.... .......T.. .......... .......... .......... ..........  
EU255294     .....A.... .......T.. .......... .......... .......... ..........  
OXA-148      .....A.... .......T.. .......... .......... .......... ..........  
EU255292     .....A.... .......T.. .......... .......... .......... ..........  
OXA-86       .....A.... .......... .......... .......... .......... ..........  
OXA-87       .....A.... .......... .......... .......... .......... ..........  
OXA-67       .....A.... .......... .......... .......... .......... ..........  














             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                485        495        505        515        525        535                
OXA-65       CAAGTCGATA ATTTTTGGCT GGTGGGTCCT TTAAAAATTA CTCCTCAGCA AGAGGCACAG  
OXA-82       .......... ........G. .......... .......... .......... ..........  
OXA-138      .......... ........G. .......... .......... .......... ..........  
OXA-115      .......... ........G. .......... .......... .......... ..........  
OXA-109      .......... .......... .......... .......... .......... ..........  
OXA-80       .......... .......... .......... .......... .......... ..........  
OXA-66       .......... .......... .......... .......... .......... ..........  
OXA-83       .......... .......... .......... .......... .......... ..........  
EU255296     .......... .........A .......... .......... .......... ..........  
OXA-79       .......... .......... .......... .......... .......... ..........  
OXA-76       .......... .......... .......... .......... .......... ..........  
OXA-131      .......... .......... .......... .......... .......... ..........  
OXA-84       .......... .......... ..C....... .......... .......... ..........  
OXA-90       .......... .......... A......... .......... .......... ..........  
OXA-130      .......... .......... .......... .......... .......... ..........  
EU255295     .......... .......... .A........ .......... .......... ..........  
OXA-108      .......... ........G. .......... .......... .......... ..........  
OXA-95       .......... .......... .......... .......... .......... ..........  
OXA-88       .......... .......... .......... .......... .......... ..........  
OXA-94       .......... .......... .......... .......... .......... ..........  
OXA-104      .......... .......... .......... .......... .......... ..........  
OXA-107      .......... ........G. .......... C......... .......... ..........  
OXA-69       .......... .......... .......... C......... .......... ..........  
OXA-110      .......... .......... .......... C......... .......... ..........  
OXA-112      .......... .......... .......... C......... .......... ..........  
OXA-92       .......... .......... .......... C......... .......... ..........  
EU255289     .......... .......... .......... .......... .......... ..........  
EU255293     .......... .......... .......... .......... .......... .........A  
OXA-89       .......... .......... .......... .......... .......... .........A  
OXA-149      .......... .......... .......... .......... .......... .........A  
OXA-77       .......... .......... .......... .......... .......... .........A  
OXA-128      .......... .......... A......... .......... .......... .........A  
OXA-68       .......... .......... A......... .......... .......... .........A  
OXA-144      .......... .......... A......... .......... .......... .........A  
OXA-117      .......... .......... A......... .......... .......... .........A  
OXA-98       .......... .......... .......... .......... .......... .........A  
OXA-78       .......... .......... A......... .......... .......... .........A  
OXA-91       .......... .......... .......... .......... .......... .........A  
OXA-116      .......... .......... .......... .......... .......... ..........  
OXA-150      .......... .......... .......... .......... .......... .........A  
OXA-75       .......... .......... .......... .......... .......A.. .........A  
OXA-93       .......... .......... .......... .......... .......... .........A  
OXA-71       .......... .......... .......... .......... .......... .........A  
EU255290     .......... .......... .......... .......... .......... .........A  
OXA-113      .......... ........G. .......... .......... .......... .........A  
EU255291     .......... .......... .......... .......... .......... ..........  
OXA-51       .......... .......... .......... .......... .......... ..........  
OXA-132      .......... .......... .......... .......... .......... ..........  
OXA-99       .......... .......... .......... .......... .......... ..........  
OXA-64       .......... .......... .......... .......... .......... ..........  
OXA-111      .......... .......... ......C... .......... .......... ..........  
OXA-106      .......... .......... .......... .......... .......... .........A  
OXA-70       .......... .......... .......... .......... .......... .........A  
EU255294     .......... .......... .......... .......... .......... .........A  
OXA-148      .......... .......... .......... .......... .......... .........A  
EU255292     .......... .......... .......... .......... .......... ..........  
OXA-86       .......... .......... .......... .......... .......... ..........  
OXA-87       .......... .......... .......... .......... .......... ..........  
OXA-67       .......... .......... .......... .......... .......... ..........  














             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                545        555        565        575        585        595                
OXA-65       TTTGCTTACA AGCTAGCTAA TAAAACGCTT CCATTTAGCC AAAAAGTCCA AGATGAAGTG  
OXA-82       .......... .......... .......... .......... .......... ..........  
OXA-138      .......... .......... .......... .......... .......... ..........  
OXA-115      .......... .......... .......... .......... .......... ..........  
OXA-109      .......... .......... .......... .......... .......... ..........  
OXA-80       .......... .......... .......... .......... .......... ..........  
OXA-66       .......... .......... .......... .......... .......... ..........  
OXA-83       .......... .......... .......... .......... .......... ..........  
EU255296     .......... .......... .......... .......... .......... ..........  
OXA-79       .......... .......... .......... .......... .......... ..........  
OXA-76       .......... .......... .......... .......... .......... ..........  
OXA-131      .......... .......... .......... .......... .......... ..........  
OXA-84       .......... .......... .......... .......... .......... ..........  
OXA-90       .......... .......... .......... .......... .......... ..........  
OXA-130      .......... .......... .......... .......... .......... ..........  
EU255295     .......... .......... .......... .......... .......... ..........  
OXA-108      .......... .......... .......... .......... .......... ..........  
OXA-95       .......... .......... .......... .......... .......... ..........  
OXA-88       .......... .......... .......... .......... .......... ..........  
OXA-94       .......... .......... .......... .......... .......... ..........  
OXA-104      ........T. .......... .......... .......... .......... ..........  
OXA-107      .......... .......... .......... .......... .......... ..........  
OXA-69       .......... .......... .......... .......... .......... ..........  
OXA-110      .......... .......... .......... .......... .......... ..........  
OXA-112      .......... .......... .......... .......... .......... ..........  
OXA-92       .......... .......... .......... .......... .......... ..........  
EU255289     .......... .......... .......... .......... .......... ..........  
EU255293     .......... .......... .......... .......... .......... ..........  
OXA-89       ...A...... .......... .......... .......... .......... ..........  
OXA-149      .......... .......... .......... .......... C......... ..........  
OXA-77       .......... .......... .......... .......... .......... ..........  
OXA-128      .......... .......... .......... .......... ..G....... ..........  
OXA-68       .......... .......... .......... .......... ..G....... ..........  
OXA-144      .......... .......... .......... .......... ..G....... ..........  
OXA-117      .......... .......... .......... .......... .......... ..........  
OXA-98       .......... .......... .......... .......... .......... ..........  
OXA-78       .......... .......... .......... .......... .......... ..........  
OXA-91       .......... .......... .......... .......... .......... ..........  
OXA-116      .......... .......... .......... .......... .......... ..........  
OXA-150      .......... .......... .......... .......... .......... ..........  
OXA-75       .......... .......... .......... .......... .......... ..........  
OXA-93       .......... .......... .......... .......... .......... ..........  
OXA-71       .......... .......... .......... .......... C......... ..........  
EU255290     .......... .......... .......... .......... C......... ..........  
OXA-113      .......... .......... .......... .......... C......... ..........  
EU255291     .......... .......... .......... .......... C......... ..........  
OXA-51       .......... .......... .......... .......... C......... ..........  
OXA-132      .......... .......... .......... .......... C......... ..........  
OXA-99       .......... .......... .......... .......... C......... ..........  
OXA-64       .......... .......... .......... .......... C......... ..........  
OXA-111      .......... .......... .......... .......... C......... ..........  
OXA-106      .......... .......... .......... .......... .......... ..........  
OXA-70       .......... .......... .......... .......... .......... .C........  
EU255294     .......... .......... .......... .......... .......... .C........  
OXA-148      .......... .......... .......... .......... .......... ..........  
EU255292     .......... .......... .......... .......... C......... ..........  
OXA-86       .......... .......... .......... .......... T......... ..........  
OXA-87       .......... .......... .......... .......... T.....C... ..........  
OXA-67       .......... .......... .......... .......... T......... ..........  














             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                605        615        625        635        645        655                
OXA-65       CAATCCATGC TATTCATAGA AGAAAAGAAT GGAAACAAAA TATACGCAAA AAGTGGTTGG  
OXA-82       .......... .......... .......... .......... .......... ..........  
OXA-138      .......... .......... .......... .......... .......... ..........  
OXA-115      .......... .......... .......... .......... .......... ..........  
OXA-109      .......... .......... .......... .......... .......... ..........  
OXA-80       .......... .......... .......... .......... .......... ..........  
OXA-66       .......... .......... .......... .......... .......... ..........  
OXA-83       .......... .......... .......... .......... .......... ..........  
EU255296     .......... .......... .......... .......... .......... ..........  
OXA-79       .......... .......... .......... .......... .......... ..........  
OXA-76       .......... .......... .......... .......... .......... ..........  
OXA-131      .......... .......... .......... .......... .......... ..........  
OXA-84       .......... .......... .......... .......... .......... ..........  
OXA-90       .......... .......... .......... .......... .......... ..........  
OXA-130      .......... .......... .......... .....T.... .......... ..........  
EU255295     .......... .......... .......... .....T.... .......... ..........  
OXA-108      .......... .......... .......... .....T.... .......... ..........  
OXA-95       .......... .......... .......... .....T.... .......... ..........  
OXA-88       .......... .......... .......... .....T.... .......... ..........  
OXA-94       .......... .......... .......... .....T.... .......... ..........  
OXA-104      .........T .......... .......... .....T.... .......... ..........  
OXA-107      .......... .......... .......... .....T.... .......... ..........  
OXA-69       .......... .......... .......... .....T.... .......... ..........  
OXA-110      .......... .......... .......... .....T.... .......... ..........  
OXA-112      .......... .......... .......... .....T.... .......... ..........  
OXA-92       .......... .......... .......... .....T.... .......... ..........  
EU255289     .......... .......... .......... .....T.... .......... ..........  
EU255293     .........T .......... .......... .....T.... .......... ..........  
OXA-89       .........T .......... .......... .....T.... .......... ..........  
OXA-149      .......... .......... .......... .....T.... .......... ..........  
OXA-77       .......... .......... .......... .....T.... .......... ..........  
OXA-128      .......... .......... .......... .....T.... .......... ..........  
OXA-68       .......... .......... .......... .....T.... .......... ..........  
OXA-144      ........T. .......... .......... .....T.... .......... ..........  
OXA-117      .......... .......... .......... .....T.... .......... ..........  
OXA-98       .......... .......... .......... .....T.... .......... ..........  
OXA-78       .......... .......... .......... .....T.... .......... ..........  
OXA-91       .......... .......... .......... .....T.... .......... ..........  
OXA-116      .........T .......... .......... .....T.... .......... ..........  
OXA-150      .......... .G........ .......... .....T.... .......... ..........  
OXA-75       .......... .......... .......... .....T.... .......... ..........  
OXA-93       .......... .......... .......... .....T.... .......... ..........  
OXA-71       .......... .......... .......... .....T.... .......... ..........  
EU255290     .......... .......... .......... .....T.... .......... ..........  
OXA-113      .......... .......... .......... .....T.... .......... ..........  
EU255291     .........T .......... .......... .....T.... .......... ..........  
OXA-51       .........T .......... .......... .....T.... .......... ..........  
OXA-132      .........T .......... .......... .....T.... .......... ..........  
OXA-99       .........T .......... .....T.... .....T.... .......... ..........  
OXA-64       .........T .......... .......... .....T.... .......... ..........  
OXA-111      .........T .......... .....T.... .....T.... .......... ..........  
OXA-106      .......... .......... .......... .....T.... .......... ..........  
OXA-70       .......... .......... .......... .....T.... .......... ..........  
EU255294     .......... .......... .......... .....T.... .......... ..........  
OXA-148      A......... .......... .......... .....T.... .......... ..........  
EU255292     .........T .......... .......... .....T.... .......... ..........  
OXA-86       .........T .......... .......... .....T.... .......... ..........  
OXA-87       .........T .......... .......... .....T.... .......... ..........  
OXA-67       .........T .......... .......... .....T.... .......... ..........  














             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                665        675        685        695        705        715                
OXA-65       GGATGGGATG TAAACCCACA AGTAGGCTGG TTAACTGGAT GGGTTGTTCA GCCTCAAGGG  
OXA-82       .......... .......... .......... .......... .......... ..........  
OXA-138      .......... .......... .......... .......... .......... ..........  
OXA-115      .......... .......... .......... .......... .......... ..........  
OXA-109      .......... .......... .......... .......... .......... ..........  
OXA-80       .......... .......... .......... .......... .......... ..........  
OXA-66       .......... .......... .......... .......... .......... ..........  
OXA-83       .......... .......... .......... .......... .......... ..........  
EU255296     .......... .......... .......... .......... .......... ..........  
OXA-79       ...G...... .......... .......... .......... .......... ..........  
OXA-76       .......... .......... .......... .......... .......... ..........  
OXA-131      .......... ......A... .......... .......... .......... ..........  
OXA-84       .......... .......... .......... .......... .......... ..........  
OXA-90       .......... ..G....... .......... .......... .......... .........A  
OXA-130      .......... ..G....... .......... .......... .......... ..........  
EU255295     .......... ..G....... .......... .......... .......... ..........  
OXA-108      .......... ..G....... .......... .......... .......... ..........  
OXA-95       .......... ..G....... .......... .......... .......... ..........  
OXA-88       .......... .......... .......... .......... .......... ..........  
OXA-94       .......... .......... .......... .......... .......... ......T...  
OXA-104      .......... ..G....... .......... .......... .......... .........A  
OXA-107      .......... .......... .......... .......... .......... ..........  
OXA-69       .......... .......... .......... .......... .......... ..........  
OXA-110      .......... .......... .......... .......... .......... ..........  
OXA-112      .......... .......... .......... .......... .......... ..........  
OXA-92       .......... .......... .......... .......... C......... ..........  
EU255289     .......... .......... .......... .......... .......... ..........  
EU255293     .......... ..G....... .......... .......... .......... ..........  
OXA-89       .......... .......... .......... .......... .......... ..........  
OXA-149      .......... .......... .......... .......... .......... .........A  
OXA-77       .......... .......... .......... .......... .......... ..........  
OXA-128      .......... .......... .......... .......... .......... ..........  
OXA-68       .......... .......... .......... .......... .......... ..........  
OXA-144      .......... .......... .......... .......... .......... ..........  
OXA-117      .......... .......... .......... .......A.. .......... ..........  
OXA-98       .......... .......... .......... .......... .......... ..........  
OXA-78       .......... .......... .......... .......... .......... ..........  
OXA-91       .......... ..G....... .......... .......... .......... ..........  
OXA-116      .......... ..G....... ...G..T... .......... .......... ..........  
OXA-150      .......... .......... .......... .......... .......... ..........  
OXA-75       .......... .......... .......... .......... .......... ..........  
OXA-93       .......... .......... .......... .......... .......... ..........  
OXA-71       .......... ..G....... .......... .......... .......... .........A  
EU255290     .......... ..G....... .......... .......... .......... .........A  
OXA-113      .......... ..G....... .......... .......... .......... .........A  
EU255291     .......... ..G....... .......... .......... .......... .........A  
OXA-51       .......... ..G....... .......... .......... .......... .........A  
OXA-132      .......... ..G....... .......... .......... .......... .........A  
OXA-99       .......... ..G....... .......... .......... .......... .........A  
OXA-64       .......... ..G....... .......... .......... .......... ..........  
OXA-111      .......... ..G....... .......... .......... .......... .........A  
OXA-106      .......... ..G....... .......... .......... .......... ..........  
OXA-70       .......... ..G....... .......... .......... .......... ..........  
EU255294     .......... ..G....... .......... .......... .........G ..........  
OXA-148      .......... ..G....... .......... .......... .......... ..........  
EU255292     .......... ..G....... .......... .......... .......... .........A  
OXA-86       .......... ..G....... .......... .......... .......... .........A  
OXA-87       .......... ..G....... .......... .......... .......... .........A  
OXA-67       .......... ..G....... .......... .......... .......... .........A  














             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                725        735        745        755        765        775                
OXA-65       AATATTGTAG CGTTCTCCCT TAACTTAGAA ATGAAAAAAG GAATACCTAG CTCTGTTCGA  
OXA-82       .......... .......... .......... .......... .......... ..........  
OXA-138      .......... .......... .......... .......... .......... ..........  
OXA-115      .......... .......... .......... .......... .......... ..........  
OXA-109      .......... .......... .......... .......... .......... ..........  
OXA-80       .......... .......... .......... .......... .......... ..........  
OXA-66       .......... .......... .......... .......... .......... ..........  
OXA-83       .......... .......... .......... .......... .......... ..........  
EU255296     .......... .......... .......... .......... .......... ..........  
OXA-79       .......... .......... .......... .......... .......... ..........  
OXA-76       .......... .......... .......... .......... .......... ..........  
OXA-131      .......... .......... .......... .......... .......... ..........  
OXA-84       .......... .......... .......... .......... .......... ..........  
OXA-90       .......... .......... .......... .......... .......... ..........  
OXA-130      .......... .......... .......... .......... .......... ..........  
EU255295     .......... .......... .......... .......... .......... ..........  
OXA-108      .......... .......... .......... .......... .......... ..........  
OXA-95       .......... .......... .......... .......... .......... ..........  
OXA-88       .......... .......... .......... .......... .......... ..........  
OXA-94       .......... .......... .......... .......... .......... ..........  
OXA-104      .......... .A........ .......... .......... .......... ..........  
OXA-107      .......... .......... .......... .......... .......... ..........  
OXA-69       .......... .......... .......... .......... .......... ..........  
OXA-110      .......... .......... .......... .......... .......... ..........  
OXA-112      .......... .....C.... .......... .......... .......... ..........  
OXA-92       .......... .......... .......... .......... .......... ..........  
EU255289     .......... .......... .......... .......... .......... ..........  
EU255293     .......... .......... .......... .......... .......... ..........  
OXA-89       .......... .......... .......... .......... .......... ..........  
OXA-149      .......... .......... .......... .......... .......... ..........  
OXA-77       .......... .......... .......... .......... .......... ..........  
OXA-128      .......... .......... .......... .......... .......... ..........  
OXA-68       .......... .......... .......... .......... .......... ..........  
OXA-144      .......... .......... .......... .......... .......... ..........  
OXA-117      .......... .......... .......... .......... .......... ..........  
OXA-98       .......... .......... .......... .......... .......... ..........  
OXA-78       .......... .......... .......... .......... ...C...... ..........  
OXA-91       .......... .......... .......... .......... .......... ..........  
OXA-116      .......... .......... .......... .......... .......... ..........  
OXA-150      .......... .......... .......... .......... .......... ..........  
OXA-75       .......... .......... .......... .......... .....T.... ..........  
OXA-93       .......... .......... .......... .......... .......... ..........  
OXA-71       .......... .A........ .......... .......... .......... ..........  
EU255290     .......... .A........ .......... .......... .......... ..........  
OXA-113      .......... .......... .......... .......... .......... ..........  
EU255291     .......... .......... .......... .......... .......... ..........  
OXA-51       .......... .......... .......... .......... .......... ..........  
OXA-132      .......... .......... .......... .......... .......... ..........  
OXA-99       .......... .......... .......... .......... .......... ..........  
OXA-64       .......... .......... .......... .......... .......... ..........  
OXA-111      .......... .......... .......... .......... .......... ..........  
OXA-106      .......... .......... .......... .......... .......... ..........  
OXA-70       .......... .......... .......... .......... .......... ..........  
EU255294     .......... .......... .......... .......... .....G.... ..........  
OXA-148      .......... .......... .......... .......... .......... ..........  
EU255292     .......... .......... .......... .......... .......... ..........  
OXA-86       .......... .......... .......... .......... .......... ..........  
OXA-87       .......... .......... .......... .......... .......... ..........  
OXA-67       .......... .......... .......... .......... .......... ..........  














             ....|....| ....|....| ....|....| ....|....| ....| 
                785        795        805        815        825        
OXA-65       AAAGAGATTA CTTATAAAAG TTTAGAACAA TTAGGTATTT TATAG 
OXA-82       .......... .......... C......... .......... ..... 
OXA-138      .......... .......... C......... .......... ..... 
OXA-115      .......... .......... C......... .......... ..... 
OXA-109      .......... .......... C......... .......... ..... 
OXA-80       .......... .......... C......... .......... ..... 
OXA-66       .......... .......... C......... .......... ..... 
OXA-83       .......... .......... C......... .......... ..... 
EU255296     .......... .......... C......... .......... ..... 
OXA-79       .......... .......... C......... .......... ..... 
OXA-76       .......... .......... C......A.. .......... ..... 
OXA-131      .......... .......... C......... .......... ..... 
OXA-84       .......... .......... C......... .......... ..... 
OXA-90       .......... .......... .......... .......... ..... 
OXA-130      .......... .......... .......... .......... ..... 
EU255295     .......... .......... .......... .......... ..... 
OXA-108      .......... .......... .......... .......... ..... 
OXA-95       .......... .......... .......... .......... ..... 
OXA-88       .......... .......... .......... .......... ..... 
OXA-94       .......... .......... .......... .......... ..... 
OXA-104      .......... .......... .......... .......... ..... 
OXA-107      .......... .......... .......... .......... ..... 
OXA-69       .......... .......... .......... .......... ..... 
OXA-110      .......... .......... .......... .......... ..... 
OXA-112      .......... .......... .......... .......... ..... 
OXA-92       .......... .......... .......... .......... ..... 
EU255289     .......... .......... .......... .......... ..... 
EU255293     .......... .......... .......... .......... ..... 
OXA-89       .......... .......... .......... .......... ..... 
OXA-149      .......... .......... .......... .......... ..... 
OXA-77       .......... .......... C......... .......... ..... 
OXA-128      .......... .......... C......... .......... ..... 
OXA-68       .......... .......... C......... .......... ..... 
OXA-144      .......... .......... C......... .......... ..... 
OXA-117      .......... .......... C......... .......... ..... 
OXA-98       .......... .......... C......... .......... ..... 
OXA-78       .......... .......... C......... .......... ..... 
OXA-91       .......... .......... .......... .......... ..... 
OXA-116      .......... .......... ....------ ---------- ----- 
OXA-150      .......... .......... C......... .......... ..... 
OXA-75       .......... ......G.G. .......... .......... ..... 
OXA-93       .......... .......... C......... .......... ..... 
OXA-71       .......... .......... .......... .......... ..... 
EU255290     .......... .......... .......... .......... ..... 
OXA-113      .......... .......... C......... .......... ..... 
EU255291     .........G .......... .......... .......... ..... 
OXA-51       .......... .......... .......... .......... ..... 
OXA-132      ........G. .......... .......... .......... ..... 
OXA-99       .......... .......... .......... .......... ..... 
OXA-64       .......... .......... .......... .......... ..... 
OXA-111      .......... .......... .......... .......... ..... 
OXA-106      .......... .......... .......... .......... ..... 
OXA-70       .......... .......... .......... .......... ..... 
EU255294     .......... .......... .......... .......... ..... 
OXA-148      .......... .......... .......... .......... ..... 
EU255292     .......... .......... .......... .......... ..... 
OXA-86       .......... .......... .......... .......... ..... 
OXA-87       .......... .......... .......... .......... ..... 
OXA-67       .......... .......... .......... .......... ..... 





2. Amino-acid alignment for all 60 OXA-51-like enzymes. Substitutions are 
 labelled with respect to OXA-65. 
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                 5          15         25         35         45         55                      
OXA-65       MNIKALLLIT SAIFISACSP YIVTANPNHS ASKSDEKAEK IKNLFNEAHT TGVLVIQQGQ  
OXA-82       .......... .......... .......... .....V.... .......... ..........  
OXA-138      ....T..... .......... .......... .....V.... .......... ..........  
OXA-115      .......... .......... .......... .....V.... .......... ..........  
OXA-109      .......... .......... .......... .....V.... .......... ..........  
OXA-80       .......... .......... .......... .....V.... .......... ..........  
OXA-66       .......... .......... .......... .....V.... .......... ..........  
OXA-83       .......... .......... .......... .....V.... .......... ..........  
EU255296     .......... .......... .......... .....V.... .......... ..........  
OXA-79       .......... .......... .......... .....V.... .......... ..........  
OXA-76       .......... .......... .......... .....V.... .......... ..........  
OXA-131      .......... .......... .......... .....V.... .......... ..........  
OXA-84       .......... .......... .......... .....V.... .......... ..........  
OXA-90       .......... .......... .......... .......... .......... ..........  
OXA-130      .......... .......... ....T..... .......... .......... ..........  
EU255295     .......... .......... ....T..... .......... .......... ..........  
OXA-108      .......... .......... ....T..... .......... .......... ..........  
OXA-95       ......F... .......... .......... .......... .......... ..........  
OXA-88       .......... .......... .......... .....K.... .......... ..........  
OXA-94       ...Q...... .......... ...S...... .......... .......... ..........  
OXA-104      .......... .......... .......... .......... .......... ..........  
OXA-107      .......... .......... .......... .....D.... .......... ......H...  
OXA-69       .......... .......... .......... .....D.... .......... ......H...  
OXA-110      .......... .......... .......... .....D.... .......... ......H...  
OXA-112      .......... .......... .......... .....D.... .......... ......H...  
OXA-92       .......... .......... .......... .....D.... .......... ......H...  
EU255289     .......... .......... .......... .....D.... .......... ......H...  
EU255293     .......... .......... .......... .....D.... .......... ......H...  
OXA-89       ....T..... .........H ...S...... .......... .......... ..........  
OXA-149      .......... .......... ...S...... .......... .......... ..........  
OXA-77       .......... .......... ...S...... .......... .......... ..........  
OXA-128      .......... .......... ...S...... .......... .......... ..........  
OXA-68       .......... .......... ...S...... .......... .......... ..........  
OXA-144      .......... .......... ...S...... .......... .......... ..........  
OXA-117      .......... .......... ...S...... .......... .......... ..........  
OXA-98       .......... .......... ...S...... .......... .......... ..........  
OXA-78       .......... .......... ...S...... .......... .......... ..........  
OXA-91       .......... .......... ...S...... .......... .......... ..........  
OXA-116      ------.... .......... ...S...... .....D.... .......... ..........  
OXA-150      .......... .......... ...S...... .......... .......... ..........  
OXA-75       ...Q...... .......... ........Y. .......... .......... ..........  
OXA-93       .......... .T........ .......... .......... .......... ..........  
OXA-71       .......... .......... .......... .......... .......... ..........  
EU255290     .......... N......... .......... .......... .......... ..........  
OXA-113      .......... .......... .......... .......... .......... ..........  
EU255291     .......... .......... .......... .......... .......V.. ..........  
OXA-51       ....T..... .......... .......... .......... .......V.. ..........  
OXA-132      ....T..... .......... .......... .......... .......V.. ..........  
OXA-99       ....T..... .......... .......... .......... .......V.. ......R...  
OXA-64       .......... .......... .......... .......G.. .......... ..........  
OXA-111      ....T..... .......... ...S...... .......... .......... ..........  
OXA-106      .......... .......... .......... .....K.... .......... ..........  
OXA-70       .......... .......... .......... .....K.... .......... ..........  
EU255294     .......... .......... .......... .....K.... .......... ..........  
OXA-148      .......... .......... .......... .....K.... .......... ..........  
EU255292     .......... .......... .......... .....K.... .......... ..........  
OXA-86       ....T..... .T........ .......... T......... .......... ..........  
OXA-87       ....T..... .T........ .......... T......... .......... ..........  
OXA-67       .......... .T........ .......... T......... .......... ..........  









             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                 65         75         85         95        105        115                    
OXA-65       TQQSYGNDLA RASTEYVPAS TFKMLNALIG LEHHKATTTE VFKWDGKKRL FPEWEKDMTL  
OXA-82       .......... .......... .......... .......... .......... ..........  
OXA-138      .......... .......... .......... .......... .......... ..........  
OXA-115      .......... .......... .......... .......... .......... ..........  
OXA-109      .......... .......... .......... .......... .......... ..........  
OXA-80       .......... .......... .......... .......... .......... ..........  
OXA-66       .......... .......... .......... .......... .......... ..........  
OXA-83       .......... .......... .......... .......... .......... ..........  
EU255296     .......... .......... .......... .......... .......... ..........  
OXA-79       .......... .......... .......... .......... .......... ..........  
OXA-76       .......... .......... .......... .......... .......... ..........  
OXA-131      .......... .......... .......... .......... .......... ..........  
OXA-84       .......... .......... .......... .......... .......... ..........  
OXA-90       .......... .......... .......... .......... .......... ..........  
OXA-130      .......... .......... .......... .......... .......... ..........  
EU255295     .......... .......... .......... .......... .......... ..........  
OXA-108      .......... .......... .......... .......... .......... ..........  
OXA-95       .......... .......... .......... .......... .......... ..........  
OXA-88       .......... .......... .......... .......... .......... ..........  
OXA-94       .......... .......... .......... .......... .......... ..........  
OXA-104      .......... .......... .......... .......... .......... ......N...  
OXA-107      .......... .......... .......... .......... ......E... ......N...  
OXA-69       .......... .......... .......... .......... ......E... ......N...  
OXA-110      .......... .......... .......... .......... ......E... ......N...  
OXA-112      .......... .......... .......... .......... ......E... ......N...  
OXA-92       .......... .......... .......... .......... ......E... ......N...  
EU255289     .......... .......... .......... .......... I.....Q... ..........  
EU255293     .......... .......... .......... .......... ....N.Q... ..........  
OXA-89       .......... .......... .......... .......... ......Q... ......N...  
OXA-149      .......... .......... .......... .......... ......Q... ......N...  
OXA-77       .......... .......... .......... .......... ......Q... ......N...  
OXA-128      .......V.. .......... .......... .......... ......Q... ......N...  
OXA-68       .......... .......... .......... .......... ......Q... ......N...  
OXA-144      .......... .......... .......... .......... ......Q... ......N...  
OXA-117      .......... .......... .......... .......... ......Q... ......N...  
OXA-98       .......... .......... .......... .......... ......Q... ......N...  
OXA-78       .......... .......... .......... .........A ......Q... ......N...  
OXA-91       .......... .......... .......... .......... ......Q... ......N...  
OXA-116      .......... .......... .......... .......... ......Q... ......N...  
OXA-150      .......... .......... .......... .......... ......Q... ......N...  
OXA-75       .......... .......... .......... .......... ......Q... ......N...  
OXA-93       .......... .......... .........S .......... ......Q... ..........  
OXA-71       .......... .......... .......... .....T.... ......Q... ..........  
EU255290     .......... .......... .......... .....T.... ......Q... C.........  
OXA-113      .......... .......... .......... .....T.... ......Q... ..........  
EU255291     .......... .......... .......... .......... ......Q... ..........  
OXA-51       .......... .......... .......... .......... ......Q... ..........  
OXA-132      .......... .......... .......... .......... ......Q... ..........  
OXA-99       .......... .......... .......... .......... ......Q... ..........  
OXA-64       .......... .......... .......... .......... ......Q... ..........  
OXA-111      .......... .......... .......... .......... ......Q... ..........  
OXA-106      .......... .......... .......... .......... ....N.Q... ..........  
OXA-70       .......... .......... .......... .......... ....N.Q... ..........  
EU255294     .......... .......... .......... .......... ....N.Q... ..........  
OXA-148      .......... .......... .......... ......S... ....N.Q... ..........  
EU255292     .......... .......... .......... .......... ....N.Q... ..........  
OXA-86       .......... ...I...... .......... .......... I.....Q... ..........  
OXA-87       .......... ...I...... .......... .......... I.....Q... ..........  
OXA-67       .......... .......... .......... .......... I.....Q... ..........  














             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                125        135        145        155        165        175                
OXA-65       GDAMKASAIP VYQDLARRIG LELMSKEVKR VGYGNADIGT QVDNFWLVGP LKITPQQEAQ  
OXA-82       .......... .......... .......... .......... ......V... ..........  
OXA-138      .......... .......... .......... .......... ......V... ..........  
OXA-115      .........L .......... .......... .......... ......V... ..........  
OXA-109      .........Q .......... .......... .......... .......... ..........  
OXA-80       .........L .......... .......... .......... .......... ..........  
OXA-66       .......... .......... .......... .......... .......... ..........  
OXA-83       ........L. .......... .......... .......... .......... ..........  
EU255296     .......... .......... .......... .......... ......Q... ..........  
OXA-79       .......... .......... .......... .......... .......... ..........  
OXA-76       .......... .......... .......... .......... .......... ..........  
OXA-131      ........V. .......... .......... .......... .......... ..........  
OXA-84       .........S .......... .......... .......... .......A.. ..........  
OXA-90       .......... .......... .......... .......... .......... ..........  
OXA-130      .......... .......... .......... .....T.... .......... ..........  
EU255295     .......... .......... .......... .....T.... .......M.. ..........  
OXA-108      .......... .......... .......... .....T.... ......V... ..........  
OXA-95       .......... .......... .......... .......... .......... ..........  
OXA-88       .......... .......... .......... .......... .......... ..........  
OXA-94       .......... .......... .......... .......... .......... ..........  
OXA-104      .......... .......... .....N.... .......... .......... ..........  
OXA-107      .......... .......... .......... .......... ......V... ..........  
OXA-69       .......... .......... .......... .......... .......... ..........  
OXA-110      ........L. .......... .......... .......... .......... ..........  
OXA-112      .......... .......... .......... .......... .......... ..........  
OXA-92       .......... .......... .......... .......... .......... ..........  
EU255289     .......... .......... .......... .......... .......... ..........  
EU255293     .......... .......... .....N.... ......H... .......... ..........  
OXA-89       .......... .......... .....N.... .......... .......... ..........  
OXA-149      .......... .......... .....N...H .......... .......... ..........  
OXA-77       .......... .....P.... .....N.... .......... .......... ..........  
OXA-128      .......... .......... .....N.... .......... .......... ..........  
OXA-68       .......... .......... .....N.... .......... .......... ..........  
OXA-144      .......... .......... .....N.... .......... .......... ..........  
OXA-117      .......... .......... .....N.... .......... .......... ..........  
OXA-98       .......... .......... .....N.... .......... .......... ..........  
OXA-78       .......... .......... .....N.... .......... .......... ..........  
OXA-91       .......... .......... .....N.... .......... .......... ..........  
OXA-116      .......... .......... .....N.... .......... .......... ..........  
OXA-150      .......... .......... .....N...H .......... .......... ..........  
OXA-75       .......... .......... .....N.... I......... .......... ..........  
OXA-93       .......... .......... .....N.... .......... .......... ..........  
OXA-71       .......... .......... .......... .......... .......... ..........  
EU255290     .......... .......... .......... .......... .......... ..........  
OXA-113      .......... .......... .......... .......... ......V... ..........  
EU255291     .......... .......... .......... .......... .......... ..........  
OXA-51       .......... .......... .......... .......... .......... ..........  
OXA-132      .......... .......... .......... .......... .......... ..........  
OXA-99       .......... .......... .......... .......... .......... ..........  
OXA-64       .......... .......... .......... .......... .......... ..........  
OXA-111      .......... .......... .......... .......... .......... ..........  
OXA-106      .......... .......... .....N.... .......... .......... ..........  
OXA-70       .......... .......... .....N.... .......... .......... ..........  
EU255294     .......... .......... .....N.... .......... .......... ..........  
OXA-148      .......... .......... .....N.... .......... .......... ..........  
EU255292     .......... .......... .....N.... .......... .......... ..........  
OXA-86       .......... .......... .......... .......... .......... ..........  
OXA-87       .......... .......... .......... .......... .......... ..........  
OXA-67       .......... .......... .......... .......... .......... ..........  














             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                185        195        205        215        225        235                
OXA-65       FAYKLANKTL PFSQKVQDEV QSMLFIEEKN GNKIYAKSGW GWDVNPQVGW LTGWVVQPQG  
OXA-82       .......... .......... .......... .......... .......... ..........  
OXA-138      .......... .......... .......... .......... .......... ..........  
OXA-115      .......... .......... .......... .......... .......... ..........  
OXA-109      .......... .......... .......... .......... .......... ..........  
OXA-80       .......... .......... .......... .......... .......... ..........  
OXA-66       .......... .......... .......... .......... .......... ..........  
OXA-83       .......... .......... .......... .......... .......... ..........  
EU255296     .......... .......... .......... .......... .......... ..........  
OXA-79       .......... .......... .......... .......... .G........ ..........  
OXA-76       .......... .......... .......... .......... .......... ..........  
OXA-131      .......... .......... .......... .......... .....Q.... ..........  
OXA-84       .......... .......... .......... .......... .......... ..........  
OXA-90       .......... .......... .......... .......... ....D..... ..........  
OXA-130      .......... .......... .......... .......... ....D..... ..........  
EU255295     .......... .......... .......... .......... ....D..... ..........  
OXA-108      .......... .......... .......... .......... ....D..... ..........  
OXA-95       .......... .......... .......... .......... ....D..... ..........  
OXA-88       .......... .......... .......... .......... .......... ..........  
OXA-94       .......... .......... .......... .......... .......... ........H.  
OXA-104      .......... .......... .......... .......... ....D..... ..........  
OXA-107      .......... .......... .......... .......... .......... ..........  
OXA-69       .......... .......... .......... .......... .......... ..........  
OXA-110      .......... .......... .......... .......... .......... ..........  
OXA-112      .......... .......... .......... .......... .......... ..........  
OXA-92       .......... .......... .......... .......... .......... ...S......  
EU255289     .......... .......... .......... .......... .......... ..........  
EU255293     .......... .......... .......... .......... ....D..... ..........  
OXA-89       .T........ .......... .......... .......... .......... ..........  
OXA-149      .......... ...P...... .......... .......... .......... ..........  
OXA-77       .......... .......... .......... .......... .......... ..........  
OXA-128      .......... ....E..... .......... .......... .......... ..........  
OXA-68       .......... ....E..... .......... .......... .......... ..........  
OXA-144      .......... ....E..... ..I....... .......... .......... ..........  
OXA-117      .......... .......... .......... .......... .......... ..E.......  
OXA-98       .......... .......... .......... .......... .......... ..........  
OXA-78       .......... .......... .......... .......... .......... ..........  
OXA-91       .......... .......... .......... .......... ....D..... ..........  
OXA-116      .......... .......... .......... .......... ....D..... ..........  
OXA-150      .......... .......... .......... .......... .......... ..........  
OXA-75       .......... .......... .......... .......... .......... ..........  
OXA-93       .......... .......... .......... .......... .......... ..........  
OXA-71       .......... ...P...... .......... .......... ....D..... ..........  
EU255290     .......... ...P...... .......... .......... ....D..... ..........  
OXA-113      .......... ...P...... .......... .......... ....D..... ..........  
EU255291     .......... ...P...... .......... .......... ....D..... ..........  
OXA-51       .......... ...P...... .......... .......... ....D..... ..........  
OXA-132      .......... ...P...... .......... .......... ....D..... ..........  
OXA-99       .......... ...P...... ........M. .......... ....D..... ..........  
OXA-64       .......... ...P...... .......... .......... ....D..... ..........  
OXA-111      .......... ...P...... ........M. .......... ....D..... ..........  
OXA-106      .......... .......... .......... .......... ....D..... ..........  
OXA-70       .......... .......H.. .......... .......... ....D..... ..........  
EU255294     .......... .......H.. .......... .......... ....D..... ......R...  
OXA-148      .......... .......... K......... .......... ....D..... ..........  
EU255292     .......... ...P...... .......... .......... ....D..... ..........  
OXA-86       .......... ...L...... .......... .......... ....D..... ..........  
OXA-87       .......... ...L.A.... .......... .......... ....D..... ..........  
OXA-67       .......... ...L...... .......... .......... ....D..... ..........  














             ....|....| ....|....| ....|....| ....| 
                245        255        265        275      
OXA-65       NIVAFSLNLE MKKGIPSSVR KEITYKSLEQ LGIL* 
OXA-82       .......... .......... .......... ....* 
OXA-138      .......... .......... .......... ....* 
OXA-115      .......... .......... .......... ....* 
OXA-109      .......... .......... .......... ....* 
OXA-80       .......... .......... .......... ....* 
OXA-66       .......... .......... .......... ....* 
OXA-83       .......... .......... .......... ....* 
EU255296     .......... .......... .......... ....* 
OXA-79       .......... .......... .......... ....* 
OXA-76       .......... .......... .........K ....* 
OXA-131      .......... .......... .......... ....* 
OXA-84       .......... .......... .......... ....* 
OXA-90       .......... .......... .......... ....* 
OXA-130      .......... .......... .......... ....* 
EU255295     .......... .......... .......... ....* 
OXA-108      .......... .......... .......... ....* 
OXA-95       .......... .......... .......... ....* 
OXA-88       .......... .......... .......... ....* 
OXA-94       .......... .......... .......... ....* 
OXA-104      .......... .......... .......... ....* 
OXA-107      .......... .......... .......... ....* 
OXA-69       .......... .......... .......... ....* 
OXA-110      .......... .......... .......... ....* 
OXA-112      .....P.... .......... .......... ....* 
OXA-92       .......... .......... .......... ....* 
EU255289     .......... .......... .......... ....* 
EU255293     .......... .......... .......... ....* 
OXA-89       .......... .......... .......... ....* 
OXA-149      .......... .......... .......... ....* 
OXA-77       .......... .......... .......... ....* 
OXA-128      .......... .......... .......... ....* 
OXA-68       .......... .......... .......... ....* 
OXA-144      .......... .......... .......... ....* 
OXA-117      .......... .......... .......... ....* 
OXA-98       .......... .......... .......... ....* 
OXA-78       .......... ....T..... .......... ....* 
OXA-91       .......... .......... .......... ....* 
OXA-116      .......... .......... ........-- ----- 
OXA-150      .......... .......... .......... ....* 
OXA-75       .......... .....S.... .....RG... ....* 
OXA-93       .......... .......... .......... ....* 
OXA-71       .......... .......... .......... ....* 
EU255290     .......... .......... .......... ....* 
OXA-113      .......... .......... .......... ....* 
EU255291     .......... .......... ...A...... ....* 
OXA-51       .......... .......... .......... ....* 
OXA-132      .......... .......... ..M....... ....* 
OXA-99       .......... .......... .......... ....* 
OXA-64       .......... .......... .......... ....* 
OXA-111      .......... .......... .......... ....* 
OXA-106      .......... .......... .......... ....* 
OXA-70       .......... .......... .......... ....* 
EU255294     .......... .....A.... .......... ....* 
OXA-148      .......... .......... .......... ....* 
EU255292     .......... .......... .......... ....* 
OXA-86       .......... .......... .......... ....* 
OXA-87       .......... .......... .......... ....* 
OXA-67       .......... .......... .......... ....* 






3. Nucleotide alignment of blaOXA-66-like genes. Substitutions are labelled with 
 respect to blaOXA-66. 
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                 5          15         25         35         45         55                      
OXA-66       atgaacatta aagcactctt acttataaca agcgctattt ttatttcagc ctgctcacct  
OXA-65       .......... .......... .......... .......... .......... ..........  
OXA-88       .......... .......... .......... .......... .......... ..........  
OXA-76       .......... .......... .......... .......... .......... ..........  
OXA-79       .......... .......... .......... .......... .......... ..........  
OXA-83       .......... .......... .......... .......... .......... ..........  
OXA-82       .......... .......... .......... .......... .......... ..........  
OXA-80       .......... .......... .......... .......... .......... ..........  
OXA-109      .......... .......... .......... .......... .......... ..........  
EU255296     .......... .......... .......... .......... .......... ..........  
OXA-115      .......... .......... .......... .......... .......... ..........  
OXA-138      .......... ..a.c..... .......... .......... .......... ..........  
OXA-84       .......... .......... .......... .......... .......... ..........  
OXA-131      .......... .......... .......... .......... .......... ..........  
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                 65         75         85         95        105        115                    
OXA-66       tatatagtga ctgctaatcc aaatcacagc gcttcaaaat ctgatgtaaa agcagagaaa  
OXA-65       .......... .......... .........t .......... ......a... ..........  
OXA-88       .......... .......... .......... .......... .....aa... ..........  
OXA-76       .......... .......... .......... .......... .......... ..........  
OXA-79       .......... .......... .......... .......... .......... ..........  
OXA-83       .......... .......... .......... .......... .......... ..........  
OXA-82       .......... .......... .......... .......... .......... ..........  
OXA-80       .......... .......... .......... .......... .......... ..........  
OXA-109      .......... .......... .......... .......... .......... ..........  
EU255296     .......... .......... .......... .......... .......... ..........  
OXA-115      .......... .......... .......... .......... .......... ..........  
OXA-138      .......... .......... .......... .......... .......... ..........  
OXA-84       .......... .......... .......... .......... .......... ..........  
OXA-131      .......... .......... .......... .......... .......... ..........  
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                125        135        145        155        165        175                
OXA-66       attaaaaatt tatttaacga agcacacact acgggtgttt tagttatcca acaaggccaa  
OXA-65       .......... .......... .......... .......... .......... ..........  
OXA-88       .......... .......... .......... .......... .......... ..........  
OXA-76       .......... .......... .......... .......... .......... ..........  
OXA-79       .......... .......... .......... .......... .......... ..........  
OXA-83       .......... .......... .......... .......... .......... ..........  
OXA-82       .......... .......... .......... .......... .......... ..........  
OXA-80       .......... .......... .......... .......... .......... ..........  
OXA-109      .......... .......... .......... .......... .......... ..........  
EU255296     .......... .......... .......... .......... .......... ..........  
OXA-115      .......... .......... .......... .......... .......... ..........  
OXA-138      .......... .......... .......... .......... .......... ..........  
OXA-84       .......... .......... .......... .......... .......... ..........  
OXA-131      .......... .......... .......... .......... .......... ..........  
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                185        195        205        215        225        235                
OXA-66       actcaacaaa gctatggtaa tgatcttgct cgtgcttcga ccgagtatgt acctgcttcg  
OXA-65       .......... .......... .......... .......... .......... ..........  
OXA-88       .......... .......... .......... .......... .......... ..........  
OXA-76       .......... .......... .......... .......... .......... ..........  
OXA-79       .......... .......... .......... .......... .......... ..........  
OXA-83       .......... .......... .......... .......... .......... ..........  
OXA-82       .......... .......... .......... .......... .......... ..........  
OXA-80       .......... .......... .......... .......... .......... ..........  
OXA-109      .......... .......... .......... .......... .......... ..........  
EU255296     .......... .......... .......... .......... .......... ..........  
OXA-115      .......... .......... .......... .......... .......... ..........  
OXA-138      .......... .......... .......... .......... .......... ..........  
OXA-84       .......... .......... .......... .......... .......... ..........  




             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                245        255        265        275        285        295                
OXA-66       accttcaaaa tgcttaatgc tttgatcggc cttgagcacc ataaggcaac caccacagaa  
OXA-65       .......... .......... .......... .......... .......... ..........  
OXA-88       .......... .......... .......... .......... .......... ..........  
OXA-76       .......... .......... .......... .......... .......... ..........  
OXA-79       .......... .......... .......... .......... .......... ..........  
OXA-83       .......... .......... .......... .......... .......... ..........  
OXA-82       .......... .......... .......... .......... .......... ..........  
OXA-80       .......... .......... .......... .......... .......... ..........  
OXA-109      .......... .......... .......... .......... .......... ..........  
EU255296     .......... .......... .......... .......... .......... ..........  
OXA-115      .......... .......... .......... .......... .......... ..........  
OXA-138      .......... .......... .......... .......... .......... ..........  
OXA-84       .......... .......... .......... .......... .......... ..........  
OXA-131      .......... .......... .......... .......... .......... ..........  
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                305        315        325        335        345        355                
OXA-66       gtatttaagt gggatggtaa aaaaaggtta ttcccagaat gggaaaagga catgacccta  
OXA-65       .......... .......... .......... .......... .......... ..........  
OXA-88       .......... .......... .......... .......... .......... ..........  
OXA-76       .......... .......... .......... .......... .......... ..........  
OXA-79       .......... .......... .......... .......... .......... ..........  
OXA-83       .......... .......... .......... .......... .......... ..........  
OXA-82       .......... .......... .......... .......... .......... ..........  
OXA-80       .......... .......... .......... .......... .......... ..........  
OXA-109      .......... .......... .......... .......... .......... ..........  
EU255296     .......... .......... .......... .......... .......... ..........  
OXA-115      .......... .......... .......... .......... .......... ..........  
OXA-138      .......... .......... .......... .......... .......... ..........  
OXA-84       .......... .......... .......... .......... .......... ..........  
OXA-131      .......... .......... .......... .......... .......... ..........  
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                365        375        385        395        405        415                
OXA-66       ggcgatgcca tgaaagcttc cgctattcca gtttatcaag atttagctcg tcgtattgga  
OXA-65       .......... .......... .......... .......... .......... ..........  
OXA-88       .......... .......... .........g .......... .......... ..........  
OXA-76       .......... .......... .......... .......... .......... ..........  
OXA-79       .......... .......... .......... .......... .......... ..........  
OXA-83       .......... .......... ....c..... .......... .......... ..........  
OXA-82       .......... .......... .......... .......... .......... ..........  
OXA-80       .......... .......... ........T. .......... .......... ..........  
OXA-109      .......... .......... ........A. .......... .......... ..........  
EU255296     .......... .......... .......... .......... .......... ..........  
OXA-115      .......... .......... ........t. .......... .......... ..........  
OXA-138      .......... .......... .......... .......... .......... ..........  
OXA-84       .......... .......... .......t.. .......... .......... ..........  
OXA-131      .......... .......... ....g..... .......... .......... ..........  
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                425        435        445        455        465        475                
OXA-66       cttgagctca tgtctaagga agtgaagcgt gttggttatg gcaatgcaga tatcggtacc  
OXA-65       .......... .......... .......... .......... .......... ..........  
OXA-88       .......... .......... .......... .......... .......... ..........  
OXA-76       .......... .......... .......... .......... .......... ..........  
OXA-79       .......... .......... .......... .......... .......... ..........  
OXA-83       .......... .......... .......... .......... .......... ..........  
OXA-82       .......... ....A..... .......... .......... .......... ..........  
OXA-80       .......... .......... .......... .......... .......... ..........  
OXA-109      .......... .......... .......... .......... .......... ..........  
EU255296     .......... .......... .......... .......... .......... ..........  
OXA-115      .......... .......... .......... .......... .......... ..........  
OXA-138      .......... .......... .......... .......... .......... ..........  
OXA-84       .......... .......... .......... .......... .......... ..........  









             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                485        495        505        515        525        535                
OXA-66       caagtcgata atttttggct ggtgggtcct ttaaaaatta ctcctcagca agaggcacag  
OXA-65       .......... .......... .......... .......... .......... ..........  
OXA-88       .......... .......... .......... .......... .......... ..........  
OXA-76       .......... .......... .......... .......... .......... ..........  
OXA-79       .......... .......... .......... .......... .......... ..........  
OXA-83       .......... .......... .......... .......... .......... ..........  
OXA-82       .......... ........G. .......... .......... .......... ..........  
OXA-80       .......... .......... .......... .......... .......... ..........  
OXA-109      .......... .......... .......... .......... .......... ..........  
EU255296     .......... .........a .......... .......... .......... ..........  
OXA-115      .......... ........g. .......... .......... .......... ..........  
OXA-138      .......... ........g. .......... .......... .......... ..........  
OXA-84       .......... .......... ..c....... .......... .......... ..........  
OXA-131      .......... .......... .......... .......... .......... ..........  
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                545        555        565        575        585        595                
OXA-66       tttgcttaca agctagctaa taaaacgctt ccatttagcc aaaaagtcca agatgaagtg  
OXA-65       .......... .......... .......... .......... .......... ..........  
OXA-88       .......... .......... .......... .......... .......... ..........  
OXA-76       .......... .......... .......... .......... .......... ..........  
OXA-79       .......... .......... .......... .......... .......... ..........  
OXA-83       .......... .......... .......... .......... .......... ..........  
OXA-82       .......... .......... .......... .......... .......... ..........  
OXA-80       .......... .......... .......... .......... .......... ..........  
OXA-109      .......... .......... .......... .......... .......... ..........  
EU255296     .......... .......... .......... .......... .......... ..........  
OXA-115      .......... .......... .......... .......... .......... ..........  
OXA-138      .......... .......... .......... .......... .......... ..........  
OXA-84       .......... .......... .......... .......... .......... ..........  
OXA-131      .......... .......... .......... .......... .......... ..........  
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                605        615        625        635        645        655                
OXA-66       caatccatgc tattcataga agaaaagaat ggaaacaaaa tatacgcaaa aagtggttgg  
OXA-65       .......... .......... .......... .......... .......... ..........  
OXA-88       .......... .......... .......... .....t.... .......... ..........  
OXA-76       .......... .......... .......... .......... .......... ..........  
OXA-79       .......... .......... .......... .......... .......... ..........  
OXA-83       .......... .......... .......... .......... .......... ..........  
OXA-82       .......... .......... .......... .......... .......... ..........  
OXA-80       .......... .......... .......... .......... .......... ..........  
OXA-109      .......... .......... .......... .......... .......... ..........  
EU255296     .......... .......... .......... .......... .......... ..........  
OXA-115      .......... .......... .......... .......... .......... ..........  
OXA-138      .......... .......... .......... .......... .......... ..........  
OXA-84       .......... .......... .......... .......... .......... ..........  
OXA-131      .......... .......... .......... .......... .......... ..........  
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                665        675        685        695        705        715                
OXA-66       ggatgggatg taaacccaca agtaggctgg ttaactggat gggttgttca gcctcaaggg  
OXA-65       .......... .......... .......... .......... .......... ..........  
OXA-88       .......... .......... .......... .......... .......... ..........  
OXA-76       .......... .......... .......... .......... .......... ..........  
OXA-79       ...G...... .......... .......... .......... .......... ..........  
OXA-83       .......... .......... .......... .......... .......... ..........  
OXA-82       .......... .......... .......... .......... .......... ..........  
OXA-80       .......... .......... .......... .......... .......... ..........  
OXA-109      .......... .......... .......... .......... .......... ..........  
EU255296     .......... .......... .......... .......... .......... ..........  
OXA-115      .......... .......... .......... .......... .......... ..........  
OXA-138      .......... .......... .......... .......... .......... ..........  
OXA-84       .......... .......... .......... .......... .......... ..........  









             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                725        735        745        755        765        775                
OXA-66       aatattgtag cgttctccct taacttagaa atgaaaaaag gaatacctag ctctgttcga  
OXA-65       .......... .......... .......... .......... .......... ..........  
OXA-88       .......... .......... .......... .......... .......... ..........  
OXA-76       .......... .......... .......... .......... .......... ..........  
OXA-79       .......... .......... .......... .......... .......... ..........  
OXA-83       .......... .......... .......... .......... .......... ..........  
OXA-82       .......... .......... .......... .......... .......... ..........  
OXA-80       .......... .......... .......... .......... .......... ..........  
OXA-109      .......... .......... .......... .......... .......... ..........  
EU255296     .......... .......... .......... .......... .......... ..........  
OXA-115      .......... .......... .......... .......... .......... ..........  
OXA-138      .......... .......... .......... .......... .......... ..........  
OXA-84       .......... .......... .......... .......... .......... ..........  
OXA-131      .......... .......... .......... .......... .......... ..........  
 
             ....|....| ....|....| ....|....| ....|....| ....| 
                785        795        805        815        825        
OXA-66       aaagagatta cttataaaag cttagaacaa ttaggtattt tatag 
OXA-65       .......... .......... t......... .......... ..... 
OXA-88       .......... .......... t......... .......... ..... 
OXA-76       .......... .......... .......a.. .......... ..... 
OXA-79       .......... .......... .......... .......... ..... 
OXA-83       .......... .......... .......... .......... ..... 
OXA-82       .......... .......... .......... .......... ..... 
OXA-80       .......... .......... .......... .......... ..... 
OXA-109      .......... .......... .......... .......... ..... 
EU255296     .......... .......... .......... .......... ..... 
OXA-115      .......... .......... .......... .......... ..... 
OXA-138      .......... .......... .......... .......... ..... 
OXA-84       .......... .......... .......... .......... ..... 
















4. Amino-acid alignment of OXA-66-like enzymes. Substitutions are labelled 
 with respect to OXA-66. 
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                 5          15         25         35         45         55                      
OXA-66       MNIKALLLIT SAIFISACSP YIVTANPNHS ASKSDVKAEK IKNLFNEAHT TGVLVIQQGQ  
OXA-65       .......... .......... .......... .....E.... .......... ..........  
OXA-88       .......... .......... .......... .....K.... .......... ..........  
OXA-76       .......... .......... .......... .......... .......... ..........  
OXA-79       .......... .......... .......... .......... .......... ..........  
OXA-83       .......... .......... .......... .......... .......... ..........  
OXA-82       .......... .......... .......... .......... .......... ..........  
OXA-80       .......... .......... .......... .......... .......... ..........  
OXA-109      .......... .......... .......... .......... .......... ..........  
EU255296     .......... .......... .......... .......... .......... ..........  
OXA-115      .......... .......... .......... .......... .......... ..........  
OXA-138      ....T..... .......... .......... .......... .......... ..........  
OXA-84       .......... .......... .......... .......... .......... ..........  
OXA-131      .......... .......... .......... .......... .......... ..........  
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                 65         75         85         95        105        115                    
OXA-66       TQQSYGNDLA RASTEYVPAS TFKMLNALIG LEHHKATTTE VFKWDGKKRL FPEWEKDMTL  
OXA-65       .......... .......... .......... .......... .......... ..........  
OXA-88       .......... .......... .......... .......... .......... ..........  
OXA-76       .......... .......... .......... .......... .......... ..........  
OXA-79       .......... .......... .......... .......... .......... ..........  
OXA-83       .......... .......... .......... .......... .......... ..........  
OXA-82       .......... .......... .......... .......... .......... ..........  
OXA-80       .......... .......... .......... .......... .......... ..........  
OXA-109      .......... .......... .......... .......... .......... ..........  
EU255296     .......... .......... .......... .......... .......... ..........  
OXA-115      .......... .......... .......... .......... .......... ..........  
OXA-138      .......... .......... .......... .......... .......... ..........  
OXA-84       .......... .......... .......... .......... .......... ..........  
OXA-131      .......... .......... .......... .......... .......... ..........  
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                125        135        145        155        165        175                
OXA-66       GDAMKASAIP VYQDLARRIG LELMSKEVKR VGYGNADIGT QVDNFWLVGP LKITPQQEAQ  
OXA-65       .......... .......... .......... .......... .......... ..........  
OXA-88       .......... .......... .......... .......... .......... ..........  
OXA-76       .......... .......... .......... .......... .......... ..........  
OXA-79       .......... .......... .......... .......... .......... ..........  
OXA-83       ........L. .......... .......... .......... .......... ..........  
OXA-82       .......... .......... .......... .......... ......V... ..........  
OXA-80       .........L .......... .......... .......... .......... ..........  
OXA-109      .........Q .......... .......... .......... .......... ..........  
EU255296     .......... .......... .......... .......... ......Q... ..........  
OXA-115      .........L .......... .......... .......... ......V... ..........  
OXA-138      .......... .......... .......... .......... ......V... ..........  
OXA-84       .........S .......... .......... .......... .......A.. ..........  
OXA-131      ........V. .......... .......... .......... .......... ..........  
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                185        195        205        215        225        235                
OXA-66       FAYKLANKTL PFSQKVQDEV QSMLFIEEKN GNKIYAKSGW GWDVNPQVGW LTGWVVQPQG  
OXA-65       .......... .......... .......... .......... .......... ..........  
OXA-88       .......... .......... .......... .......... .......... ..........  
OXA-76       .......... .......... .......... .......... .......... ..........  
OXA-79       .......... .......... .......... .......... .G........ ..........  
OXA-83       .......... .......... .......... .......... .......... ..........  
OXA-82       .......... .......... .......... .......... .......... ..........  
OXA-80       .......... .......... .......... .......... .......... ..........  
OXA-109      .......... .......... .......... .......... .......... ..........  
EU255296     .......... .......... .......... .......... .......... ..........  
OXA-115      .......... .......... .......... .......... .......... ..........  
OXA-138      .......... .......... .......... .......... .......... ..........  
OXA-84       .......... .......... .......... .......... .......... ..........  




             ....|....| ....|....| ....|....| .... 
                245        255        265            
OXA-66       NIVAFSLNLE MKKGIPSSVR KEITYKSLEQ LGIL 
OXA-65       .......... .......... .......... .... 
OXA-88       .......... .......... .......... .... 
OXA-76       .......... .......... .........K .... 
OXA-79       .......... .......... .......... .... 
OXA-83       .......... .......... .......... .... 
OXA-82       .......... .......... .......... .... 
OXA-80       .......... .......... .......... .... 
OXA-109      .......... .......... .......... .... 
EU255296     .......... .......... .......... .... 
OXA-115      .......... .......... .......... .... 
OXA-138      .......... .......... .......... .... 
OXA-84       .......... .......... .......... .... 






















5. Nucleotide alignment of blaOXA-69-like genes. Substitutions are labelled with 
 respect to blaOXA-69. 
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                 5          15         25         35         45         55                      
OXA-69       atgaacatta aagcactctt acttataaca agcgctattt ttatttcagc ctgctcacct  
OXA-92       .......... .......... .......... .......... .......... ..........  
OXA-107      .......... .......... .......... .......... .......... ..........  
OXA-110      .......... .......... .......... .......... .......... ..........  
OXA-112      .......... .......... .......... .......... .......... ..........  
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                 65         75         85         95        105        115                    
OXA-69       tatatagtga ctgctaatcc aaatcacagt gcttcaaaat ctgatgacaa agcagagaaa  
OXA-92       .......... .......... .......... .......... .......... ..........  
OXA-107      .......... .......... .......... .......... .......... ..........  
OXA-110      .......... .......... .......... .......... .......... ..........  
OXA-112      .......... .......... .......... .......... .......... ..........  
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                125        135        145        155        165        175                
OXA-69       attaaaaatt tatttaacga agcacacact acgggtgttt tagttatcca tcaaggtcaa  
OXA-92       .......... .......... .......... .......... .......... ..........  
OXA-107      .......... .......... .......... .......... .......... ..........  
OXA-110      .......... .......... .......... .......... .......... ..........  
OXA-112      .......... .......... .......... .......... .......... ..........  
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                185        195        205        215        225        235                
OXA-69       actcaacaaa gctatggtaa tgatcttgct cgtgcttcga ccgagtatgt acctgcttcg  
OXA-92       .......... .......... .......... .......... .......... ..........  
OXA-107      .......... .......... .......... .......... .......... ..........  
OXA-110      .......... .......... .......... .......... .......... ..........  
OXA-112      .......... .......... .......... .......... .......... ..........  
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                245        255        265        275        285        295                
OXA-69       accttcaaaa tgcttaatgc tttgatcggc cttgagcacc ataaggcaac caccacagaa  
OXA-92       .......... .......... .......... .......... .......... ..........  
OXA-107      .......... .......... .......... .......... .......... ..........  
OXA-110      .......... .......... .......... .......... .......... ..........  
OXA-112      .......... .......... .......... .......... .......... ..........  
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                305        315        325        335        345        355                
OXA-69       gtatttaaat gggatgggga aaaaaggcta ttcccagaat gggaaaagaa catgacccta  
OXA-92       .......... .......... .......... .......... .......... ..........  
OXA-107      .......... .......... .......... .......... .......... ..........  
OXA-110      .......... .......... .......... .......... .......... ..........  
OXA-112      .......... .......... .......... .......... .......... ..........  
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                365        375        385        395        405        415                
OXA-69       ggcgatgcta tgaaagcttc cgctattccg gtttatcaag atttagctcg tcgtattgga  
OXA-92       .......... .......... .......... .......... .......... ..........  
OXA-107      .......... .......... .......... .......... .......... ..........  
OXA-110      .......... .......... ....C..... .......... .......... ..........  
OXA-112      .......... .......... .......... .......... .......... ..........  
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                425        435        445        455        465        475                
OXA-69       cttgagctca tgtctaagga agtgaagcgt gttggttatg gcaatgcaga tatcggtacc  
OXA-92       .......... .......... .......... .......... .......... ..........  
OXA-107      .......... .......... .......... .......... .......... ..........  
OXA-110      .......... .......... .......... .......... .......... ..........  








             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                485        495        505        515        525        535                
OXA-69       caagtcgata atttttggct ggtgggtcct ctaaaaatta ctcctcagca agaggcacag  
OXA-92       .......... .......... .......... .......... .......... ..........  
OXA-107      .......... ........G. .......... .......... .......... ..........  
OXA-110      .......... .......... .......... .......... .......... ..........  
OXA-112      .......... .......... .......... .......... .......... ..........  
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                545        555        565        575        585        595                
OXA-69       tttgcttaca agctagctaa taaaacgctt ccatttagcc aaaaagtcca agatgaagtg  
OXA-92       .......... .......... .......... .......... .......... ..........  
OXA-107      .......... .......... .......... .......... .......... ..........  
OXA-110      .......... .......... .......... .......... .......... ..........  
OXA-112      .......... .......... .......... .......... .......... ..........  
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                605        615        625        635        645        655                
OXA-69       caatccatgc tattcataga agaaaagaat ggaaataaaa tatacgcaaa aagtggttgg  
OXA-92       .......... .......... .......... .......... .......... ..........  
OXA-107      .......... .......... .......... .......... .......... ..........  
OXA-110      .......... .......... .......... .......... .......... ..........  
OXA-112      .......... .......... .......... .......... .......... ..........  
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                665        675        685        695        705        715                
OXA-69       ggatgggatg taaacccaca agtaggctgg ttaactggat gggttgttca gcctcaaggg  
OXA-92       .......... .......... .......... .......... c......... ..........  
OXA-107      .......... .......... .......... .......... .......... ..........  
OXA-110      .......... .......... .......... .......... .......... ..........  
OXA-112      .......... .......... .......... .......... .......... ..........  
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                725        735        745        755        765        775                
OXA-69       aatattgtag cgttctccct taacttagaa atgaaaaaag gaatacctag ctctgttcga  
OXA-92       .......... .......... .......... .......... .......... ..........  
OXA-107      .......... .......... .......... .......... .......... ..........  
OXA-110      .......... .......... .......... .......... .......... ..........  
OXA-112      .......... .....C.... .......... .......... .......... ..........  
 
             ....|....| ....|....| ....|....| ....|....| ....| 
                785        795        805        815        825        
OXA-69       aaagagatta cttataaaag tttagaacaa ttaggtattt tatag 
OXA-92       .......... .......... .......... .......... ..... 
OXA-107      .......... .......... .......... .......... ..... 
OXA-110      .......... .......... .......... .......... ..... 











6. Amino-acid alignment of OXA-69-like enzymes. Substitutions are labelled 
 with respect to OXA-69. 
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                 5          15         25         35         45         55                      
OXA-69       MNIKALLLIT SAIFISACSP YIVTANPNHS ASKSDDKAEK IKNLFNEAHT TGVLVIHQGQ  
OXA-92       .......... .......... .......... .......... .......... ..........  
OXA-107      .......... .......... .......... .......... .......... ..........  
OXA-110      .......... .......... .......... .......... .......... ..........  
OXA-112      .......... .......... .......... .......... .......... ..........  
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                 65         75         85         95        105        115                    
OXA-69       TQQSYGNDLA RASTEYVPAS TFKMLNALIG LEHHKATTTE VFKWDGEKRL FPEWEKNMTL  
OXA-92       .......... .......... .......... .......... .......... ..........  
OXA-107      .......... .......... .......... .......... .......... ..........  
OXA-110      .......... .......... .......... .......... .......... ..........  
OXA-112      .......... .......... .......... .......... .......... ..........  
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                125        135        145        155        165        175                
OXA-69       GDAMKASAIP VYQDLARRIG LELMSKEVKR VGYGNADIGT QVDNFWLVGP LKITPQQEAQ  
OXA-92       .......... .......... .......... .......... .......... ..........  
OXA-107      .......... .......... .......... .......... ......V... ..........  
OXA-110      ........L. .......... .......... .......... .......... ..........  
OXA-112      .......... .......... .......... .......... .......... ..........  
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                185        195        205        215        225        235                
OXA-69       FAYKLANKTL PFSQKVQDEV QSMLFIEEKN GNKIYAKSGW GWDVNPQVGW LTGWVVQPQG  
OXA-92       .......... .......... .......... .......... .......... ...S......  
OXA-107      .......... .......... .......... .......... .......... ..........  
OXA-110      .......... .......... .......... .......... .......... ..........  
OXA-112      .......... .......... .......... .......... .......... ..........  
 
             ....|....| ....|....| ....|....| ....| 
                245        255        265        275      
OXA-69       NIVAFSLNLE MKKGIPSSVR KEITYKSLEQ LGIL* 
OXA-92       .......... .......... .......... ....* 
OXA-107      .......... .......... .......... ....* 
OXA-110      .......... .......... .......... ....* 













7. Nucleotide alignment of blaOXA-98-like genes. Substitutions are labelled with 
 respect to blaOXA-98. 
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                 5          15         25         35         45         55                      
OXA-98       ATGAACATTA AAGCACTCTT ACTTATAACA AGCGCTATTT TTATTTCAGC CTGCTCACCT  
OXA-77       .......... .......... ......c... .......... .......... ..........  
OXA-68       .......... .......... .......... .......... .......... ..........  
OXA-91       .......... .......... .......... .......... .......... ..........  
OXA-117      ~~~~~~~~~~ ~~~~~~~~.. .......... .......... .......... ..........  
OXA-150      .......... .......... .......... .......... .......... ..........  
OXA-128      .......... .......... .......... .......... .......... ..........  
OXA-144      .......... .......... .......... .......... .......... ..........  
OXA-116      ~~~~~~~~~~ ~~~~~~~~.. .......... .......... .......... ..........  
OXA-149      .......... ....C..... .......... .......... .......... ..........  
OXA-78       .......... .......... .......... .......... .......... ..........  
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                 65         75         85         95        105        115                    
OXA-98       TATATAGTGT CTGCTAATCC AAATCACAGT GCTTCAAAAT CTGATGAAAA AGCAGAGAAA  
OXA-77       .......... .......... .......... .......... .......... ..........  
OXA-68       .......... .......... .......... .......... .......... ..........  
OXA-91       .......... .......... .......... .......... .......... ..........  
OXA-117      .......... .......... .......... .......... .......... ..........  
OXA-150      .......... .......... .......... .......... .......... ..........  
OXA-128      .......... .......... .......... .......... .......... ..........  
OXA-144      .......... .......... .......... .......... .......... ..........  
OXA-116      .......... .......... .......... .......... .......c.. ..........  
OXA-149      .......... .......... .......... .......... .......... ..........  
OXA-78       .......... .......... .......... .......... .......... ..........  
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                125        135        145        155        165        175                
OXA-98       ATTAAAAATT TATTTAACGA AGCACACACT ACGGGTGTTT TAGTTATCCA ACAAGGCCAA  
OXA-77       .......... .......... .......... .......... .......... ..........  
OXA-68       .......... .......... .......... .......... .......... ..........  
OXA-91       .......... .......... .......... .......... .......... ..........  
OXA-117      .......... .......... .......... .......... .......... ..........  
OXA-150      .......... .......... .......... .......... .......T.. ..........  
OXA-128      .......... .......... .......... .......... .......... ..........  
OXA-144      .......... .......... .......... .......... .......... ..........  
OXA-116      .......... .......... .......... .......... .......... ..........  
OXA-149      .......... .......... .......... .......... .......T.. ..........  
OXA-78       .......... .......... .......... .......... .......... ..........  
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                185        195        205        215        225        235                
OXA-98       ACTCAACAAA GCTATGGTAA TGATCTTGCT CGTGCTTCGA CCGAGTATGT ACCTGCTTCG  
OXA-77       .......... .......... .......... .......... .......... ..........  
OXA-68       .......... .......... .......... .......... .......... ..........  
OXA-91       .......... .......... .......... .......... .......... ..........  
OXA-117      .......... .......... .......... .......... .......... ..........  
OXA-150      .......... .......... .......... .......... .......... ..........  
OXA-128      .......... .......... ..t....... .......... .......... ..........  
OXA-144      .......... .......... .......... .......... .......... ..........  
OXA-116      .......... .......... .......... .......... .......... ..........  
OXA-149      .......... .......... .......... .......... .......... ..........  
OXA-78       .......... .......... .......... .......... .......... ..........  
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                245        255        265        275        285        295                
OXA-98       ACCTTCAAAA TGCTTAATGC TTTGATCGGC CTTGAGCACC ATAAGGCAAC CACTACAGAA  
OXA-77       .......... .......... .......... .......... .......... ..........  
OXA-68       .......... .......... .......... .......... .......... ..........  
OXA-91       .......... .......... .......... .......... .......... ..........  
OXA-117      .......... .......... .......... .......... .......... ..........  
OXA-150      .......... .......... .......... .......... .......... ..........  
OXA-128      .......... .......... .......... .......... .......... ..........  
OXA-144      .......... .......... .......... .......... .......... ..........  
OXA-116      .......... .......... .......... .......... .......... ..........  
OXA-149      .......... .......... .......... .......... .......... ..........  
OXA-78       .......... .......... .......... .......... .......... ........c.  
 200 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                305        315        325        335        345        355                
OXA-98       GTATTTAAGT GGGACGGGCA AAAAAGGCTA TTCCCAGAAT GGGAAAAGAA CATGACCCTA  
OXA-77       .......... .......... .......... .......... .......... ..........  
OXA-68       .......... .......... .......... .......... .......... ..........  
OXA-91       .......... .......... .......... .......... .......... ..........  
OXA-117      .......... .......... .......... .......... .......... ..........  
OXA-150      .......... .......... .......... .......... .......... ..........  
OXA-128      .......... .......... .......... .......... .......... ..........  
OXA-144      .......... .......... .......... .......... .......... ..........  
OXA-116      .......... .......... .......... .......... .......... ..........  
OXA-149      .......... .......... .......... .......... .......... ..........  
OXA-78       .......... .......... .......... .......... .......... ..........  
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                365        375        385        395        405        415                
OXA-98       GGCGATGCTA TGAAAGCTTC CGCTATTCCG GTTTATCAAG ATTTAGCTCG TCGTATTGGA  
OXA-77       .......... .......... .......... .......... .....c.... ..........  
OXA-68       .......... .......... .......... .......... .......... ..........  
OXA-91       .......... .......... .......... .......... .......... ..........  
OXA-117      .......... .......... .......... .......... .......... ..........  
OXA-150      .......... .......... .......... .......... .......... ..........  
OXA-128      .......... .......... .......... .......... .......... ..........  
OXA-144      .......... .......... .......... .......... .......... ..........  
OXA-116      .......... .......... .......... .......... .......... ..........  
OXA-149      .......... .......... .......... .......... .......... ..........  
OXA-78       .......... .......... .......... .......... .......... ..........  
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                425        435        445        455        465        475                
OXA-98       CTTGAACTCA TGTCTAATGA AGTGAAGCGT GTTGGTTATG GCAATGCAGA TATCGGTACC  
OXA-77       .......... .......... .......... .......... .......... ..........  
OXA-68       .......... .......... .......... .......... .......... ..........  
OXA-91       .......... .......... .......... .......... .......... ..........  
OXA-117      .......... .......... .......... .......... .......... ..........  
OXA-150      .......... .......... ........A. .......... .......... ..........  
OXA-128      .......... .......... .......... .......... .......... ..........  
OXA-144      .......... .......... .......... .......... .......... ..........  
OXA-116      .......... .......... .......... .......... .......... ..........  
OXA-149      .......... .......... ........A. .......... .......... ..........  
OXA-78       .......... .......... .......... .......... .......... ..........  
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                485        495        505        515        525        535                
OXA-98       CAAGTCGATA ATTTTTGGCT GGTGGGTCCT TTAAAAATTA CTCCTCAGCA AGAGGCACAA  
OXA-77       .......... .......... .......... .......... .......... ..........  
OXA-68       .......... .......... a......... .......... .......... ..........  
OXA-91       .......... .......... .......... .......... .......... ..........  
OXA-117      .......... .......... a......... .......... .......... ..........  
OXA-150      .......... .......... .......... .......... .......... ..........  
OXA-128      .......... .......... a......... .......... .......... ..........  
OXA-144      .......... .......... A......... .......... .......... ..........  
OXA-116      .......... .......... .......... .......... .......... .........g  
OXA-149      .......... .......... .......... .......... .......... ..........  
OXA-78       .......... .......... a......... .......... .......... ..........  
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                545        555        565        575        585        595                
OXA-98       TTTGCTTACA AGCTAGCTAA TAAAACGCTT CCATTTAGCC AAAAAGTCCA AGATGAAGTG  
OXA-77       .......... .......... .......... .......... .......... ..........  
OXA-68       .......... .......... .......... .......... ..g....... ..........  
OXA-91       .......... .......... .......... .......... .......... ..........  
OXA-117      .......... .......... .......... .......... .......... ..........  
OXA-150      .......... .......... .......... .......... .......... ..........  
OXA-128      .......... .......... .......... .......... ..g....... ..........  
OXA-144      .......... .......... .......... .......... ..G....... ..........  
OXA-116      .......... .......... .......... .......... .......... ..........  
OXA-149      .......... .......... .......... .......... C......... ..........  







             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                605        615        625        635        645        655                
OXA-98       CAATCCATGC TATTCATAGA AGAAAAGAAT GGAAATAAAA TATACGCAAA AAGTGGTTGG  
OXA-77       .......... .......... .......... .......... .......... ..........  
OXA-68       .......... .......... .......... .......... .......... ..........  
OXA-91       .......... .......... .......... .......... .......... ..........  
OXA-117      .......... .......... .......... .......... .......... ..........  
OXA-150      .......... .G........ .......... .......... .......... ..........  
OXA-128      .......... .......... .......... .......... .......... ..........  
OXA-144      ........T. .......... .......... .......... .......... ..........  
OXA-116      .........t .......... .......... .......... .......... ..........  
OXA-149      .......... .......... .......... .......... .......... ..........  
OXA-78       .......... .......... .......... .......... .......... ..........  
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                665        675        685        695        705        715                
OXA-98       GGATGGGATG TAAACCCACA AGTAGGCTGG TTAACTGGAT GGGTTGTTCA GCCTCAAGGG  
OXA-77       .......... .......... .......... .......... .......... ..........  
OXA-68       .......... .......... .......... .......... .......... ..........  
OXA-91       .......... ..g....... .......... .......... .......... ..........  
OXA-117      .......... .......... .......... .......a.. .......... ..........  
OXA-150      .......... .......... .......... .......... .......... ..........  
OXA-128      .......... .......... .......... .......... .......... ..........  
OXA-144      .......... .......... .......... .......... .......... ..........  
OXA-116      .......... ..g....... ...g..t... .......... .......... ..........  
OXA-149      .......... .......... .......... .......... .......... .........A  
OXA-78       .......... .......... .......... .......... .......... ..........  
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                725        735        745        755        765        775                
OXA-98       AATATTGTAG CGTTCTCCCT TAACTTAGAA ATGAAAAAAG GAATACCTAG CTCTGTTCGA  
OXA-77       .......... .......... .......... .......... .......... ..........  
OXA-68       .......... .......... .......... .......... .......... ..........  
OXA-91       .......... .......... .......... .......... .......... ..........  
OXA-117      .......... .......... .......... .......... .......... ..........  
OXA-150      .......... .......... .......... .......... .......... ..........  
OXA-128      .......... .......... .......... .......... .......... ..........  
OXA-144      .......... .......... .......... .......... .......... ..........  
OXA-116      .......... .......... .......... .......... .......... ..........  
OXA-149      .......... .......... .......... .......... .......... ..........  
OXA-78       .......... .......... .......... .......... ...c...... ..........  
 
             ....|....| ....|....| ....|....| ....|....| ....| 
                785        795        805        815        825        
OXA-98       AAAGAGATTA CTTATAAAAG CTTAGAACAA TTAGGTATTT TATAG 
OXA-77       .......... .......... .......... .......... ..... 
OXA-68       .......... .......... .......... .......... ..... 
OXA-91       .......... .......... t......... .......... ..... 
OXA-117      .......... .......... t......... .......... ..... 
OXA-150      .......... .......... .......... .......... ..... 
OXA-128      .......... .......... .......... .......... ..... 
OXA-144      .......... .......... .......... .......... ..... 
OXA-116      .......... .......... t......... .......... ..... 
OXA-149      .......... .......... T......... .......... ..... 









8. Amino-acid alignment of OXA-98-like enzymes. Substitutions are labelled 
 with respect to OXA-98. 
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                 5          15         25         35         45         55                      
OXA-98       MNIKALLLIT SAIFISACSP YIVSANPNHS ASKSDEKAEK IKNLFNEAHT TGVLVIQQGQ  
OXA-77       .......... .......... .......... .......... .......... ..........  
OXA-68       .......... .......... .......... .......... .......... ..........  
OXA-91       .......... .......... .......... .......... .......... ..........  
OXA-117      ~~~~~~.... .......... .......... .......... .......... ..........  
OXA-150      .......... .......... .......... .......... .......... ..........  
OXA-128      .......... .......... .......... .......... .......... ..........  
OXA-144      .......... .......... .......... .......... .......... ..........  
OXA-116      ~~~~~~.... .......... .......... .....D.... .......... ..........  
OXA-149      .......... .......... .......... .......... .......... ..........  
OXA-78       .......... .......... .......... .......... .......... ..........  
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                 65         75         85         95        105        115                    
OXA-98       TQQSYGNDLA RASTEYVPAS TFKMLNALIG LEHHKATTTE VFKWDGQKRL FPEWEKNMTL  
OXA-77       .......... .......... .......... .......... .......... ..........  
OXA-68       .......... .......... .......... .......... .......... ..........  
OXA-91       .......... .......... .......... .......... .......... ..........  
OXA-117      .......... .......... .......... .......... .......... ..........  
OXA-150      .......... .......... .......... .......... .......... ..........  
OXA-128      .......V.. .......... .......... .......... .......... ..........  
OXA-144      .......... .......... .......... .......... .......... ..........  
OXA-116      .......... .......... .......... .......... .......... ..........  
OXA-149      .......... .......... .......... .......... .......... ..........  
OXA-78       .......... .......... .......... .........A .......... ..........  
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                125        135        145        155        165        175                
OXA-98       GDAMKASAIP VYQDLARRIG LELMSNEVKR VGYGNADIGT QVDNFWLVGP LKITPQQEAQ  
OXA-77       .......... .....P.... .......... .......... .......... ..........  
OXA-68       .......... .......... .......... .......... .......... ..........  
OXA-91       .......... .......... .......... .......... .......... ..........  
OXA-117      .......... .......... .......... .......... .......... ..........  
OXA-150      .......... .......... .........H .......... .......... ..........  
OXA-128      .......... .......... .......... .......... .......... ..........  
OXA-144      .......... .......... .......... .......... .......... ..........  
OXA-116      .......... .......... .......... .......... .......... ..........  
OXA-149      .......... .......... .........H .......... .......... ..........  
OXA-78       .......... .......... .......... .......... .......... ..........  
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                185        195        205        215        225        235                
OXA-98       FAYKLANKTL PFSQKVQDEV QSMLFIEEKN GNKIYAKSGW GWDVNPQVGW LTGWVVQPQG  
OXA-77       .......... .......... .......... .......... .......... ..........  
OXA-68       .......... ....E..... .......... .......... .......... ..........  
OXA-91       .......... .......... .......... .......... ....D..... ..........  
OXA-117      .......... .......... .......... .......... .......... ..E.......  
OXA-150      .......... .......... .......... .......... .......... ..........  
OXA-128      .......... ....E..... .......... .......... .......... ..........  
OXA-144      .......... ....E..... ..I....... .......... .......... ..........  
OXA-116      .......... .......... .......... .......... ....D..... ..........  
OXA-149      .......... ...P...... .......... .......... .......... ..........  
OXA-78       .......... .......... .......... .......... .......... ..........  
 
             ....|....| ....|....| ....|....| ....| 
                245        255        265        275      
OXA-98       NIVAFSLNLE MKKGIPSSVR KEITYKSLEQ LGIL* 
OXA-77       .......... .......... .......... ....* 
OXA-68       .......... .......... .......... ....* 
OXA-91       .......... .......... .......... ....* 
OXA-117      .......... .......... .......... ..... 
OXA-150      .......... .......... .......... ....* 
OXA-128      .......... .......... .......... ....* 
OXA-144      .......... .......... .......... ....* 
OXA-116      .......... .......... .......... ..... 
OXA-149      .......... .......... .......... ....* 



































































































































































The Linkage of Specific blaOXA-51-like Genes in Acinetobacter 
baumannii to Common Multi-resistant Clones. 
 
B.A. EVANS1, A. HAMOUDA1, K. J. TOWNER2 & S.G.B. AMYES1. 
Centre for Infectious Diseases, University of Edinburgh, Edinburgh1, Nottingham  
University Hospitals NHS Trust2. 
 
Background: 
Multidrug-resistant Acinetobacter baumannii is a major nosocomial pathogen that 
has become endemic in many areas. The intrinsic blaOXA-51-like genes of this species 
have been proposed as a genotypic marker for rapid identification, however there are 
many variants in the blaOXA-51-like gene group. The aim of this study was to 




A panel of 20 geographically and temporally diverse A. baumannii isolates was 
screened for blaOXA-23-like, blaOXA-40-like, blaOXA-58-like, and blaOXA-51-like genes, 
ISAba1, ISAba2 and ISAba3 by PCR amplification. blaOXA-51-like products were 
sequenced and identified using BLAST and MultAlin software. MICs were carried 
out following standard British Society for Antimicrobial Chemotherapy procedure. 
Pulsed-field gel electrophoresis (PFGE) typing was performed using ApaI restriction 
endonuclease and the similarity of the banding patterns were analysed by 
BioNumerics version 4 software. 
 
Results: 
The majority of these diverse isolates fall into three major groups based on the 
carriage of blaOXA-51-like enzymes. Ten isolates contain blaOXA-66, three contain 
blaOXA-69, and four contain blaOXA-71, with the remaining three isolates each 
containing a unique enzyme. Each enzyme was associated with distinct genotype 
clusters. The blaOXA-66 and blaOXA-69 groups contain ISAba1, but not the blaOXA-71 
group. blaOXA-58, ISAba2 and ISAba3 are associated with one another and are spread 
across the groups. All isolates were resistant to ceftazidime, one isolate was resistant 
to imipenem and meropenem, two isolates had intermediate resistance to imipenem 
and meropenem, and two isolates had intermediate resistance to imipenem only. 
 
Conclusions: 
These data indicate that individual blaOXA-51-like genes are associated with specific 










The OXA-51-like Enzymes of Acinetobacter baumannii: Markers of 
Success? 
 
B.A. EVANS1, A. HAMOUDA1, K. J. TOWNER2 & S.G.B. AMYES1. 
Centre for Infectious Diseases, University of Edinburgh, Edinburgh1, Nottingham  




Acinetobacter baumannii has become a prevalent nosocomial pathogen due to th
spread of major epidemic lineages. The diversity of the intrinsic blaOXA-51-like genes 
may provide insights into the evolution of this species. This study aimed to examine 
the relationship between the sequences of the OXA-51-like enzyme family and the 
properties of a collection of A. baumannii isolates. 
 
Methods: 
Sixty A. baumannii isolates had their blaOXA-51-like gene amplified by PCR using 
external primers, and the products sequenced and ide tified using BLAST and 
MultAlin software. The external primers allowed the simultaneous identification of 
ISAba1 upstream of the blaOXA-51-like genes. MICs for imipenem and meropenem 
were determined according to British Society for Antimicrobial Chemotherapy 
(BSAC) guidelines. Isolates were assigned to sequence groups (SGs) based on PCR 
amplification of fragments of their blaOXA-51-like, ompA and csuE genes. All publicly 
available OXA-51-like amino-acid sequences were retrieved and used to construct a 
linkage map showing the relationships of the enzymes to one another. 
 
Results: 
The linkage map revealed that some of the enzymes form closely related clusters 
while others are less closely related. The largest number of isolates, including 
European clone II, contained enzymes in the OXA-66 cluster, and were assigned to 
SG1. The second largest group of isolates, including European clone I, contained 
enzymes in the OXA-69 cluster, and were assigned to SG2. The third largest isolate 
group, including European clone III, were assigned to SG3 and contained an OXA-
71 enzyme. Eight isolates contained enzymes not found in a major cluster, or could 
not be assigned to a SG. ISAba1 was found upstream of the blaOXA-51-like gene in ten 
isolates, but was only associated with enzymes on bra ch tips in the OXA-66 and 
OXA-69 clusters. MICs for imipenem and meropenem ranged from 0.06 and 0.12 
mg/L respectively up to >128 mg/L for both antibiotics. Isolates with ISAba1 
upstream of the blaOXA-51-like gene tended to have MICs towards the higher end of this 
range, from 0.5 and 2 mg/L up to 8 and 32 mg/L. 
 
Conclusion: 
SG1 and SG2 represent the most prevalent epidemic lineages of A. baumannii and 
encode specific sub-sets of OXA-51-like enzymes. SG3 is not as prevalent, but is 
also associated with a specific OXA-51-like enzyme. A minority of isolates cannot 
be grouped using this typing scheme. Evolution of the OXA-51-like enzymes 
appears to be occurring in real time. 
 
 233 
Typing and blaOXA-51-like genes of Acinetobacter baumannii. 
 
B.A. EVANS1, A. HAMOUDA1, K. J. TOWNER2 & S.G.B. AMYES1. 
Centre for Infectious Diseases, University of Edinburgh1; Nottingham  
University Hospitals NHS Trust2. 
 
Background: 
The degree of genetic flux within Acinetobacter baumannii may cause problems for 
genome-wide typing techniques. This study aimed to compare pulsed-field gel 
electrophoresis (PFGE) and multi-locus sequence typing (MLST) schemes, and to 
evaluate the intrinsic blaOXA-51-like gene as a typing scheme candidate. 
 
Methods: 
A collection of 28 epidemiologically unrelated A. baumannii isolates were analysed 
by PFGE with restriction endonuclease Apa1, and results analysed using 
BioNumerics version 4 software. The gltA, rpoD, gdhB, gyrB, recA, cpn60, gpi and 
blaOXA-51-like genes were amplified and sequenced. Sequences were analysed using 
Multalin software, and isolates assigned to sequence types. Analysis of MLST 
profiles, blaOXA-51-like genes, and selection pressures on the MLST loci and blaOXA-51-
like genes were carried out using START2 and Minitab15 software. 
 
Results: 
Twenty-three novel alleles for the MLST loci and 13 novel sequence types were 
identified. Isolates containing the same blaOXA-51-like allele were assigned to the same 
or closely related sequence types. In contrast, some isolates containing the same 
blaOXA-51-like gene demonstrated <50% relatedness by PFGE, and were more closely 
related to isolates containing different genes. Analysis of selection pressure using the 
Nei-Gojobori method gave dN/dS ratios for gltA, rpoD, gdhB, gyrB, recA, cpn60, gpi 
and blaOXA-51-like genes of 0.0000, 0.0000, 0.0615, 0.0264, 0.0624, 0.000 , 0.0347 
and 0.2111 respectively. The dN/dS ratio for the blaOXA-51-like genes compared to the 
seven MLST loci was significantly higher (p<0.001). 
 
Conclusions: 
PFGE was less satisfactory for analysing a diverse A. baumannii population than 
MLST, and blaOXA-51-like gene content of isolates correlated more strongly with 
MLST data than with PFGE. The blaOXA-51-like genes are under greater positive 
selection pressure than the MLST loci, though the value is not so high as to preclude 












Novel genetic context of multiple blaOXA-58-like genes in Acinetobacter 
genospecies 3. 
 
B.A. EVANS1, A. HAMOUDA1, K. J. TOWNER2 & S.G.B. AMYES1. 
Centre for Infectious Diseases, University of Edinburgh, Edinburgh1, Nottingham  
University Hospitals NHS Trust2. 
 
Objectives: 
The spread of carbapenemase genes within Gram negative b cteria is of great cause 
for concern. In 2008, the first report of a blaOXA-58 gene outwith Acinetobacter 
baumannii was reported in Acinetobacter genospecies 3. We had also identified a 
genospecies 3 isolate encoding a bl OXA-58-like gene, and the aim of this study was to 




Restriction analysis of rRNA was used to confirm identity to the species level.  
Susceptibility to imipenem and meropenem was determined through the plate 
doubling dilution method. Screening by PCR for blaOXA-51-like, blaOXA-23-like, blaOXA-40-
like and blaOXA-58-like genes was carried out. Analysis of the genetic enviro ment 
surrounding the blaOXA-58-like gene was conducted by sequencing inverse PCR 
products and gene-walking fragments. The structure of the surrounding sequence was 
confirmed using internal primers, which were also ued to screen other blaOXA-58-like 
positive isolates in our collection. 
 
Results: 
Restriction analysis confirmed the isolate belonged to Acinetobacter genospecies 3. 
The isolate showed reduced susceptibility to imipenem and meropenem with MICs 
of 2 mg/L for both antibiotics. The isolate was negative for a blaOXA-51-like, blaOXA-23-
like or blaOXA-40-like gene, but positive for a blaOXA-58-like gene. Analysis of the genetic 
environment of the blaOXA-58-like gene revealed the gene was within a novel genetic 
structure. Upstream of the blaOXA-58-like gene was the left-hand end of an ISAba3 
element, interrupted by an ISAba125 element. The elements contained putative 
promoter sequences. Downstream was an ar C1 and a lysE gene, followed by a 
sequence similar to the Re27 element described previously. Following this was a 
complex region containing the right-hand end of an ISAba3 tnpA gene, interrupted by 
an incomplete tnpA gene with 99% similarity to ISAba3, itself interrupted by an 
ISAba125 sequence. This region was followed by a second blaOXA-58-like gene. All 
other blaOXA-58-like positive isolates in our collection were negative for ISAba125 
upstream of blaOXA-58. 
 
Conclusion: 
This study is the first to report multiple copies of a blaOXA-58-like gene in an 
Acinetobacter genospecies 3 isolate, and has identified a novel structure containing 
two blaOXA-58-like genes and two ISAba125 sequences. The ISAba125 elements may 




High Prevalence of Unrelated Multidrug-resistant Acinetobacter 
baumannii Isolates in Pakistani Military Hospitals. 
 
B. EVANS1, A. HAMOUDA1, S.A. ABBASI2, F.A. KHAN2 & S.G.B. AMYES1. 




Nosocomial infections with multidrug-resistant (MDR) Acinetobacter baumannii are 
an increasing problem worldwide. This study investigated the properties of 
Acinetobacter isolates from Pakistani hospitals. 
 
Methods: 
Twenty Acinetobacter isolates were obtained over two months from two military 
hospitals in Rawalpindi, Pakistan. They were genotyped by 16S-23S intergenic 
rRNA restriction analysis and assayed for antibiotic susceptibility. PCRs for 
blaOXA-23-like, -40-like, -58-like and -51-like genes, insertion sequences ISAba1, 2 
and 3, and the A. baumannii ATPase gene were conducted. Isolate relatedness was 
determined by PFGE typing. 
 
Results: 
The isolates were identified as A. baumannii (17), Acinetobacter species 3 (1), 
Acinetobacter species 13TU (1), and 1 was an unidentified Acinetobacter species. A. 
baumannii isolates were resistant to between 4 and 15 of the antibiotics tested, 
including imipenem, piperacillin/tazobactam and cefop razone/sulbactam. Twelve of 
the A. baumannii isolates were resistant to 5 different classes of antibiotic, 11 
encoded the blaOXA-23 gene, 12 encoded ISAba1, 6 encoded ISAba2, and 1 encoded 
ISAba3. PCR products were obtained for ISAba1 upstream of all blaOXA-23 genes, and 
downstream in 9 isolates. Twelve isolates were negative by PCR for the ATPase 
gene suggesting the presence of an inserted genomic island. PFGE analysis 
demonstrated that isolates were not clonal. More resistant isolates were associated 
with carriage of blaOXA-23, blaOXA-66, -69, or the novel blaOXA-144, ISAba1 and a 
negative ATPase PCR result. 
 
Conclusion: 
The high prevalence of MDR A. baumannii infections in hospitals in Pakistan in in- 
and out-patients caused by non-clonal isolates combined with high carriage of mobile 
resistance elements and genomic islands that may facilitate the acquisition of further 











Distribution of Intrinsic Plasmid Rep Genes and their Association 
with Class D OXA Carbapenemase Genes in European Isolates of 
Acinetobacter baumannii. 
 
K .J. TOWNER1, B. EVANS2, A. BERTINI3, S. G. B. AMYES2, A. CARATTOLI3. 
1Nottingham University Hospitals NHS Trust, UK, 2University of Edinburgh, UK 




Carbapenem-resistant strains of A. baumannii pose an increasing threat worldwide. 
This study examined the distribution of intrinsic plasmids in European isolates of A. 




96 randomly selected isolates (comprising 17 different PFGE types) of A. baumannii 
from 25 hospitals in 17 European countries were screned by PCR for specific class 
D carbapenemase genes and 16 different groups of plasmid rep genes (GR1 - 16) 
found in A. baumannii, with results confirmed by DNA sequencing where necessary. 
   
Results: 
All 96 isolates contained at least one (maximum five) of the 16 groups of rep genes. 
Those detected were GR6, including the repAci6 gene (93 isolates), GR2, including 
repAci1 (67 isolates) and repAci2 (3 isolates), GR10 (repAciX, 51 isolates), GR12 
(repAci12, 10 isolates), GR16 (reppAB49, 6 isolates), GR3 (repAci3, 4 isolates), 
GR4 (repAci4, 3 isolates), GR14 (repp4AYE, 1 isolate). OXA-58-like genes (22 
isolates) were associated with carriage of the repAci1, repAci3, repAci4 and 
repAciX genes, OXA-40-like genes (6 isolates) with repAci2, repAciX and 
repp2SDF, and OXA-23-like genes (7 isolates) with repAci1 and repAciX. 
    
Conclusions: 
The repAci1 and repAciX genes are associated with the Re27 sequence, which 
seems to be a favoured insertion site for structures carrying class D OXA genes. 
Although class D OXA genes are also associated with other plasmids, the presence 
of repAci1 and repAciX may indicate a particular propensity for strains to acquire 
such genes. Most intrinsic Acinetobacter plasmids are non-self-transferable, butthe 
almost ubiquitous repAci6 gene is associated with a tr  locus that could serve to 
mobilise other plasmids carrying antibiotic resistance genes such as those for class D 
carbapenemases. 
 
 
